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Summary 
Annual National Report on the Drug Situation 
(Edition 2007) 
 
The report on the Drug Situation in the G. D. of Luxembourg has been prepared on 
behalf of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), a 
decentralised agency of the European Union. It has been edited by the Luxembourgish 
focal point of the EMCDDA and provides an overview of current developments regarding 
the political and legal framework, the epidemiological situation, demand reduction 
interventions and selected key issues of current interest in the fields of drugs and drug 
addiction. 
 
 
Political, legal and organisational framework 
 
Following the parliamentary elections of June 1999 the government entrusted the 
Ministry of Health with the overall coordination of drug-related demand and risk reduction 
actions. This led to the creation of the national drug coordinator’s office in 2000. 
 
The 2004 governmental programme has introduced no changes concerning 
competences and attributions in the drugs field and constituted the framework for the 
elaboration of the strategy and action plan 2005-2009 for the fight against drugs and 
drug addiction. The national strategy and action plan 2005-2009 relies upon the 
priorities of the Ministry of Health and a sustained collaboration with field actors and civil 
society. In order to optimize its impact, the new action plan has taken into account 
pertinent elements issued from EU and EC treaties, the EU anti drugs strategy 2005-
2012 and the EU drugs action plan 2005-2008 having been endorsed under the 
Luxembourg presidency. The general aim of the national strategy and action plan is to 
contribute to a high level of protection in terms of public health, public security and social 
cohesion. 
 
An effective drug strategy should rely on two pillars, namely on demand reduction and 
supply reduction as also on four transversal axes: risk, damage, nuisance reduction, 
research and information, international relations and finally coordination mechanisms. 
The national drug coordinator, jointly with the Interministerial Committee on Drugs (ICD), 
follows up the implementation process of the national drug action plan. In 2006 the 
national drugs coordinator has been appointed chair of the ICD. 
 
The global budget of the Ministry of Health granted to drug-related services and 
programs went up from 1,270,169 EUR in 1999 to 5,770,643 - EUR in 2004, indicating a 
progression rate of 354% since 1999. The 2006 budget figures 6,584,000 - EUR 
representing a supplementary raise of 14.9% in reference to the 2005 budget. In regard 
to the 2007 budget, 6,689,000 - EUR have been allocated to concerned services 
representing an increase of 1.6% compared to 2006. Human resources dedicated to 
specialised state financed drug agencies have known a significant increase from 30.75 
full time posts in 2000 to 73.5 in 2007.  
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Epidemiological Indicators 
 
The total number of drug users in the world is estimated at some 200 million people, 
equivalent to about 5 percent of the global population aged 15-64. Cannabis remains by 
far the most widely used drug (some 159 million people), followed by amphetamine-type 
stimulants (+ 33.5 million people), which include amphetamines (+ 25 million people) 
and ecstasy (almost 8.5 million people). The number of opiate abusers is estimated at 
16 million people, of which 11 million are heroin abusers. Around 14 million people are 
cocaine users. 
 
In the last decade, the most important increase besides cannabis, applies to ATS 
(including ecstasy) followed by cocaine and opiates. A similar evolution is observed 
within the EU and the micro-geographical level of the Grand Duchy of Luxembourg, 
however accompanied by more or less sustained local variations with regard to 
prevalence. 
 
National drug prevalence in the general population  
 
Drug prevalence in school population 
 
Comparable data from national school surveys conducted between 1992 and 2000, 
show increasing lifetime prevalence in young people (16-20 years) for all common illicit 
substances. According to the most representative studies, the disproportional increase 
of cannabis and ATS deserves particular attention. In relation to younger school 
populations (13-14 and 15-16 years), one observes a similar trend, particularly visible 
when it comes to lifetime prevalence of cannabis use. The use of opiates by school-
aged youngsters shows a low prevalence having progressed weakly within the 
considered period. 
 
National prevalence of problem drug use (PDU) 
Data on institutional contacts and  
drug treatment demands 
 
The number of problem PDUs indexed by national institutions in 2006 figures 4,571 
(2002: 4,701) (in this figure double counting is included meaning that a given person 
could have been indexed twice and more by different institutions. It is thus not 
representing the actual prevalence, which has to be assessed by other methods). For 
comparison, 2,383 users have been indexed by national specialised drug demand 
reduction agencies and 2,318 drug law offenders by supply reduction agencies in 2002. 
In 2006 the same agencies have indexed 2,755 and 1,816 persons respectively. As the 
frequency of multiple contacts did not change over recent years, these figures suggest 
that in total and since 2002 fewer people have come in contact with drug agencies and 
even more positive is the fact that an increasing proportion of PDUs seek contact with 
treatment services and less show contacts with law enforcement agencies. 
 
10% (5%) of respondents are first treatment demanders, all treatment centres included. 
More recently, one has observed a stabilization of treatment demands in outpatient drug 
agencies and inpatient therapeutic centres whereas detoxification demands and 
contacts with low threshold drug agencies are clearly increasing. 
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Socio-demographic profiles of PDUs 
 
The male/female ratio of the PDU population is 3:1. The last ten years the proportion of 
indexed non-native PDUs has shown strong variations but a clearly increasing tendency 
since 2003. The population of non-natives drug users largely consists of Portuguese 
nationals, a proportion constantly increasing until 2004. Although the proportion 
stabilised since then, it is still consistently higher than the one observed in general 
population. Notably, one observes a remarkable increase of PDUs of French origin 
(22%). This trend is confirmed by last 6-years data on drug law offenders. 
 
The mean age of indexed PDUs evolved from 28 years and 4 months in 1995 to 30 
years and 11 months in 2006. The gap between youngest and oldest PDUs continues to 
grow, notably by the increase of PDUs aged 40 and more. One observes an average 
aging of the population of long-term drug injectors and a sensitive decrease in age 
referred to “new” PDUs. Worth mentioning also the significant increase of the average 
age of overdose victims and an important but currently decreasing proportion of minors 
among drug law offenders. For the first time since reliable data are available rates of 
first cannabis use, in 11-13 years old youngsters are over 35%. Respectively 88% and 
43% of current PDUs have tried cannabis and heroin (i.v.) while being minor of age. In 
1995 the same proportions figured 71% and 23%. Most interestingly, evolution of drug 
use patterns tend to accelerate in terms of shorter time spans separating first non-iv use 
from first iv-use. This acceleration is also observed as far as first treatment demands are 
concerned. PDUs tend to contact drug treatment facilities at an earlier stage, which may 
be due to a more diversified offer currently available. 
 
The residential status of indexed respondents has improved over the last years. In 
1995, 31% of the users were disposing of a stable accommodation; in 2006 the same 
proportion figures 76%. This improvement is partly due to various accommodation and 
housing projects for addicted people set up in the framework of the drug action plan. An 
increasing number of PDU report to live alone. This evolution should be paid particular 
attention to since it increases overdose and other health-related risks.    
 
All indicators included, employment status of PDUs did not improve over the last years. 
After a high level stabilisation (46-50%) during the past 5 years, the unemployment rate 
is still significantly high, and settled at 67% in 2006. 
 
Problem drug use prevalence and consume trends 
 
The first national multi-methods PDUs prevalence study, published in 2001 (Origer 
2001), provides a prevalence rate of 8.42 per thousand inhabitants aged 15-64 (absolute 
figure 2,450 PDUs). According to indirect follow-up indicators (Origer, 2005), prevalence 
figures applied to the national population aged 15-64 currently situate between 2,500 
and 2,800 PDUs.  
 
Intravenous heroin use associated to poly-drug use has been reported as the most 
common consume pattern in PDUs. As already reported, the switch to intravenous drug 
use occurs earlier. The ratio of intravenous opiates consume to the inhalation mode has 
stabilised at 2:1. The prevalence of the use of cocaine as primary drug continues to 
increase, which is partly due to increased availability on the national market. 
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The number of persons in contact with the national specialised network for (preferential) 
cannabis use had known a sensitive increase the last three years but decreased again 
in 2004 and stabilised in 2005-2006. Amphetamine like substances and ecstasy are 
only weakly represented, which, however, does not inform about prevalence in general 
population as RELIS data refer to PDUs and not to the overall population of recreational 
drug users.  
 
The proportion of poly drug use (88% in 2006) is stable after a record level of 92% in 
2004. The average ages at first time consumption of a preferred drug and illicit drugs 
in general, show a slow but continuous decrease for the last 8 years. In 2006, age of first 
use of cocaine (iv/non-v) and heroin (non-iv) stabilised, contrarily to average ages of first 
intravenous heroin use and even more significantly the average age at first cannabis use 
(almost 1/3 of respondents were not older than 13 at the moment of first cannabis use). 
In general, the proportion of PDUs aged more than 39 years and of users less than 19 
years is increasing continuously as well as the gap between these two groups. 
 
Drug-related morbidity and mortality 
 
HBV (hepatitis B) and the HIV/AIDS prevalence among PDUs have not been increasing 
in recent years while the infection of HCV (hepatitis C) showed a clear progression. 
Data from the Laboratory of Retrovirology of the CRP-Santé suggest a long term and 
discontinuous decreasing tendency of average proportion of IVDUs in newly diagnosed 
HIV cases until 2004. HIV infection rates in IVDUs situate around 4 percent and are 
witnessing a currently stable trend. A new study (Origer and Removille, 2007) based on 
serological testing, confirmed a significant increase in HCV prevalence in PDUs and 
IVDUs during recent years, especially in prison settings. 
 
The implementation of the 2000-2004 and 2005-2009 action plans has been 
accompanied by a significant decrease of overdose cases in the Grand-Duchy of 
Luxembourg (2005: 8 cases). This decrease is mainly observed for male victims, the 
number of female overdose victims has remained stable for the last 5 years. Expressed 
in the number of overdose cases in the general population of the Grand-Duchy of 
Luxembourg, this proportion figured 1.76 overdose deaths per 100,000 inhabitants in 
2005 (2000: 5.9 cases per 100,000 inhabitants). In 2006, 4.13 overdose deaths per 
100.000 inhabitants have been registered, thus showing a new increase likely to be 
confirmed by 2007 figures. An expert working group currently analyses possible reasons 
for this evolution such as high purity variation of street drugs currently on the market and 
generalized polydrug use including a series of pharmaceutics with potentially dangerous 
interactions patterns with illegal drugs. Forensic data from 1992 to 2006 show that the 
most frequently involved substance in drug-related death is heroin, followed by 
methadone and cocaine. Since 2000, methadone traces in blood samples of overdose 
victims have been increasingly detected. 
 
The vast majority of victims are male (83%) and their mean age at the moment of death 
has been showing an important increase over the past 10 years (in 1992: 28.4 years and 
in 2006: 32.5 years). The number of victims aged less than 20 years remained relatively 
unchanged during observation period. A confirmed majority of acute drug death victims 
are known by law enforcement agencies for their drug user “career”, which average 
durations of 10 years. Worth mentioning also that more than 80% of the known victims 
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followed at least one treatment before their death and half of the latter had an 
accommodation that could be qualified as stable. 
A confirmed majority of drug-related victims are natives. During the entire observation 
period Portuguese citizens stand in second place, followed by Italian and French 
natives. Recently, one could observe an increasing number of victims from border 
countries (BE, DE, F) and a decreasing number of victims of Portuguese origin. 
 
In 2006, 19 indirect drug death cases have been indexed. Main causes of indirect 
deaths between 1996 and 2006 are, in order of importance: suicide, traffic accidents, 
undefined intoxication, associated cardio-vascular or pulmonary complications, drug 
(pharmaceutics) addiction, liver failure and immune deficiency diseases.  
 
The overall number of indexed direct and indirect drug death cases informs about drug-
related mortality. Drug-related mortality prevalence has been showing small variations 
between 1996 and 2005 figuring roughly 26 to 33 cases per year. In 2006, 38 drug-
related deaths have been reported (19 direct and 19 indirect drug related death cases).   
 
 
Law enforcement indicators1 
 
Seizures of illicit substances at the national level 
 
Striking variations have been observed as to the quantity of illicit substances seized 
since the beginning of the nineties. A longitudinal data analysis indicates a general 
decreasing tendency of heroin, cocaine and cannabis seizures until 20022. Since 2002 
however, one observes a significant increase in the quantity of drug seizures mainly 
concerning heroin and herbal cannabis. Cocaine seizures (quantity) are highly variable 
since the beginning of the nineties. 
 
Seizures of all substances have increased in terms of quantity compared to 2005 
although the number of seizures is stable and the number of offenders involved in 
seizures has been showing an overall decreasing trend. This may suggest that greater 
quantities of drugs are trafficked by smaller groups of traffickers. A confirmed majority of 
offenders are involved in cannabis traffic and are non-natives.  
  
The first national seizures of ecstasy type substances (MDMA, MDA, etc.) were 
recorded in 1994. The availability of ecstasy appeared to soar between 1994 and 1996 
however stabilization at low level occurred the last ten years. 
  
Drug law offenders and prison sentences 
 
The number of police records for presumed offences against the modified drug law of 
1973 went from 764 1995 to 1,200 in 2006. A similar evolution has been observed with 
regard to the number of drug law offenders. In 2006, 225 (155 in 2005) arrests for 
presumed offences against the modified 1973 drug law have been reported. However, in 
recent years, the number of police records, the number of drug law offenders and the 
number of persons arrested on the same charge have stabilised or even decreased in 
recent years. 
 
88% of drug law offenders are male, a proportion which has been varying between 79% 
and 90% during the last ten years. Since 1998, the proportion of non-native drug law 
                                                                  
1  If not specified, data refer to 2006. Figures between brackets refer to 2005 if not specified. 
2  Non–transit drugs destined to the national market  
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offenders went from 50% to 66% (68%). In 2006, 30% of the registered cases are first 
drug law offenders (lowest level since 1998); the percentage of minors in drug law 
offenders has increased from 5.4% in 1993 to 13.8% in 2003 and decreased again to 
6.7% in 2006. National prison data of 2006 refer to 1,043 (1,341) new admissions of 
which 243 (23.3%) were related to drug law offences; a proportion having represented 
42.6% in 1996.  
 
 
Profile of the national drug market 
 
According to observational data provided the Judicial Police an all decentralised national 
police units, a majority of illicit drugs consumed in the Grand Duchy of Luxembourg 
originate from the Netherlands, followed by Belgium and Morocco. Heroin consumed in 
Luxembourg originate primarily from Afghanistan, Laos and Myanmar. Cocaine 
distributed on the national illegal market originates mainly from Brazil and ATS like 
substances mostly come from the Netherlands followed by Poland and the Czech 
Republic. The road network is still the main transport and transit route of drugs destined 
to the national market.  
 
For several years, expansion of more structured distribution networks by organized 
criminal associations has been reported. The national market increasingly attracts “drug 
professionals” aiming to set up a purely commercial distribution network. The proportion 
of non-natives involved in drug trafficking has been increasing over the last four years 
and may be stabilising according to 2006 data. Asylum demanders implicated in illicit 
cocaine trafficking mainly originate from West African countries, particularly the Ivory 
Cost. Currently also Albanian citizens are of particular concern to law enforcement 
authorities. In regard to heroin trafficking, no predominant profile of nationality has been 
reported. A large number of drug traffickers come from North Africa by transiting through 
Belgium. Numerous traffickers have changed from heroin to cocaine traffic and currently 
are also involved in cannabis traffic. Given the geographical position of Luxembourg, the 
national police forces closely cooperate with border countries and the Netherlands and 
do participate in large scale joint operations in the framework of international policy 
cooperation agreements aiming at the setup of a surveillance and intervention 
mechanism to fight illicit drug traffic originating from the Netherlands and drug trafficking 
and consumption at the regional level  
 
Overall, the national drug market has become of a more aggressive nature in terms 
of selling techniques. Dealers increasingly tend to actively approach confirmed or 
potential clients. 
 
Compared to the situation in 2003, purity of all reported substances are lower in 2006 
except for cocaine that is showing a fairly stable quality during the same period. 
Attention has to be paid to the striking differences in maximum and minimum purities as 
well as to a historically high maximum concentration of THC (over 25%) in cannabis 
samples seized in Luxembourg in 2006. Prices show broad ranges for heroin and 
cocaine, and a still ongoing decrease for ecstasy like products. Cannabis and derivates 
however have known certain stability during the last 5 years as far as street prices are 
concerned.  
 
Since 2003 no new clandestine drug laboratory has been dismantled thus far. Local 
cultures of cannabis and magic mushrooms are rather insignificant in terms of quantity 
and quality. The perceived illicit drug availability in general population is high and follows 
a weakly increasing trend according to recent surveys. 
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Harm reduction activities 
 
The number of sterilised syringes (2006: 332,347/ 1996: 76,259) distributed in the 
framework of the national needle exchange program has been constantly rising from the 
start of the latter until 2005. The same trend is observed with regard to the number of 
used syringes collected [2006: 282,909 (85%)/ 1996: 28,646 (38%)]. An increasing 
majority of injectors (35%) procure their syringes in specialised agencies followed by 
pharmacies and automatic dispensers. The number of contacts registered by low 
threshold structures has increased dramatically over the last 8 years and literally 
exploded from 2004 onwards (2006: 63,129 / 2005: 47,730/ 1996: 6,456). The number of 
syringes distributed by the same agencies has been following a similar evolution 
although stabilising for the first time in 2005 and even decreasing in 2006.  
 
The number of clients of the national methadone substitution programme went from 
30 in 1993 to 105 in 2006 (decreasing since 1998). In addition to the methadone 
substitution programme financed by the Ministry of Health, PDUs also address 
substitution treatment demands to licensed GPs. Data delivered by the Union of Health 
Insurance Founds refer to 939 different patients who did receive substitution treatment in 
2006 (2002: 889 patients) by means of the prescription of methadone or buprenorphine 
containing medicaments by 121 prescribing GPs (1999: 125). 
 
 
Most Relevant Trends 
 
All indicators included an overall stabilization of PDU prevalence has been observed 
from 2004 onwards. However, quality of street drugs went down, which had as a 
consequence a fairly spectacular increase in syringes distributed (with low quality drugs 
more injections are necessary to reach the same effect) and the overall spread of 
polydrug use. The number of drug-related deaths has been decreasing significantly with 
the implementation of the national drug action plans. The recent increase of overdose 
cases is thought to be associated to changing consume patterns and high variations of 
purity of street drugs and not to an increasing overall PDU prevalence. There is a great 
concern about infectious diseases in drug users and in particularly IVDUs. HIV is low 
and stable; however, hepatitis C in PDUs has been increasing continuously. Latest 
research results based on serological testing (Origer & Removille, 2007) suggest HCV 
infection rates over 70% and even higher prevalence rates in prison populations. 
 
The most relevant developments at the response side result from the implementation of 
the national drug strategy and its associated action plans. Over the last years 
counselling and specialized care networks have been developed, which had as a 
positive and proven consequence that PDUs start treatment at an early stage of their 
drug career. Coordination mechanisms have been reinforced between NGOs and 
national authorities. Drug action plans have allowed disposing of financial means that 
have known a disproportional increase compared to the time preceding drug action 
plans. If primary prevention is considered most important, there have been visible 
improvements in early intervention measures. Major efforts have also been made in the 
diversification of care offers and finally harm reduction measures have been significantly 
developed. Housing offers and reintegration programmes have obviously contributed to 
improve socio-professional situations as document by latest RELIS data. Substitution 
treatment, special care and low threshold offers have been decentralised and continue 
to be so. 
 12
 
 
Consistency between Indicators 
 
Demand reduction indicators are highly consistent with supply reduction data (see fig. 
4.2). Both indicators are suggesting a stabilisation of problematic drug use at the 
national level. Interestingly harm reduction activity indicators are witnessing an inverse 
evolution if compared to DR an SR data. For instance the number of distributed syringes 
has been increasing until 2004 and the number of contacts registered in low threshold 
agencies also went up consistently. Possible explanations of this evolution are the 
decrease in street drugs’ quality inducing more frequent injections and an important 
increase and diversification of low threshold offers during the same period. Thus, the 
latter trends are not in contradiction with a confirmed general stabilisation of PDU 
prevalence. 
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Part A: New Developments and Trends 
 
 
1. National Policies and Context 
 
 
Overview 
 
Drug use is defined as behavioural pattern potentially associated to health and social 
damage. Consequently national drug policies are based on shared political 
competencies and responsibilities. Furthermore, in terms of intervention strategies, the 
more holistic concept of addictive behaviour is gaining in importance and influences 
increasingly policy debates. 
 
National parliamentary elections of June 2004 have resulted in a new coalition 
government of social democrats (CSV) and socialists (LSAP). Competencies and 
ministerial attributions in the drugs field have not been modified. The governmental 
declaration of 20043, and the subsequent coalition agreements, emphasised the need of 
further development and diversification of specialised health care, an adapted approach 
towards law enforcement by means of legislative amendments and the promotion of 
harm reduction measures, were appropriate.   
 
In June 2005, the Minister of Health presented the new drug strategy and action plan 
2005 – 2009, elaborated by the National Drug Coordinator who was also appointed chair 
of the Interministerial Committee on Drugs (ICD) by the Minister of Health in 2006. The 
referred action plan is based on the evaluation outcome of the previous action plan and 
the assessment of current and future needs. One of the first achievements of the new 
drugs action plan is the implementation of the first national drug consumption room in 
Luxembourg City (July 2005). A mid-term evaluation of the state of implementation of the 
2005-2009 drugs action plan will be published by the end of 2007. 
 
• LEGAL FRAMEWORK (NNIA) 
 
o Laws (2000-2007) 
 
The basic national drug law, namely: ‘Loi concernant la vente de substances 
médicamenteuses et la lutte contre la toxicomanie4’ regulates both, the selling of 
controlled medicaments and the fight against drug addiction and dates back to the 19 
February 1973. It has been last amended by the law of 8 August 2000. 
 
- law of 27 April 20015 modifying the basic drug law of 19 February 1973. Besides the 
decriminalisation of cannabis use, alleviation of penalties for simple drug use, and an 
enhanced overall differentiation of penalties according to the type of drug offences and 
the nature of controlled substances involved, the law of 27 April 2001 foresees a legal 
framework for a series of harm reduction and maintenance measures, namely, drug 
substitution treatment, needle exchange and other state accredited means, which, in 
addition to article 13 of the grand ducal decree of 30 January 2002 (see below) could 
materialise in shooting galleries or medically controlled heroin distribution programmes.  
                                                                  
3 Governmental Declaration of 2004, http://www.gouvernement.lu/salle_presse/actualite/2004/08/04declaration/index.html 
4 Official gazette A 1973, p.319  
5 Official gazette A 2001, p.1180 (Adoption: 27/04/2001, Entry in force: 17/05/2001) 
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- law of 14 June 20016 endorses the Convention on Laundering, Search, Seizure and 
Confiscation of the proceeds from crime of the Council of Europe (Strasbourg 8 
November 1990) introducing amendments to the criminal code and the basic modified 
drug law from 19 February 1973. 
 
- law of 11 August 20067 on the fight against tobacco regulates advertising of tobacco 
and related products, the prohibition of smoking in certain areas and the prohibition of 
sale of oral tobacco.  Main legal amendments concern an increase of the number of 
smoke free public areas, a prohibition of smoking in catering establishments, a general 
prohibition of advertising, the prohibition of tobacco sale to minors under 16 and the 
prohibition of import and sale of tobacco in forms of candy or toys. The prohibition of 
smoking in spaces where food is served can be compassed by the implementation of 
separate smoking rooms, not exceeding 25 % of the total area, with specifically installed 
smoke extraction systems. Access is denied to youngsters aged less than 16 years. 
Pubs and bars are only concerned during core hours as far as they serve meals. 
Hospitals are allowed to install one smoking room exclusively reserved to patients. 
 
Fines in relation to offences in regard to publicity, sale and import of oral tobacco and 
tobacco-like toys and candies range from 25 to 50,000 euros. Fines related to smoking 
in prohibited areas vary from 25 to 250 Euros for clients and up to 1,000 euros for the 
operator or manager of the venue. Sanctions for selling tobacco to minors lie between 
251 to 1,000 euros. Legal amendments also concern the modified law of 17 June 1994 
on security and health at workplace, the modified law of 16 April 1979 on general status 
of state civil servants and the modified law of 24 December 1985 on general status of 
communal civil servants. These amendments concern the protection of non-smokers at 
the workplace which underlies the responsibility of the employer. Due to the extend of 
modifications, the modified law of 24 March 1989 has been abrogated.  
 
- law of 18 September 20078 lowers the alcohol concentration tolerance level from 
0.8‰ to 0.5‰ and the introduction of a level below 0.2‰ for specific categories of 
drivers (young drivers and professional drivers). Fines are applied and driving 
licence “points” are subtracted if alcohol level is equal or superior to 0.5‰, respectively 
0.2 ‰. An immediate driving license withdrawal will be applied for 8 working days: 
- in case of an alcohol level equal or superior to 1,2‰ 
- in case of refusal to submit oneself to an alcohol or drug test, 
- in case of exceeding the speed limit of 50% of the authorised maximum 
speed, the excess being of at least 40km/h. 
 
It also provides a legal framework to roadside (illegal) drug testing by means of rapid 
tests (Drugwipe II). Tolerance levels according to types of drugs are as following: 
 
THC: 2ng/ml      ATS: 50ng/ml     Cocaine: 50ng/ml      Opiates: 20ng/ml 
 
o Grand Ducal Decrees (2004/2007) 
 
-  The grand ducal decree of 16 March 20069 defines maximum prescription 
periods for methylphenidate, oral morphine, transdermic fentanyl, buprenorphine, 
hydromorphone and methadone. 
                                                                  
6 Official gazette A 2001, p.1708, (Adoption: 14/06/2001, Entry in force: 17/06/2001) 
7 Official gazette A 2006, p.2265, (Adoption: 13/07/2006, Entry in force: 05/09/2006) 
8 Official gazette A 2007, p.33475, (Adoption: 18/09/2007, Entry in force: 01/10/2007) 
9 Official gazette A 2006, p.1156, (Adoption: 16/03/2006, Entry in force: 31/03/2006) 
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-  The grand ducal decree of 18 January 200510 establishes the model of 
prescription forms of narcotic based pharmaceutics. The referred prescription form 
contains 2 separate annexes. The first to be used in case of substitution treatment and 
the second to be completed in case of other types of medical treatments. 
 
-  The grand ducal decree of 7 October 200411 modifies the national list of 
controlled psychotropic substances. 
The following substances complete annex A: 
2C-I (2,5-diméthoxy-4-iodophénéthylamine) 
2C-T-2 (2,5-diméthoxy-4-éthylthiophénéthylamine) 
2C-T-7 (2,5-diméthoxy-4-(n)-prophylthiophénéthylamine) 
TMA-2 (2,4,5-triméthoxyamphétamine) 
Annex B includes GHB, “acide gamma-hydroxybutyrique” in the list of nationally 
controlled substances. 
 
-  The grand ducal decree of 30 January 200412 modifies the substance lists 
annexed to the grand ducal decree of 2 February 1995. (List cf. footnote.) 
 
As regards regulation mechanisms on the control of substances and precursors, 
the national drug legislation relies on the following Grand ducal decrees, amended (text 
or annexes) according to decisions on new substances’ inscription into national law: 
 
-      Grand ducal decree of 4 March 1974 regarding certain toxic substances 
- Grand ducal decree of 20 March 1974 regarding certain psychotropic substances 
- Grand ducal decree of 26 March 1974 establishing the list of controlled narcotics 
- Grand ducal decree of 8 May 1993 regarding commerce of narcotics and psychotropic substances 
- Grand ducal decree of 2 February 1995 regarding the production and distribution of certain substances 
used in the illicit production of narcotics and psychotropic substances 
- Grand ducal decree of 6 February 1997 regarding substances listed in schedules III and IV of the UN 
Convention on psychotropic substances of 21 February 1971. 
- Grand ducal decree of 30 January 2004 modifying the grand ducal decree of 2 February 199513 
- Grand ducal decree of 13 February 2007 on the surveillance and commerce of drug  precursors14 
 
The full text of the current basic national drug law as well as recent decrees can be 
accessed trough the following web sites: http://www.legilux.public.lu or 
http://eldd.emcdda.europa.eu. 
 
                                                                  
10Official gazette A 2005, (Adoption: 18/01/2005, Entry in force: 14/02/2005) Règlement grand-ducal du 18 janvier 2005 
déterminant le modèle du carnet à souches prévu à l’article 30-1 de la loi modifiée du 19 février 1973 concernant la vente 
de substances médicamenteuses et la lutte contre la toxicomanie.  
http://www.legilux.public.lu/leg/a/archives/2005/0211402/0211402.pdf?SID=cac954462991e49701fd54f107a49282#page=
5 
11 Official gazette A 2004, (Adoption: 07/10/2004, Entry in force: 21/10/2004) Règlement grand-ducal du 7 octobre 2004 
modifiant le règlement grand-ducal modifié du 20 mars 1974 concernant certaines substances psychotropes ainsi que le 
règlement grand-ducal modifié du 6 février 1997 relatif aux substances visées aux tableaux III et IV de la Convention sur 
les substances psychotropes, faite à Vienne, le 21 février 1971. 
http://www.legilux.public.lu/leg/a/search/resultHighlight/index.php?linkId=4&SID=e598ed3498d37aa98708757b0b038d49 
12 Official gazette A 2004, (Adoption: 30/01/2004, Entry in force: 13/02/2004) 
Règlement grand-ducal du 30 janvier 2004 modifiant le règlement grand-ducal modifié du 2 février 1995 relatif à la 
fabrication et à la mise sur le marché de certaines substances utilisées pour la fabrication illicite de stupéfiants et de 
substances psychotropes. 
http://www.legilux.public.lu/leg/a/search/resultHighlight/index.php?linkId=1&SID=e0622007c5892b499e6269171b466eaf 
13 Official gazette A 2004, (Adoption: 13/02/2007, Entry in force: 22/02/2007) 
Règlement grand-ducal du 13 février 2007 relatif à la surveillance du commerce des précurseurs de drogues […]. 
14 Official gazette A 2007, (Adoption: 30/01/2004, Entry in force: 13/02/2004) 
Règlement grand-ducal du 30 janvier 2004 modifiant le règlement grand-ducal modifié du 2 février 1995 relatif à la 
fabrication et à la mise sur le marché de certaines substances utilisées pour la fabrication illicite de stupéfiants et de 
substances psychotropes. 
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o Projects and propositions of law 
 
As far as previous propositions of law are concerned, the “Proposition of establishing a 
prescription programme for cannabinoids-based medicaments”, deposited in 2004, has 
been disapproved by the State Council in its statement of 26/10/2004 (Doc. Parl.5020). 
 
Project of law of 16 July 2004 modifying the modified law of 14 February 1955 
concerning public traffic regimentation15 (Doc.Parl. 5366). The project of law foresees 
among other measures in the framework of traffic security, the implementation of rapid 
onsite drug tests. (see selected topics 2006: Drugs and Driving) 
 
Project of law of 31 January 2006 concerning the fight against tobacco (Doc. Parl. 5533). 
 
Project of law of 14 February 2006 prohibiting the sale of alcoholic drinks to minors aged 
less than 16 years (Doc. Parl. 5543). Prohibition of sale of alcoholic drinks to minors 
aged less than 16 years is extended to all forms of commerce, as supermarkets and 
petrol stations. Meanwhile the referred law has been voted. 
 
o Laws implementation 
 
Legally speaking, police has no discretional power: every offence, once ascertained, 
must be reported. However, depending on the case, (e.g. first ‘interpellation’ for 
cannabis use) it may occur that no further action is taken. Once a drug law offence case 
has been reported to the Public Prosecutor, the latter decides on the opportunity to 
prosecute or not. The legal concept of ‘prosecution opportunity’ may be applied, which 
implies a case-by-case decision. 
 
The law of 27 April 200116 modifying the basic drug law of 19 February 1973 by 
decriminalising cannabis use, and enhancing the differentiation of penalties according to 
the type of drug offences and the nature of controlled substances involved and the 
grand ducal decree of 30 January 200217 on substitution treatment, have largely 
contributed to increase the congruity between drug legislations and prosecution routines. 
Also, current drug legislation and prosecution policies put higher priority on drug dealing 
and trafficking than on drug consumption and promote harm and risk reduction 
measures.                                                                               
 
• INSTITUTIONAL FRAMEWORK, STRATEGIES AND POLICIES (NNIA) 
 
o Coordination arrangements  
 
Following the 1999 parliamentary elections, the coordination of drug demand reduction, 
risk reduction and research has been transferred to the Ministry of Health. In November 
2000 a National Drug Coordinator was appointed by the Minister of Health. He is in 
charge of the overall co-ordination in the domains of drug-related demand and harm 
reduction and represents Luxembourg at the international level. However, supply 
reduction and international cooperation aspects remain a competence of the Ministry of 
Justice and the Ministry of Foreign Affairs respectively.  
 
                                                                  
15 Loi modifiée du 14 février 1955 concernant la réglementation de la circulation sur toutes les voies publiques. (Entry in 
force: 07/03/1955) 
16 Official gazette A 2001, p.1180 (Adoption: 27/04/2001, Entry in force: 17/05/2001) 
17 Official gazette A 2002, p.232 (Adoption: 30/01/2002, Entry in force: 12/02/2002) 
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At the national level, the co-ordination among the competent ministries takes place in the 
Inter-ministerial Commission on Drugs (ICD). In 2006, the national drugs coordinator has 
been appointed chair of the ICD by the Minister of Health. The ICD is composed of 
senior delegates from the main governmental departments and delegates from selected 
NGO’s and constitutes the top decision level with respect to co-ordination and 
orientation of actions. Both, the ICD and the Ministry of Health are responsible for the 
implementation of national drugs strategies and action plans, supervise field activities 
and are bound to guarantee an effective consultation process with other involved 
ministries (e.g. Justice, Foreign Affairs). The ICD meets 4 to 6 times yearly. There are 
four permanent agenda items: the implementation of action plans, the early warning 
system on drugs, emerging trends and legal changes and international affairs. 
Outcomes of the ICD meeting are transmitted to all competent ministers and national 
media in order to ensure complete public visibility. 
 
The more technical co-ordination between the Ministry of Health, the Ministry of Justice 
and the Ministry of National Education respectively occurs through the ‘HEALTH – 
JUSTICE’ and the ‘HEALTH – EDUCATION’ ministerial groups.  
 
At the governmental level, there exists a Special Parliamentary Commission on Drugs as 
an advisory body to the government.  
 
A close link between the EMCDDA national focal point and the policy level is ensured by 
the fact that the head of focal point has been appointed National Drug Co-ordinator. The 
national Drug coordinator is also the head of the national delegation within the Horizontal 
Drugs Group and the national permanent correspondent within the Pompidou Group. 
Furthermore, he is a member of the national substitution treatment surveillance 
commission and the national AIDS surveillance commission. 
 
At the micro-level the drug coordinator meets monthly with conventioned NGOs 
(collaboration platforms) in order to share information and elaborated responses to 
emerging trends. A new forum called ‘COCSIT’ has been created by the specialised 
drug agencies with the objective to follow up drug trends and to advice national 
authorities. The national drug coordinator is regularly invited by COCSIT and participates 
actively in its work.  
 
o National plan and/or strategies 
 
The national drugs strategy and action plan 2005-2009 has been endorsed by the State 
Council in May 2005 and officially presented by the Minister of Health and the national 
drug coordinator in July 2005. 
 
Having taken into consideration the EU drugs strategy 2005-2012 and the EU drugs 
action plan 2005-2008, endorsed under Luxembourg Presidency in June 2005, the 
national strategy and drugs action plan are meant to contribute to a high level of health 
protection, public security and social cohesion and rely on two policy pillars, namely 
supply reduction and demand reduction.  
 
Furthermore the national action plan includes, in addition to international cooperation 
and research, information, evaluation (retained by the EU action plan), two more cross-
cutting themes: coordination and harm, risk and nuisance reduction. Luxembourg 
considers the latter two activity fields to be essential and of transversal nature. 
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The national plan contains 43 separate actions associated to a clear definition of tasks, 
involved management actors, financial requirements and deadlines. The action plan 
reflects priorities set by the government: primary prevention (4 projects), treatment and 
care (6), socio-professional reintegration (5), reduction of risks and damages (5), 
research, evaluation and information (8), supply reduction (7), coordination and 
international relations (8). Special focus is placed on primary prevention (considered as 
crucial), offers of accommodation and housing, socio-professional reinsertion measures 
and therapeutic offers.  
 
A mid-term evaluation of the state of implementation of the 2005-2009 drugs action plan 
will be published by the end of 2007. A final external output evaluation will be 
undertaken in the course of 2009. 
 
o Implementation of policies and strategies 
 
The outcome of a national drugs action plan highly relies on the way it has been 
elaborated. The successive action plans reflect the general strategy of the Ministry of 
Health in order to optimize the overall interventions in the fight against drugs and drug 
addiction in the light of stated priorities, assessed needs and available resources. It 
constitutes an open framework meaning that complementary projects can be included if 
required. In 2004, in order to best meet current needs in the elaboration of the 2005-
2009 action plan, the national drug coordinator has launched a second multilateral 
consultation process involving ministerial departments, specialised NGOs and civil 
society. The priorities set by the Ministry of Health were discussed and, if necessary, 
complementary measures were added. A consensus on priority rankings of listed actions 
has been reached among involved parties. Finally all retained actions were structured in 
a clear, simple and output oriented way as follows: ‘1. Description/objective of action – 2. 
Responsibilities – 3. Budget – 4.Outcome – 5. Deadlines for outcome and evaluation’. 
 
The active involvement of specialised NGOs and civil society from the very start of the 
conceptualisation work and consensus making prior to the implementation phase have 
shown to be a major criteria to guarantee an effective implementation process. Indeed 
87% of the measures retained by the 2000-2004 national drugs action plan have been 
materialised within the retained deadlines. The measures not yet implemented (e.g. 
heroin distribution programme) have been delayed not for technical, budgetary or 
administrative reasons but for political ones. These actions have been included in the 
new drugs action plan, and by the time of writing one of the most controversial delayed 
actions has been implemented: the first national drug consumption room. 
 
Summarily one should stress that the multilateral involvement of competent actors and 
the fact that most agencies involved in the implementation process are financed and 
controlled by the centrally coordinating Ministry of Health highly promote the 
effectiveness of the national strategic model. 
 
o Impact of policies and strategies  
 
As the 2000 - 2004 drugs action plan was the first of its kind to be implemented at the 
national level any comparison with previous achievements must be considered with 
care. However, it is a fact that budgetary means and the implementation of new drug-
related facilities and programmes have known an extraordinary increase during the 
referred period. Implementation progress of the drugs action plan have been kept on the 
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political agenda since its start in 2000 and consequently the pressure to perform was 
continuously high. Media also contributed to this enhanced awareness and activity 
boosting, especially since they have been able to identify a central personalised key 
actor in the person of the national drug coordinator. Another positive side effect of the 
drugs action plan is an increased commitment of NGOs and civil society in the drug 
policies as they have been involved since the very beginning of the process. The general 
public has largely welcomed drug action plans since it enables them to follow up public 
efforts to fight a problem that is of great concern for them and to compare announced 
objectives with achieved actions. 
 
As far as the final output is concerned there is no doubt that the national strategy and 
drugs action plan have met specific national needs. An internal evaluation showed that 
nearly all projects retained in the action plan have been realised. Budgetary means 
invested allowed to increase resources in terms of primary prevention, to extend 
admission capacities of low threshold services, to increase the number of post-
therapeutic offers, to regionalize ambulatory treatment offers, to improve technical 
control measures related to substitution treatment, to reduce risks and damages, 
especially related to synthetic drugs and the transmission of certain infectious diseases, 
endemic to the population of PDUs, to reduce considerably the number of drug 
overdoses and finally to promote research activities in the field. 
 
As far as the mid-term evaluation of the 2005-2009 drugs action plan is concerned, first 
results indicated a high progress level in terms of project implementation and increase of 
required resources. 
 
• BUDGET AND PUBLIC EXPENDITURE18  
 
o Law enforcement, social and health care, research, international actions, 
coordination and national strategies 
 
The structure of the national state budget does not allow for a comprehensive drug 
budget allocation analysis since several budgetary subsections include both, drug 
specific and other activities. The same comment applies to the funding of drug treatment 
activities that are ensured by specialised agencies and general health care services and 
to research and training centres. Therefore, in accordance to national needs and the 
work plan of the EMCDDA, a national study on direct economic costs of drug policies 
and interventions has been performed from 1999 to 2002 and refers to data from 1999 
(Origer 2002 b). (Etude du coût économique direct des interventions et de la politique 
publique en matière de drogues et de toxicomanies). The original research report can be 
accessed under:  http://www.relis.lu. In the framework of 2006 EMCDDA contractual 
requirements an update of the Origer 2002 study has been performed and main results 
are produced in the selected issues section. 
As a national study on drug related expenses is highly time and cost intensive, the NFP 
has decided to follow-up the budgetary evolution between two consecutive national 
studies by means of the most representative indicator, which is the annual budget of the 
Ministry of Health allocated to drug-related activities. Figure 1.1 shows the budgetary 
progression since the implementation of the first drugs action plan (2000 - 2004) and 
figure 1.2 summarises the annual progression of budget of the Ministry of Health and 
human resources allocated to drug-related activities to the mid-term evaluation period. 
                                                                  
18 See related chapter in Part B 
 20
 
 
Fig. 1.1 Annual budget of the Ministry of Health allocated to drug-related activities 2000 - 2006 
Year 2000 2001 2002 2003 2004 2005 2006 
Budget (EUR) 2,066,000.- 3,210,000.- 4,294,000.- 4.862,000.- 5,771,000.- 6,196,000.- 6,584,000.- 
Progression rate Reference year 55% 108% 135% 180% 200% 217% 
Source: Projet de loi concernant le budget des recettes et des dépenses de l’Etat pour l’exercice 2006. Volume 1.  
(Ministère des Finances 1999-2006) 
 
 
Fig. 1.2 Annual progression of budget of the Ministry of Health and human resources allocated to drug-related activities 
2004 - 2007  
Budget Year 2004 2005 2006 2007 
Budget (EUR) 5,771,000.- 6,196,000.- 6,584,000.- 6.689.000.- 
Annual progression rate Reference year 7.36% 6.27% 1.59% 
Annual cumulative progression rate Reference year 7.36% 14.09% 15.91% 
Dedicated human resources (Full Time Equivalent) 59.5 63.5 69.25 73.5 
Annual progression rate Reference year 6.72% 9.06% 6.14% 
Annual cumulative progression rate Reference year 6.72% 16.39% 23.53% 
Source: Projet de loi concernant le budget des recettes et des dépenses de l’Etat pour l’exercice 2006/2007. Volume 1.  
(Ministère des Finances 1999-2007) 
 
o Funding arrangements 
 
Funding of drug-related interventions is centralised at state level. There exist no 
specific regional or local funding mechanisms. Few drug prevention activities are 
subsidised by council districts on an ad hoc basis. Respective ministries or 
governmental departments, according to their attributions, are co-ordinating the creation, 
the implementation and the funding of required infrastructures. Governmental 
departments directly rely on the state budget while NGOs involved in drug treatment or 
research activities have either signed a financial and quality control agreement called 
‘convention de collaboration’ with concerned ministries or are financed on basis of 
regular subventions. The convention between the ministries and NGOs entitles the 
former to control the functioning and the financial management of each NGO via a 
governmental delegate within a management committee, called ‘coordination platform’. 
 
The Ministry of Health guaranteed financial and human resources required for the 
implementation of the drugs action plan 2000 - 2004. The funding of the 2005 - 2009 
action plan is subject to annual budgetary decisions. Specific local projects designed by 
non-governmental actors requiring external financial support are generally submitted to 
respective ministries or to other national funding sources (Fund Against Drug Trafficking, 
Foundations, private funds, etc.) or international bodies (EU, EMCDDA, etc.). Proposals 
are analysed and might be supported by short-term state subventions. One may add that 
the EDDRA questionnaire is applied as a standard application form for drug-related 
projects’ funding requests addressed to the Ministry of Health. 
 
• SOCIAL AND CULTURAL CONTEXT 
 
o Public opinions of drug issues (NNIA) 
 
No large-scale national public opinion survey focusing on drugs and drug addiction has 
been conduced thus far. Several surveys however have included items on public 
perceptions on legal and illegal drugs at the local or regional level. Several local or 
community based surveys on public opinions and attitudes towards drugs and drug use 
have been conduced in recent years. Results of these surveys have been produced in 
the 2003 report. 
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o Attitudes to drugs and drug users (NNIA)  
 
Within the scope of the Eurobarometer 57.2, a public opinion poll named “Attitudes and 
opinions of young people in the European Union on drugs19” was carried out in the 15 
Member States between April and June 2002 at the request of the European 
Commission. This survey included a representative sample of the national population 
aged 15 to 24. In Luxembourg this public opinion poll was performed by ILRES in 2002 
in the framework of EUROBAROMETER wave surveys. 
 
In 2004 a Flash Eurobarometer 158 survey “Young people and Drugs” was conducted at 
the request of the European Commission with the objective to study the evolution of the 
attitudes on drugs of the target group. The same questionnaire as for the Eurobarometer 
57.2 survey of 2002 was used and 7,659 young people aged between 15 and 24 were 
interviewed face to face between April and May 2004. In Luxembourg, this survey was 
also performed by ILRES and 571 young people were interviewed (nat. representativity).  
 
Tab. 1.1. Main reasons for trying drugs, stopping use and consequences of drug use (2002/2004) 
QUESTION a. Main reasons for experimenting 
1. Curiosity 2. Peer pressure 3. Thrill seeking 4. Problems at home 5. Expected effects 
 
2002 2004 2002 2004 2002 2004 2002 2004 2002 2004 
LU 58.5 63 44.2 37 17.6 26 45.6 44 26.7 32 
EU 61.3 64 46.4 45 40.7 37 29.7 32 21.5 22 
 QUESTION b. Main reasons why it is hard to stop using drugs 
 1. Dependence 2. Lack of willpower 3. Effects of drugs 4. Peer pressure 5. Loneliness 
LU 66.6 78 44.0 50 45.3 45 24.6 20 21.1 20 
EU 73.9 72 50.5 50 40.5 41 27.4 28 16.2 16 
QUESTION c. Consequences of drug use 
 1. 
Dependence 
2. Problems with the 
law 
3. Mental 
problems 
4. Communicable 
diseases 
5. Relief from pain 
or stress 
LU 52.3 63 32.1 36 33.2 32 32.4 30 26.5 22 
EU 63.0 64 38.3 39 35.4 40 33.7 33 26.4 25 
 
Expected effects and problems at home seem to be major arguments for experimenting 
drugs for youngsters in Luxembourg in 2004. Compared to 2002, the argument of thrill 
seeking has gained more importance even if it is still situated below the European 
average. There is no significant variation in the ranking of the reasons most often 
chosen in 2004 compared to 2002. In 2004, it seems that lesser youngsters rate 
problems with the law, mental problems, communicable diseases and relief from pain or 
stress as a consequence of drug use as the European average. 
 
Tab. 1.2. Perceived dangerousness of different substances (2002/2004) 
Assessment of danger of the three substances:  % of “very dangerous” responses 
1. Heroin 2. Ecstasy 3. Cannabis 
 
2002 2004 2002 2004 2002 2004 
Luxembourg 87.2 87 60.6 63 16.2 19 
EU 88.8 89 63.5 66 20.6 24 
                                                                  
19 EORG (2002). Public opinion regarding attitudes and opinions of young people in the European Union on drugs 
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The percentages of responses among young people in Luxembourg approach the 
ranking of the European average. The population of youngsters in Luxembourg, all 
though presenting a higher risk rating in 2004 compared to 2002, seem to perceive 
cannabis as less dangerous than the European average.  
 
Tab. 1.3  Priorities in management of drug-related problems (2002/2004) 
Most effective methods of management 
1. Measures against dealers 
and traffickers 
2. Treatment and 
rehabilitation 3. Information campaigns  
2002 2004 2002 2004 2002 2004 
Luxembourg 70.2 65 34.2 37 46.4 41 
EU 59.1 60 53.3 53 38.9 42 
 
The opinions from young people in Luxembourg differ from the European average. 
Priority is given to measures of repression against dealers and traffickers. Luxembourg’s 
youngsters quote the effectiveness of information campaigns as second priority, 
reflecting the European average. Treatment and rehabilitation measures are seen as 
lesser effective methods in the management of drug related problems compared with the 
average EU figures.  
 
Other results worth mentioning are that 82% of youngsters in Luxembourg declared 
knowing people who use cannabis (European average: 68%) and 56% declared knowing 
people who use drugs other than cannabis (EU av.:47%). 59% of youngsters declared 
having already been offered cannabis (EU av.:50%). 
 
The public debate on the creation of injection rooms and heroin distribution programmes 
has been highly influenced by the perceived need to reduce nuisance and risks 
associated to iv drug use. Moreover, the fact that a high percentage of the homeless 
people population is composed of drug addicts, public debate tends to assimilate related 
nuisance predominantly to drug addicts although a significant proportion of homeless 
persons are primarily alcohol abusers, youngsters on the run or clandestine people.  
 
The Governmental declaration of 2004 and the subsequent coalition agreements as well 
as the drugs action plan of the Ministry of Health put emphasis on the need to develop 
primary prevention measures, therapeutic treatment offers, post-therapeutic structures 
and socio-professional reinsertion measures.  
 
o Initiatives in Parliament and civil society  
 
In May 2006 the Parliament organized a so called “actuality session” on drugs that put 
special attention to the state of implementation of the EU and the national drugs strategy 
and action plans and activities of the NFP, which witnesses the increasing implication of 
MPs in the follow up of drug policies. 
 
The amendment of the national driving code allows police forces, among other changes, 
to use new drug detection devices for roadside testing. A new anti-tobacco law came 
into force in 2006 that among other measures prohibits smoking in restaurants and the 
selling of cigarettes to minors. Taxes on so-called “alcopops” were also increased 
significantly. The construction project of a permanent building in Luxembourg City 
hosting the TOXIN centre, which includes the national injection room, was subject to 
major discussions between the Ministry of Health, the City of Luxembourg and civil 
society. Although the necessity of such a centre is widely recognized, the location this 
permanent centre should be constructed on is largely controversial. 
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o Media representations  
 
A national and international press review on drugs, jointly compiled by the State’s Press 
Service and the NFP since 1998, allows a close follow-up of the media approach 
towards the drug phenomenon. Most of national media provide objective information 
although a few more socially oriented radio stations and newspapers put further 
emphasis on controversial, yet constructive, analysis of the current situation.  
 
The NFP performed routine analysis of main daily and weekly Luxembourg newspapers 
published between August 2006 and July 2007. The screening revealed that nearly 30% 
of the articles covered themes of supply reduction. They mainly addressed drug traffic, 
drug seizures, arrests and court decisions and addressed the evolution of the drug 
scene in the area of the main railway station of Luxembourg City. Special interest was 
put on the impact of the drug consumption room. The future construction of a permanent 
building (replacing the temporary structure near the central railway station) was 
frequently mentioned in press. Articles covering themes like driving under influence (of 
alcohol, cannabis or other substances) have been largely discussed. The danger of 
designer drinks (alcopops) for youngsters, as well as alcohol abuse, continue to be 
important topics. Articles concerning NGOs mainly referred to annual reports and their 
local activity. Some major weekly newspapers focussed on national drug policies and 
the national drugs action plan. The tendency to refer to a more holistic concept of 
addictions has been observed. Gambling and other addictive behaviours have been 
largely discussed. A number of articles informed about the launch of the EMCDDA 
annual report 2006 as also the launch of the national focal point RELIS 2006 report, 
including main information about the European and national drug situations. The Reitox 
Academy on public expenditures was also an important topic in several local 
newspapers.  
 
Concerning international topics, most interest concerned Afghanistan’s drug situation 
followed by important drug traffic cases and seizures. Citations of international 
organisations involved in drug issues, EU strategy and action plan have been relatively 
rare. One may note that, even though the topics were quite varied, press interest 
focussed predominantly on national topics.   
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2. Drug Use in the General Population and specific sub-groups 
 
 
Overview 
 
Drugs referred to in the present report include narcotic drugs and psychotropic 
substances covered by the international drug control conventions (the Single Convention 
on Narcotic Drugs of 1961, as amended by the 1972 Protocol, the Convention on 
Psychotropic Substances of 1971 and the Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988). Drugs not listed in the latter UN 
conventions are addressed by the present strategy only in the context of their associated 
use to listed drugs. 
 
‘Drug use’ is hereinafter defined as the self-administration of a psychoactive substance, 
that, when ingested, affects mental processes. Psychoactive substances may be of licit 
or illicit production, sale, or use and associated risks may be considered more or less 
important. 
 
Prevalence estimations on drug use in the general population are based on data 
collected in more (e.g. schools) or less (general population: age group 15-64 years) 
targeted and representative samples of the national overall population. According to the 
most recent surveys, cannabis and derivates are by far the most common illicitly used 
psychoactive substances in the national population followed by Amphetamine Type 
Stimulants (ATS). Cannabis use is still increasing and shows the highest prevalence 
regardless considered age categories, whereas the prevalence of other psychoactive 
drugs varies according to age and data collection setting factors. 
‘Hard drugs’ and ecstasy are considered to be the most dangerous substances by 
general public. The hierarchy of perceived risks associated to referred drugs is 
independent of respondents’ age.  
 
• DRUG USE IN THE GENERAL POPULATION (NNIA) 
 
To date, no national, large-scale (representative) general population survey on drug use 
has been conduced. Several community or targeted population surveys however allow 
estimating current prevalence. It should be stressed that a new HBSC study is 
underway. The section on drug use in youngsters will allow to updating a series of 
current data. 
 
A primary prevention pilot project at community level was launched by the CePT in 1995. 
In 2000, 13 council districts participated in this project. In the framework of this project a 
non-representative survey on drug use in general population (reference 1: “Fischer 1999 
study”) was conducted. The survey results currently indicate most valid data in terms of 
non-representative description of drug use in general population.  
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REFERENCE 1. Fischer U. CH. Et Krieger W. (1999) Suchtpräventioun an der Gemeng – Entwicklung, 
Durchführung und Evaluation eines Modells zur gemeindeorientierten Suchtprävention, CePT, Luxembourg. 
EN: Drug prevention at the communal level 
 
 Year of data collection 1998 
 Single/repeated study Single study  
 Context  Drug Prevention – Public Health – Cross sectional 
 Area covered 7 council districts of the Grand Duchy of Luxembourg 
 Age range 12-60 years  
 Data coll. Procedure Anonymous self-administrated questionnaires  
 Sample size 667 valid cases 
Source: Fischer 1999 
 
 
A second survey organized by the CePT was published in 2000 (“Fischer 2000 study”). 
Even if cannabis consumption was the main subject of the study, several other 
substances have been taken into account. The samples have been drawn on the one 
hand from a cinema visitor’s population in Luxembourg City (ref.:2.1) and on the other 
hand from a population of 6 council districts (ref.:2.2). 
 
 
 
 
Fig. 2.1 Lifetime prevalence according to age (valid %)
(Fischer 1999)
0
5
10
15
20
Cannabis 4.5 18.9 15.6 1.4
Ecstasy 0.6 2.5 1.8 0
LSD 0.6 0.6 4.8 0
Cocaine 0 0.6 4.2 0
Heroin 0 0.6 2.4 0
12-16 years 17- 25 years 26 - 40 years 41 - 60 years
 
 
REFERENCE  2.1: Fischer U. CH. (2000) Cannabis in Luxemburg – Eine Analyse der aktuellen Situation, CePT,               
Luxembourg. EN.: Cannabis in Luxembourg 
 Year of data collection 1999 
 Single/repeated study Single study  
 Context  Drug Prevention – Public Health – Cross sectional 
 Area covered Cinemas in Luxembourg-City 
 Age range 15-64 years  
 Data coll. Procedure On-site interviews  
 Sample size 991 valid cases 
 Sampling procedure 
 
 Remark 
Random sampling of cinema customers 
 
Detailed results of both surveys are provided in EMCDDA standard tables 
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Fig. 2.2  Current and lifetime prevalence of cannabis use according to age: Cinema 
sample (valid %)
(Fischer 2000)
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REFERENCE  2.2: Fischer U. CH. (2000) Cannabis in Luxemburg – Eine Analyse der aktuellen Situation, CePT,              
Luxembourg. EN.: Cannabis in Luxembourg 
 Year of data collection 1999 
 Single/repeated study Single study  
 Context  Drug Prevention – Public Health – Cross sectional 
 Area covered 6 district councils 
 Age range 12 to 60 years  
 Data coll. Procedure Mail questionnaire  
 Sample size 486 valid cases 
 Sampling procedure 
 Response rate 
Random sampling  
27.7% 
 
 
Regarding lifetime prevalence, the Fischer 1999 study reveals that youngsters from the 
age group 17 to 25 (18.9 %) are most vulnerable to cannabis consumption. The Fischer 
2000 study even reveals 40.1% of lifetime prevalence concerning cannabis use (cinema 
sample). 
 
Discussions are currently held with the CRP-Santé to collaborate in a general study on 
health behaviour in general population in order to include items on drug use. This study 
may be conduced in 2008. 
 
• DRUG USE IN THE SCHOOL AND YOUTH POPULATION 
 
National school surveys may be divided in two categories. A first category refers 
exclusively to drug prevalence surveys in schools; the second refers to cross-sectional 
surveys combining data collection in school settings and other youth environments.  
Fig. 2.3 Current and lifetime prevalence of cannabis use according to age
Sample: Council districts (valid %)
(Fischer 2000)
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To be stressed that a new HBSC study is underway. The section on drug use in 
youngsters will allow to updating a series of current data. 
 
Surveys: category 1 
REFERENCE 1:  Matheis J. et al. (1995) ‘Schüler an Drogen’, IEES, Luxembourg.    
EN.: Students and Drugs 
Year of data collection 1992 
Single/repeated study Repeated study 1983 – 92 
Context  Public Health 
Area covered Nation wide 
Type of school 5th years of all types of secondary school classes at the national level 
Age range 16-20 years (AGE ENTERING 5TH CLASS) 
Data coll. Procedure Anonymous self-administrated questionnaires in school classes 
Sample size 1,341 
Response rate (M, F, T) 96% 
Matheis and Prussen (1985) have conducted a survey on 1983 data relying on the same 
methodological criteria than the 1995 survey. The referred study will be addressed in the 
comparative analysis part. 
 REFERENCE 2:   
 
Dickes P. et al. (1996), La consommation de drogues légales et illégales des élèves des 
6ième de l’enseignement secondaire et des 8ième de l’enseignement secondaire technique, 
CEPS/INSTEAD. Luxembourg. 
EN.: The use of licit and illicit drugs by students in 6th and 8th classes of national secondary 
schools. 
 Year of data collection 1994 
 Single/repeated study Single study 
 Context  Drug prevention. Commissioned by the National Drug Prevention Centre (CePT) 
 Area covered City of Luxembourg 
 Type of school 6th secondary school level and 8th secondary technical school level 
 Age range 13-16 years 
 Data coll. Procedure Anonymous self-administrated questionnaires in school classes 
 Sample size 650 
 Response rate (M, F, T) 100% 
 
 
 
 
 
 
Fig. 2.4 Lifetime prevalence of drug use according to age (valid %) 
(Matheis, Prussen 1995)
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    Source : Dickes 1996 
 
 REFERENCE 3:  
 
Das Wohlbefinden der Jugend – HBSC Studie (in press), Ministère de l’Education 
Nationale de la Jeunesse et des Sports, Direction de la Santé, Luxembourg.  
EN.: Health and Health Behaviour of Young People 
 
 Year of data collection 1999 
 Single/repeated study Repeated study (intended each 4 years) 
 Context  Health and Health Behaviour among Young People – WHO cross-national study 
 Area covered Nation wide, representative 
 Type of school Secondary schools 
 Age range 12-21 years 
 Data coll. Procedure Anonymous self-administrated questionnaires in school classes 
 Sample size 7,347 
Response rate (M,F,T) 97% 
 
 
The consumption of illegal drugs has clearly increased the last years. A comparison of 
the Matheis 1992 study and the most recent HBSC 2000 study reveal that in 1992, 
18.1% of secondary school students of 5th class in secondary school (16-20 years) 
declared having had contact with illegal drugs. In 2000, this proportion increased to 
41.1%. The HBSC study even reports a proportion of nearly 50% of youngsters aged 18 
having consumed at least once in their life an illegal drug. However, the consumption of 
“hard” drugs is not widespread among youngsters. Approximately 4 to 5% of youngsters 
report consumption of “hard” drugs, mostly due to experimenting, while a lower 
Substance Lifetime prevalence (13-16 years) Current use prevalence (13 – 16 years) 
Cannabis  
Solvents 
Heroin  
Cocaine    
LSD    
4.5% 
3.7% 
5.2% 
1.4% 
1.8% 
2.9% 
2.9% 
0.8% 
1.2% 
1.4% 
Fig. 2.5  Lifetime prevalence according to age (valid %) 
(HBSC 2000)
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Cocaine 1.5 0.8 2.2 1.5 1.6 2.3 2 5.3 9
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LSD 0.4 0.3 1.7 1.3 1.7 1.5 2.7 5.6 8.5
Mushrooms 0.4 0.3 2.3 3.2 4.9 7 7.1 9.9 13.7
12 ans 13 14 15 16 17 18 19 20
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proportion effectively develops a related dependency. Cannabis consumption however 
increased the last years. A major proportion of students (15.1%), not especially 
youngsters from risk groups, reported repeated cannabis consumption over the last 
year. 
 
Surveys: category 2 
 
 
Fig 2.6  Lifetime prevalence of drug use according to age groups 
(valid %)
(Meisch 1998)
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REFERENCE 4 : Meisch, P. (1998), Les drogues de type ecstasy au Grand-duché de Luxembourg, 
CePT, Luxembourg. EN: Ecstasy type drugs in the G. D. of Luxembourg 
 Year of data collection 1997 
 Single/repeated study Single 
 Context Public Health – primary drug prevention 
 Area covered Nation wide 
 Type of school 2nd and 6th years of classical (N: 311) and technical (N: 355) secondary schools 
 Age range 13-22 years (13-14: N347; 15-17: N193; 18-22: N118) 
 Data coll. Procedure Self-administrated questionnaires 
 Sample size 666 
 Sampling frame Schools participating in the “European ‘Health-Schools’ network 
 Response rate (M,F,T) 100% 
 REFERENCE 5: Fischer U. CH. (2000), Cannabis – Eine Analyse der aktuellen Situation, CePT, 
Luxembourg. EN.: Cannabis – Rapid assessment of the current national situation. 
 Year of data collection 1999 
 Single/repeated study Single 
 Context Cannabis prevalence  
 Area covered Nation wide 
 Type of school 2nd and 6th years of secondary schools 
 Age range 13-20 years 
 Data coll. Procedure Self-administrated questionnaires 
 Sample size 562 
 Sampling frame Schools selected on basis of their geographical situation (national representativity), 
exhaustive student sampling within the selected schools. 
 Response rate (M, F, T) 100% 
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SYNOPSIS OF MAIN COMPARABLE RESULTS AND OBSERVED TRENDS 
 
LIFETIME PREVALENCE: SCHOOL POPULATION: 
 
Prevalence figures for age group 12-20, provided by HBSC (2000) and Fischer (1999) 
vary between narrow limits and stress increasing lifetime prevalence rates for cannabis, 
psilocybin and amphetamines/ecstasy, in accordance to results of previous surveys. The 
most relevant differences according to gender are lower prevalence figures for females 
with regard to cannabis, amphetamines and magic mushrooms use but a higher 
prevalence of medicament use.  
 
The HBSC study (2000), the Fischer study (2000) and the serial surveys by Matheis 
(1985/95) provide trends in lifetime prevalence between 1983 and 1999 applied to age 
group 16-20. Cannabis use has shown the most significant increase during the referred 
period. Also on the increase in order of importance are magic mushrooms, ecstasy, 
cocaine and heroin. LSD and solvents use shows stable figures since 1992. 
 
Regarding age group 13-14, one should emphasise the increase of cannabis (9.7 - 
10.5%) and cocaine (1.6 - 2%) lifetime prevalence over the last two years. In age group 
15-16 years, all prevalence rates show increasing figures since 1992 (cannabis: 27.7%, 
psilocybin: 4.1%). Compared with the latter group, age group 17-18 (HBSC) shows 
doubled lifetime prevalence rates except for cannabis, medicaments and solvents. 
 
Fig. 2.7  Current and lifetime prevalence of cannabis use according to school levels (valid %) 
(Fischer 2000)
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Fig. 2.8  LIFETIME PREVALENCE: SCHOOL POPULATION - 12-20 years 
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Fig. 2.11   LIFETIME PREVALENCE: SCHOOL POPULATION - 15-16 years 
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LAST 12 MONTHS PREVALENCE: SCHOOL POPULATION 
 
The HBSC survey (2000) is the only to provide last 12 months national prevalence 
figures in 12 to 20 years aged schoolchildren. Results mirror respective proportions of 
lifetime prevalence rates with particular emphasis on high cannabis (22.5%), psilocybin 
(3.3%) and amphetamines (2.2%) prevalence. Gender differences reflect the results of 
the lifetime prevalence surveys except for amphetamines use that is proportionally 
higher in females during the last 12 months. Medicaments use in females during last 
year is more prevalent than in males.  
Fig. 2.10   LIFETIME PREVALENCE: SCHOOL POPULATION - 13-14 years 
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Fig. 2.9  LIFETIME PREVALENCE: SCHOOL POPULATION - 16-20 years 
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Fig. 2.12  LAST 12 MONTHS PREVALENCE: SCHOOL POPULATION - 12-20 years (HBSC 2000) 
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LAST 30 DAYS PREVALENCE: SCHOOL POPULATION 
 
Fischer (1999) provides last 30 days prevalence figures for 13 to 18 year old school 
children. Cannabis and ecstasy prevalence figure 13.8% and 1.1%, respectively. Heroin, 
cocaine and LSD prevalence rates are close to last 12 months prevalence rates. Gender 
breakdowns are currently not available. 
 
• DRUG USE AMONG SPECIFIC GROUPS 
 
In 2007, the National EMCDDA focal point published the results of action research on 
HIV and hepatitis infections in drug users (Origer and Removille, 2007) 
 
 
 REFERENCE  c.1 
Origer A., Removille N., (2007) Prévalence et propagation des hépatites virales 
A,B,C et du HIV au sein de la population problématique de drogues d’acquisition 
illicite, Point Focal OEDT / CES / CRP-Santé. Luxembourg. 
EN: Prevalence study on HIV, HCV, HBV and HAV in PDUs In Luxembourg 
 Year 1995 
 Single/repeated study Single 
 Context HIV, HCV and injecting drug use prevalence national PDU population  
 Area covered In- and outpatient drug agencies and national prisons 
 Type sample Random sampling during 8 months in 2005  
 Age range > 17  
 Data coll. Procedure ANONYMOUS SELF-ADMINISTRATED QUESTIONNAIRES AND SEROLOGICAL 
TESTING 
 Sample size 366 
 Sampling frame Random sampling 
 Response rate (M, F, T) 33.96% 
MAIN RESULTS:  
- 67.21% of PDUs reported at least 1 prison stay during the last 10 years 
- of which 56.1% report drug use in prison 
- of which 54.3% report IVDU in prison 
 
• ATTITUDES TO DRUGS AND DRUG USERS 
 
Worth mentioning here are the serial surveys performed by ILRES in 1996 and 2000 in 
the framework of EUROBAROMETER wave surveys n°44.3 (1996) and 54.4 (2000) (EC 
2001). 
 
REFERENCE European Commission (2001). Public opinion regarding security and victimisation in the E.U. Contact with 
drug related problems. Eurobarometer surveys n° 44.3 and 54.1, Brussels 
 Year of data collection 1996 and 2000 
 Single/repeated study Repeated study  
 Context  Eurobarometer 
 Area covered National representativity 
 Age range 12-60 years  
 Data coll. Procedure Phone interviews  
 Sample size 609 valid cases 
Fig. 2.13  LAST 30 DAYS PREVALENCE: SCHOOL POPULATION - 13-20 years 
(Fischer 2000)      
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Figure 2.14 presents the distribution of answers to the question: ‘Over the last 12 
months, how often were you personally in contact with drug-related problems in the area 
where you live?’ (e.g. seeing people dealing in drugs, taking or using drugs, finding used 
syringes, etc.). 
 
Fig. 2.14 Contact with drug-related problems 
 (ILRES 1996, 2000) 
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Although the observed percentages are low compared with most of the other EU 
Member States, a slight increase of the number of respondents reporting contact with 
drug-related problems has been observed in 2000. 
 
 
3. Prevention 
 
 
Overview 
 
Capacity building, awareness raising and mobilization of individual resources and 
promoting protective factors are the main benchmarks as far as national prevention 
strategies are concerned. Measures may target the general public or selective, specific 
or risk populations or communities.  
 
The present chapter provides a summary of recent universal and selective prevention 
measures undertaken at the national level. More detailed information and examples of 
good practice can be found in the EDDRA database of the EMCDDA under:  
http://eddra.emcdda.eu.int/ 
 
The national drugs action plan 2005-2009 addresses primary prevention as a main 
intervention area. 
The priorities of the drug prevention action plan as approved in 2005 are as follows: 
 
- Interventions in school and youth environments, peer education and multipliers; 
- Drugs at the workplace; 
- Cannabis, Alcopops and XTC use in youngsters; 
- Primary prevention intervention methods and impact assessment; 
- Mass media campaigns; 
- Multidisciplinary training programmes; 
- Documentation strategies. 
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The National Prevention Centre on Drug Addiction (CePT), which has started its 
activities in 1996, covers illicit drug use prevention as well as other types of addictive 
behaviour. Legally speaking the CePT is a foundation financed by the Ministry of Health.  
 
A second important actor in the field of primary drug prevention is the Division of 
Preventive Medicine of the Directorate of Health. Although the latter coordinates 
activities in the larger field of public health promotion and prevention, it plays a major 
role, jointly with the CePT in the definition of the overall framework of addiction 
prevention. 
 
The overall coordination of counselling, treatment and low threshold interventions is 
within the competence of the AST (Department of Directorate of Health, future division of 
Drug Addiction and Social Medicine) and the national drug coordinator’s office. The 
AST has coordination and financial control missions (supervision of financial contract 
implementation of subsidised NGOs) in the field of drug addiction and psychiatry. 
Furthermore, the national drug coordinator is responsible for the conceptualisation and 
the implementation of activities included in the drugs action plan 2005 - 2009 (see 1.1). 
 
Direct drug prevention expenditures reached 672,000.- euros in 2000 and 830,000.- 
euros in 2006. These figures include staff and operating costs of agencies and 
ministerial department specialised20 in drug prevention. In coming years the total 
expenditure will know a significant increase since 4 actions/programmes have been 
included in the 2005-2009 drugs action plan.  
 
EDDRA has largely contributed to the promotion of a more scientific oriented evaluation 
approach at the national level. The Ministry of Health has implemented a modified 
version of the EDDRA questionnaire as a standard for funding requests for and 
evaluation of drug related projects.  
 
Training interventions in drug demand reduction are increasingly developed at the 
national level. The CePT publishes an annual training directory including training 
activities ranging from evaluation methodologies to demand reduction action-research 
strategies targeted at drug prevention and public health actors, educators, youth 
animators and teachers. The ‘Recherche et Innovation Pédagogiques et Technologiques 
(SCRIPT)’ department is actively involved in the referred training activities. The 
Department for Scientific and Applied Research may finance training activities following 
request. In the framework of its 10th anniversary, the CepT published a manual on the 
training of multipliers in primary drug prevention available at www.cept.lu.  
 
As regards ad-hoc continuous training of national field actors, most of the involved 
structures are conventioned by the government and as such rely on the Ministry of 
Health’s regulation on continuous training. 
 
 
 
 
 
 
                                                                  
20 The exact estimation of prevention related costs is hazardous since multiple factors influence the development of a 
youngster. Education, leisure activities, sport, etc may have a positive impact on resources building; they however cannot 
be quantified in terms of exclusive input. 
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• UNIVERSAL PREVENTION 
 
o School 
 
Drug prevention programmes in schools are not mandatory. National drug prevention 
activities integrated within national school programmes have mainly resulted from 
corporate actions of different governmental and non-governmental actors: Ministry of 
Family and Integration – National Youth Service (SNJ), Ministry of Health - Division of 
Social and Preventive Medicine, Ministry of National Education –  Psychological Care 
and Educational Orientation Department (CPOS) and since 1996, the National Addiction 
Prevention Centre (CePT). 
 
The CPOS is permanently represented in all secondary schools by at least one trained 
psychologist and several ad hoc teachers. In major schools there are supplementary 
trained social workers. Among other tasks, they are supposed to detect, at the very early 
stage, problems or behaviours in relation to substance abuse. Drug and addiction topics 
are included in more general courses as for instance, hygiene or ethics, which might not 
be mandatory. However, on the school director’s demand, trained staff from the CePT 
does intervene. Furthermore, the Grand-Ducal Police organises school courses for the 
6th classes of primary school and 7th classes of secondary schools provided by 
specialized police teams out of regional police units and from the drug department of the 
Judicial Police. 
 
In recent years particular attention has been paid to: 
• School prevention and other related prevention projects 
• Elaboration and follow-up of prevention measures 
• Advice for prevention in school environments  
• Mediator between school establishments and police units  
• Prevention in secondary classic education and technical education settings 
 
In 2006, 800 hours of information sessions have been provided to 130 schools and other 
organizations. The same amount of hours has already been provided in October 2007. 
 
In 2000, the CePT in collaboration with the SCRIPT started a pilot project called 
‘d’Schoul op der Sich’ (School on quest) (see EDDRA and standard table 19) running 
for two years and having been evaluated in 2003. The aim of this participative project 
consisted in creating prevention groups among all participating secondary schools in 
order to initiate a process of reflection on drug related themes.  
 
Meanwhile, three basic training sessions were offered to the project partners by the 
CePT and the Police, a two-years training module for teachers was offered by the 
SCRIPT and a further training of “multipliers in primary prevention” was organised by the 
CePT.  
 
During 2003/2004 some of the most effective prevention activities have further been 
organized in the participating schools. In 2004, the CePT managed to set up a primary 
prevention tool adjustable to the needs of the different secondary schools. 
 
MSF (Youth Solidarity Project) was associated to the project in terms of complementary 
service providing at the level of crisis intervention. The project was called “Solution 
finding in case of drug abuse in school” (see standard table 19).  As school directors 
might see no other choice than to dismiss students showing drug consume, the MSF 
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project is meant to act as a mediator between concerned students, parents and school 
direction, by proposing counselling and a series of alternative measures.  
 
In 2004, the SCRIPT organized three different prevention projects in school settings. 
The “Extra-Tour Sucht”, a mobile interactive exhibition on prevention aims to reach 
students aged 15 to 18 years. This project has been pursued in 2003/2004 in 3 different 
secondary schools. 800 students of 40 classes have participated in this interactive 
course composed of 5 different elements. 35 members of educational staff were trained 
to animate the exhibition. A prevention project called “What’s up?” aims at conflict 
management, responsibility awareness raising and well-being by the method of 
interactive theatre. This project addresses to students of the 6th class of secondary 
schools, teachers and parents. The project” School is developing: growing strong 
together” aims at promoting health and especially drug prevention in the framework of 
primary schools. In 2004, 4 primary schools participated in this project. 
 
In the framework of the partnership ‘European Healthy School and Drugs‘(EHSD), 
coordinated by the Trimbos Institut (NL), the CePT actively participates in the 
development of improved and innovative instruments and approaches in the field of drug 
prevention in schools. Specific workgroups address concepts such as multipliers, 
evaluation or monitoring systems. A European manual on drug prevention in schools 
documents the final outcome of the EHSD project. In 2002 was published the manual 
“Making schools a healthier place- manual on effective school-based drug prevention”. 
 
The project ‘OUT-TIME’ jointly implemented by the CePT and the SNJ links drug 
prevention to adventure pedagogical instruments and focus on pupils in 5th and 6th 
classes of primary schools. Target groups are educational staff, pupils and parents. The 
methodology of the project is based on the hypothesis that youngsters who are 
physically in a good shape, are mentally challenged and who can rely on stable 
orientation marks such as empathic parents show a lower probability to use (abuse) 
drugs. A possible way to do drug prevention could therefore consist in providing 
opportunities for the latter experiences in a secured framework so as to transmit the 
message that numerous of these emotions can be reached without using drugs. Stress 
and frustration management, experience of personal limits, relaxation after physical and 
mental efforts are some of the targeted experiences. During 2004, 13 primary school 
classes have participated in the project which takes place in a Youth centre in the 
countryside. The ‘OUT-TIME project has been evaluated by the University of Koblenz. 
 
o Family 
 
Even though interventions aiming at the promotion of positive life experiences within the 
family and the kindergarten are not expressively addressed in the national drug 
prevention action plan, there are local or regional initiatives focusing on information and 
advice providing to teachers and the organisation of parents’ evenings during which 
educational and health topics are discussed. 
 
Active collaboration between the CePT and parent’s association at each education level 
does exist. In 2001 CePT has released the so called ‘prevention boxes’ (see standard 
table 19) including didactic material destined to potential multipliers as for instance 
teachers, parents and youth animators. The first prevention box, targeting 3 to 6 years 
old children has been released in September 2001. Due to its success, the 3-6 years 
prevention box will be reedited and a second one for children aged 11 to 15 years has 
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been released in 2002. In 2004, seminars on the “prevention boxes” took place in 
different communities participating in the project of addiction prevention in local 
communities. 
 
To date, there exists no outreach prevention programme specifically aiming at parents, 
pregnant women, childbirth or young parents. 
 
o Community 
 
As most of drug related interventions and strategies prevention in community settings 
are organised centrally and nation wide, projects are rarely initiated by the local 
community level without close collaboration of national authorities. 
 
Generally speaking, local and regional communities do rarely dispose of a 
comprehensive drug prevention strategy. Commonly, a given national agency initiates 
projects, defines the general intervention framework and seeks active collaboration with 
community authorities in order to meet local needs. The observed situation is mainly due 
to geographical parameters of the Grand Duchy. At present only two agencies focus on 
interventions in recreational settings, namely the CePT (community project21) and the 
MSF Solidarity Youth (on site-interventions planned). 
 
The CePT is continuously developing the project “adventure circuit”, an instrument for 
interactive and tangible drug prevention targeting general population. This itinerant 
exhibition has been prepared in 2004 by more than 40 volunteers who have fine-tuned 
and further developed the concept for a national prevention tour. 
In October 2004, the European Congress “Motivation and Qualification of Volunteers“ 
(MoQuaVo) was organised by the CePT in Luxembourg. The objective of the congress 
was ‘new competences and capabilities’ building for volunteers. More detailed 
information can be found under http://www.ecbap.net/. 
 
• SELECTIVE 
 
o Recreational Settings 
 
Numerous programmes in recreational settings take place at the community level, 
church and youth organisations or sport-oriented clubs. The latter are not necessarily 
drug specific and as such difficult to list exhaustively.   
 
                                                                  
21 In the beginning of 1995, a pilot project on community-based drug prevention has been launched by CePT (see 
EDDRA). The main idea was to focus prevention activities on the very environment and daily life experiences of young 
people. Various demand reduction activities have been undertaken, either developed by CePT, SNJ and several youth 
centres, or initiated by the respective District Councils. 13 district councils and 150 volunteers are currently involved in the 
project. The funding of this community project is jointly ensured by the involved district councils, the EU (Drug Prevention 
Programme DG-V) and CePT.  
The primary aim of the project is to improve communication skills on drugs, to increase participants’ abilities in handling 
conflicts, stress and frustration (age range: 12 to 65 years) and to set up autonomous groups to continue implementing 
local prevention measures. In each participating municipality, prevention groups were composed of local volunteers who 
were asked to organise local drug-prevention activities related to their specific needs. Cornerstone concepts of the project 
are as follows: - Multidisciplinary drug prevention, - Tailor-made community solutions, - Health promotion with regard to 
risk and protective factors, - Holistic and systemic approach, - Target groups oriented, - Routine evaluation 
The community-based prevention network is an ongoing project, which is expected to develop its proper dynamic over the 
time. The idea was to switch from a centrally coordinated pilot project to routine and autonomous local programmes. 
 38
Since its creation in 1995, the CePT, has initiated projects in the field of active leisure 
organisation: anti-drug discos, art performances, theatre, media supports (films, 
cartoons, etc.), seminars, ambulatory exhibitions, travel experiences, etc. The CePT 
increasingly ensures the national co-ordination of such activities. 
A broad offer of activities for youngsters integrating the drug prevention topic as one of 
the various components of Health education is developing. The latter approach is 
believed to have more impact on youngsters (users and non users) than a drug-centred 
approach. Indeed, human interactions in daily life situations as for instance adventure or 
sports activities are most adequate as a conceptual framework for the progressive 
integration of drug-related prevention initiatives. 
 
In this respect, the demand reduction activities organised by the “Mondorf Group” (joint 
initiatives of border regions of France, Germany, Belgium and Luxembourg) jointly with 
the CePT and SNJ combine a non drug-centred approach with intercultural 
components in organising corporate leisure activities for youngsters from border 
countries based on the concept of “adventure pedagogy”. The annual “adventure 
weeks 22” do fit in a broader programme named “Adventure pedagogy and primary 
addiction prevention”. Those activities primarily aim to provide the opportunity to 
youngsters to experience group dynamics, conflict management, limit and risk 
assessment as well as the feeling of solidarity within a group of socially and culturally 
different people. The program further aims at the reduction of risk factors and the 
enhancement of protection factors, by focussing on youngsters and their environment, 
rather than on drugs and addiction. Currently regional teams specialised in drug 
prevention meet in autonomous working and training groups and report activities to the 
Mondorf Group. 
 
The CePT closely collaborates with the National School for Physical Education and 
Sports (ENEPS) in the framework of a project called ‘Give strength to children’. 
Information and training sessions in presence of a top professional sportsman have 
been organised. A working group has been set up in order to elaborate a concept for 
future activities. A programme called ‘Sport and drug prevention’ started in the course 
of 2002.  
 
Currently there exist no legal framework regulating prevention and harm reduction 
intervention in recreational settings such as on site information providing or pill testing. 
Discussions and a related parliamentary motion during the amendment process of the 
national drug legislation (amended in 2001) did not bring up a final decision on the 
matter. Prevention material and info flyers on synthetic drugs and multiple drug use are 
provided to bars and nightlife establishments by the initiative of CePT or on demand. 
There remains however an obvious lack of interventions in the referred settings. The 
improvement of data systems on quality of synthetic drugs to be assessed by the 
national early warning system is a permanent topic of the ICD meetings. 
 
Major organisers of techno or rave events occasionally do contact the national drug 
coordinator’s office and law enforcement agencies in order to seek advice and to inform 
on planed events. However, there is no legal obligation to do so. Moreover, nightlife 
venues are recommended to apply common saver nightlife guidelines by prevention 
agencies, but once again, there is no legally binding framework.  
 
                                                                  
22 See EDDRA 
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The law of 29 June 1989 on taverns (inns)23 management regulates the functioning of 
establishments licensed to serve alcoholic beverages in terms of control measures and 
security standards to meet (laid down by subsequent grand-ducal decrees). No 
reference is explicitly made to illegal drug use. The Ministry of Finances controls the 
application of the law at the national level. As far as nightlife venues are concerned, 
organisers have to fulfil security and hygiene standards defined and controlled by special 
departments of the ministry of Labour24 and the ministry of Health.  
 
The governmental declaration of 2004 puts emphasis on the risks of alcoholic mix-drinks 
(alcopops) and the high prevalence among youngsters. A special working group chaired 
by the Ministry of Health has proposed further measures to reducing the consumption of 
alcohol and alcopops. Measures implemented by 2006 are a significant raise of taxes 
imposed on alcopops, 16 years minimum age for the purchase of alcoholic beverages 
and zero tolerance for young drivers. The special working group continues its work for 
an undefined duration. 
 
An exploratory study on the current situation and needs with regard of prevention in 
nightlife settings has been included in the drugs action plan 2005 – 2009, but not 
performed thus far. 
 
o At-risk groups / At-risk families 
 
On January 2006, MDs without frontiers - Youth Solidarity in collaboration with the Public 
Prosecutor's Department of Youth Protection and the Judicial Police- Drugs Unit 
launched a new project called CHOICE, which is based upon a pilot project of “early 
intervention of first drug offenders” (FreD) initiated by the Federal ministry of health and 
social security of Germany. The target group consists of youngsters aged 12 to 17 who 
entered in conflict with drug law. The overall aim of CHOICE is to offer youngsters an 
early and short-term intervention in order to prevent further development of drug abuse 
and drug addiction. An "in-take" interview allows assessing whether a participation in the 
CHOICE project or an individual psychological follow up is indicated. A CHOICE group 
consists of four interactive sessions (6 to 8 participants) which provide information on 
drugs, legislation and treatment services, promote auto-reflexion, reinforcement of 
personnel skills and motivation to change attitudes towards drugs. 
 
In a first phase, the project is regionally limited to the judicial district of Luxembourg City. 
Police members hand out CHOICE flyers to youngsters in breach with drug law including 
all information on the intervention and inform the Public Prosecutor's department of 
Youth Protection. The youngsters and eventually their parents contact MDs without 
frontiers within two weeks and the latter inform the Public Prosecutor on the participation 
level. A certificate testifies the participation of the youngster. In 2006, 52 CHOICE 
sessions have been organized. An external evaluation is foreseen for 2008. 
 
The 2004-2009 governmental programme also underlines the necessity to further 
develop prevention programme for youngsters with regard to polydrug use and in 
particular the increasing use of alcoholic mix-drinks. 
 
                                                                  
23 Loi du 29 juin 1989 portant réforme du régime des cabarets. Entry in force 29/06/1989 
24 A special department of the ministry of Labour called ITM is in charge of issuing and controlling security standards for 
workplaces and places with public access. The ITM standard ITM-CL54.1 addresses night and festivity venues. These 
standards are legally binding. The ITM has to provide a formal authorisation before the opening of a given venue. 
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Furthermore, special attention is currently given to Youngsters and to the local 
Portuguese community. In the framework of the EU PIC-Equal programme, a project 
on ethno-specific prevention measures is about to be set-up. The latter focuses on 
linguistic and socio-cultural specificities of ethnic minorities and in particular Portuguese 
natives. Budgetary means are foreseen for 2007 to implement specific prevention and 
treatment options for recent immigrants. More precisely a project called” DIM” (Early 
intervention mobile) is meant to inform on risk behaviour and provide free infectious 
disease testing in difficult to access populations, such as immigrants. 
 
In this context and due to an increased prevalence of HIV infection cases, AIDS and 
drug related problems in the Portuguese speaking community of the Grand-Duchy of 
Luxembourg, the Committee of AIDS Surveillance in collaboration with the Ministry of 
Health have commissioned an exploratory study on current knowledge and needs of the 
target group in relation to HIV prevention (Dellucci, 2006). 
 
By means of anonymous questionnaires and semi-structured interviews, 270 persons, 
thereof 24 persons interviewed, have answered questions addressing their way of living, 
perceived importance to HIV prevention, HIV screening, drug dependence, sexual 
behaviour, needs of information. 
 
Particularly attention has been paid to the section “AIDS and Drugs” of the 
questionnaires. Intravenous drug use (29.1%), sexual intercourses (28.9%) and 
homosexual intercourses (12.4%) have been referred most frequently as HIV 
transmission risk factors. Also 93.2% of the respondents identified a high risk of infection 
associated to the sharing of injection material with an HIV infected person. Accordingly, 
82.9% would recommend a HIV test in case injection equipment had previously been 
used by other persons. Among respondents, 6 persons qualified themselves as injecting 
drug users. Five of them (83.3%) indicated to undergo an HIV screening in case of using 
shared injection material, a proportion identical to the one observed in the total sample 
(82.9%). Concerning the exchange of injection material, 5 persons declared practicing 
exchange, one of them frequently, the others rarely. 
 
In general, half of respondents believed themselves sufficiently informed on AIDS. 
However, 11.1% of respondents asked information concerning the topic “AIDS and 
Drugs”. Most of respondents showed to be sensitized to the dangers of a transmission 
via intravenous drug use. 
 
Content analysis of the semi-structured interviews showed that references to HIV 
transmission by infected syringes in the context of drug use came in second place 
followed by sexual intercourses. Concerning HIV protection, syringe exchange has been 
rarely mentioned. As far as the assessment of risk groups is concerned, drug users have 
been perceived as a particularly exposed population to HIV infection. Respondents 
declared drug users as the major source of newly infected HIV cases in Luxembourg 
notably in relation to intravenous drug use. Generally, AIDS has been perceived as a 
disease concerning above all specific risk-groups such as homosexuals, prostitutes, 
non-natives and intravenous drug users. 
 
Results show respondents not belonging to perceived risk groups underestimated HIV 
infection risks for themselves and overrated risk associated to more vulnerable groups. 
The study identified needs of information concerning risks and protective factors, 
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measures of prevention, AIDS and sexuality, AIDS and drug dependence, screening and 
socio-medical support. 
 
However a specific HIV prevention programme for the Portuguese speaking community 
is not deemed to be appropriated since focusing on a specific community could provoke 
various resistances. The study recommends, among others, a linguistic diversity as far 
as prevention messages and the composition of counselling teams are concerned. 
 
Finally the CePT introduced an EU project in the framework of the Grundtvig-
Programme called ‘Promotion of social and personal competences in socially 
unprivileged persons’ – PROSKILLS. Its objective is to elaborate didactic material for 
multipliers working in the field of the promotion of social and personal competences. 
Germany, Finland, Greece, Italy, Slovenia and Hungary collaborate in the project. The 
material output will be presented in 2008. 
 
• INDICATED PREVENTION 
 
o Children at risk with individually attributable risk factors 
 
See Part B, chapter 12 (vulnerable groups). 
 
 
4. Problem Drug Use and the Treatment Demand Population 
 
 
Overview 
 
At the national level ‘problem drug use’ (PDU) or ‘harmful use’ is defined according to 
the WHO Lexicon of Alcohol and Drug terms (Geneva, 1994): ’A pattern of psychoactive 
substance use that is causing damage to health, physical or mental. Harmful use 
commonly, but not invariably, has adverse social consequences […]. 
 
Data on PDUs presented in this chapter originate from the national drug monitoring 
system RELIS developed and maintained by the national EMCDDA focal point. The 
RELIS network includes specialised drug agencies (100% coverage), psychiatric 
departments of a series of general hospitals, law enforcement agencies and national 
prisons. 
 
According to recent indicators, prevalence figures applied to the national population 
aged 15-64 situate between 2,500 and 2,800 the number of PDUs.  
 
Overall, most demand and supply reduction indicators are showing a fairly established 
stabilisation or even a decrease of PDU prevalence at the national level. 
 
Intravenous heroin use associated to poly-drug use has been reported as the most 
common consume pattern in PDUs. The recent increase in low quality cocaine use in 
combination with heroin has not been confirmed by 2006 data. Ecstasy-like substances 
and ATS show an increasing demand even though seizure figures do suggest an 
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inverse and currently stable trend. The use of most ‘new synthetic substances’25 recently 
detected in other EU Member States has not been reported thus far. 
All indicators on cannabis use (problematic and recreational) have been on the 
increase for several years but tend to stabilise more recently. Cannabis showing high 
THC concentrations (max: 25%, mean: 11%) is increasingly found on the national 
market.     
 
The ratio of intravenous opiates consume to the inhalation mode has stabilised at 2:1. 
Provision of ‘blowing paraphernalia’ (e.g. aluminium foils) by specialised drug agencies 
may have influenced consume patterns.  
 
The mean age of first use of cannabis, ecstasy and i.v. heroin tends to decrease. Also, 
the average age, applied to the total PDU population and to od victims has markedly 
increased over the last 6 years. The proportion of PDUs aged 39 and more and those 
younger than 19 years has constantly increased as well as the standard deviation of 
the observed age distribution meaning that the gap between youngest and oldest 
problem drug users tends to increase. Furthermore, increases have been noted with 
regard to the proportion of minors in the overall PDU population and to the percentage 
of students in problem drug users until 2003. In reference to years 2004/2005 a 
stabilisation, and as far as police data is concerned, a downward trend has been 
observed. 
 
The average ages of native and non-native problem drug users tend to balance. The 
average ages at the moment of first consume of the current main drug and illicit drugs 
in general have shown a slow but constant downward trend for the last 7 years. In 
contrast to 1995 data, the switch to intravenous drug use occurs earlier in 2006. 
 
• PREVALENCE AND INCIDENCE ESTIMATES OF PDU 
 
Data presented in the present chapter have been provided by the latest drug prevalence 
study on PDUs aged between 15 and 64 years (hereinafter referred to “2001 study”) 
conducted by the focal point between 1999 and 2001 (Origer 2001)26 and refers to the 
years 1999 and 2000. Since there have been no national prevalence study since 2000, 
indirect indicators have been further observed and produced in order to assess the 
general evolution of PDU prevalence.   
 
Data from 1999 and 2000 have been considered in comparison with first national drug 
prevalence figures from 1997. The following methods have been applied: Case finding 
(CF), capture-recapture on 2,3 and 4 sources (CR 2,3,4), truncated Poisson model 
associated to Zelterman’s and Chao’s estimators (tPm), and four different multiplier 
methods using data from law enforcement sources, drug mortality registers (D1, 2, 3) 
and treatment agencies (T). 
 
 
 
 
 
                                                                  
25 Substances such as MBDB, 4-MTA, Ketamin, PMMA 2C-I, 2C-T-2, 2C-T-7, 2C-D,  2C-E, TMA-2, BZP, TFMPP, 5-MeO-
DIPT, 5-MeO-DMT, AMT, ALEPH 7, DXM, DPT, mCPP.   
26 Downloadable at http://www.relis.lu 
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Fig 4.1. Prevalence estimation of problem HRC drug use (1997 – 2000)                                                                      
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  Source: Origer 2001 
 
Tab. 4.1.  Prevalence and prevalence rates according to selected sub-groups (1997 – 2000) 
 1997 1999 2000 
GENERAL POPULATION 
National population on 1st July 421,000 432,450 438,500 
National population aged between 15 and 54 years on 1st July  239,818 245,308 248,440 
HRC USERS IN CONTACT WITH THE NATIONAL INSTITUTIONAL NETWORK 
(low threshold agencies not included) 
Total number of indexed users (multiple counts excluded) / 1,198 1,024 
Number of drug treatment demanders in specialised institutions 
                                                        Outpatient
                                                              Inpatient
 
/ 
/ 
757 
624 
218 
637 
557 
178 
Number of drug law offenders (ad minima consume of HRC drug(s)) / 551 510 
PROBLEM USE: MAIN DRUG – HEROIN 
Prevalence heroin 1,680 1,975 2,010 
Total prevalence rate – heroin 4  /1000 4.57  /1000 4.58 /1000 
Total prevalence rate – heroin – age: 15-54 7 /1000 8.05  /1000 8.09 /1000 
INTRAVENOUS DRUG USE (IVDU) 
Prevalence IVDU 1.370 1.780 1.715 
Total prevalence rate – IVDU 3.25 /1000 4.12 /1000 3.91/1000 
Total prevalence rate – IVDU – age: 15-54 5.71 /1000 7.26 /1000 6.90/1000 
Source: Origer 2001 
 
In order to validate estimated prevalence rates, data from different sources had to be 
considered. As shown in chart 4.1., prevalence estimates from 1997 to 2000 indicate a 
moderate upward trend in compliance with the observed evolution of indirect drug use 
indicators (1997: reference year, all values set to zero).  
 
As can be seen in graph 4.2., all indirect indicators, except number of acute drug deaths 
and low threshold contacts, have been showing a significant downward trend. The fact 
that the number of ODs has increased in 2006 mismatches the evolution of all other 
indirect indicators. A special expert group currently studies this phenomenon which may 
be due more to changes in consume patterns than it indicates an increase in PDUs.   
Number of low threshold admission have known an increase primarily because low 
threshold offers have been diversified and opening hours enlarged and thus do not allow 
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to state an increase in the drug population prevalence. Substitution treatment demands 
are on the decrease for the first time since the creation of the substitution programme. 
 
Taking into account the previous comments, one may state that PDU prevalence tends 
to stabilise, or maybe even to decrease at the national level. A second national drug 
prevalence study, which is foreseen for year 2009, in the framework of a final evaluation 
of the drugs action plan will provide more information of the current situation. 
 
Graph 4.2. suggests another interesting hypothesis related to the impact of harm 
reduction measures on indirect prevalence indicators. The increase of the number of 
low threshold contacts and distributed syringes seems to be associated to the 
stabilisation or decrease of indicators such as overdose cases and drug related 
offences. Also this trend coincides with the period of the first national action plan. 
 
Fig. 4.2. Prevalence estimates (problem use of high risk drugs) and evolution of selected indirect indicators  
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Source: Origer 2006 
 
LOCAL PREVALENCE STUDIES 
 
Due to the specificity of the national drug scene and the geographical dimension of the 
country, local prevalence studies are not considered as a priority.  
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NATIONAL ‘DRUG SCENES’ 
 
Summarily four different problem drug user groups are to be distinguished at the national 
level: 
- a sub-group of cannabis consumers, mainly minors, located in specific areas of the 
municipal park of Luxembourg-City. The referred group is a rather closed one 
showing poor contact with other drug scenes. Male and female users are 
represented equally. Cannabis use is also significantly associated to ecstasy 
consume in youngsters. 
 
- A second group, the so-called ‘disco scene’, is often event-related and limited to 
rave or other dancing or party locations. This group is composed of youngsters 
between 15 and 20 years mainly attracted by ecstasy like substances and cannabis. 
 
- The ’hard scene‘ is characterised by a fair heterogeneity regarding age of users and 
consumed substances. However, composed by a majority of male users, the social-
economic situation of this specific group is precarious. Female users who join this 
scene mostly do so for prostitution purposes and constitute a high risk group as 
regards overdosing (e.g. shorter drug careers than males). Currently the main drug 
to be found on the drug market is low quality cocaine. 
 
- The exclusive ‘cocaine scene’ is described as a fairly dispersed one and difficult to 
access since cocaine consume mainly takes place in privacy. Typical cocaine 
users/abusers are middle age men of upper classes. Recently, however, cocaine use 
has largely spread within the street PDU population. 
 
CHARACTERISTICS OF INDEXED PDUs 
Relying on a multi-sectorial data network including specialised in- and outpatient 
treatment centres and low threshold facilities, general hospitals as well as law 
enforcement agencies and national prisons, RELIS enables the assessment of new 
trends in the problem drug users population in general as well as in drug treatment 
demanders in particular. NFP has opted for a holistic monitoring of the drug population. 
The following data are provided by RELIS thus referring to all HRC drug users indexed 
by the national specialised treatment and law enforcement network and, as such, 
defined as problem drug users. 
 
The number of problem PDUs indexed by national institutions in 2006 figures 
4.580(2002: 4,701) (in this figure double counting is included meaning that a given 
person could have been indexed twice and more by different institutions. It is thus not 
representing the actual prevalence, which has to be assessed by other methods). For 
comparison, 2,383 users have been indexed by national specialised drug demand 
reduction agencies and 2,318 drug law offenders by supply reduction agencies in 2002. 
In 2006 the same agencies have indexed 2,764 and 1,816 persons respectively. As the 
frequency of multiple contacts did not change over recent years, these figures suggest 
that in total and since 2002 fewer persons have come in contact with drug agencies and 
even more positive is the fact that an increasing proportion of PDUs seek contact with 
treatment services and less show contacts with law enforcement agencies. 
 
10% (5%) of respondents are first treatment demanders, all treatment centres included. 
More recently, one has observed a stabilization of treatment demands in outpatient drug 
agencies and inpatient therapeutic centres whereas detoxification demands and 
contacts with low threshold drug agencies are clearly increasing. 
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The male/female ratio of the PDU population is 3:1. The last ten years the proportion of 
indexed non-native PDUs has shown strong variations but a clearly increasing tendency 
since 2003. The population of non-natives drug users largely consists of Portuguese 
nationals, a proportion constantly increasing until 2004. Although the proportion 
stabilised since then, it is still consistently higher than the one observed in general 
population. Notably, one observes a remarkable increase of PDUs of French origin 
(22%). This trend is confirmed by last 6-years data on drug law offenders. 
 
The mean age of indexed PDUs evolved from 28 years and 4 months in 1995 to 30 
years and 11 months in 2006. The gap between youngest and oldest PDUs continues to 
grow. One observes an average aging of the population of long-term drug injectors and 
a sensitive decrease in age referred to “new” PDUs. Worth mentioning is the significant 
increase of the average age of overdose victims and a significant but currently 
decreasing proportion of minors among drug law offenders STUP. Respectively 88% 
and 43% of current PDUs have tried cannabis and heroin (i.v.) while being minor of age. 
In 1995 the same proportions figured 71% and 23%. Most interestingly evolution of drug 
use patterns tend to accelerate in terms of shorter time spans separating first non-iv use 
from first iv-use. This acceleration is also observed as far as first treatment demands are 
concerned. PDUs tend to contact drug treatment facilities at an earlier stage, which may 
be due to a more diversified offer currently available. 
 
The mean age of native and non-native problem drug users tends to balance. Average 
age at first use of illicit HRC drugs has decreased approximately 3 years from 1995 to 
2004 and increased again in 2006 (2004:12Y8M; 2006:15Y3M). In 2006 age of first use 
of cocaine (iv/non-iv) and heroin (non-iv) stabilised, contrarily to average ages of first 
intravenous heroin use and even more significantly the average age at first cannabis use 
(almost 1/3 of respondents were not older than 13 at the moment of first cannabis use). 
In general, the proportion of PDUs aged more than 39 years and of users less than 19 
years is increasing continuously as also the gap between these two groups. 
 
Intravenous heroin use associated to poly-drug use has been reported as the most 
common consume pattern in PDUs. The proportion of poly drug use 88% has reached 
stabilisation after a record level in 2004 (92%). As already indicated, the switch to 
intravenous drug use occurs earlier. The ratio of intravenous opiates consume to the 
inhalation mode has stabilised at 2:1. The prevalence of the use of cocaine as primary 
drug continues to increase, which is partly due to increased availability on the national 
market. Ecstasy-like substances and ATS show an increasing demand even though 
seizure figures do suggest an inverse and currently stable trend. 
 
All indicators on cannabis use (problematic and recreational) have been on the increase 
for several years. Cannabis showing high THC concentrations (max: 25%, mean: 11%) 
is increasingly found on the national market. 
 
The number of persons in contact with the national specialised network for (preferential) 
cannabis use had known a sensitive increase the last three years but decreased again 
in 2004 and stabilised in 2005/2006. Amphetamine like substances and ecstasy are 
only weakly represented, which however does not inform about prevalence in general 
population as RELIS data refer to PDUs and not to the overall population of recreational 
drug users.  
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The residential status of indexed PDUs has improved over the last years. The 
geographical distribution suggests that the southern region (41,8%) and the centre 
region (38,3%) are the most representative. The northern region (13,7%), after multi-
annual increase show signs of stabilisation  (2004:17%). 
 
Recent data suggest that the employment status of respondents tend to worsen. Also 
the unemployment rate has increased in 2006 (72%). The decrease of financial 
autonomy of PDUs is associated to an increasing social dependency. Although a 
continuous decline at the level of revenues of illegal origin and a moderate decrease of 
the proportion of PDUs presenting major depths have to be underlined. 
 
• TREATMENT DEMAND INDICATOR 
 
o Profile of clients in treatment  (characteristics, patterns of use) 
 
By substance used 
 
The main substance involved in drug treatment demands is heroin. Prevalence rates 
fluctuate around 70% and 80% (60% iv / 20% non iv). In 2006, an increase of 10% in 
preference for intravenous heroin use was noted compared to 2005. The heroin 
inhalation mode has stabilised for several years. Polydrug use is the most observed 
consume pattern (88%). The i.v. heroin sub-population shows the highest mean age 
(32Y6M) of all treatment groups. 6% of the latter are first treatment demanders 
compared to 8% of non-iv heroin users. 
 
Cocaine use as main reason of treatment demand showed a significant increase in 
2004 and 2005 (20%) and decreased again in 2006 (14%), which is consistent with 
current supply indicators. Mean age of preferential cocaine using treatment demanders 
is 27 years and 1 month. With 7% (5%) of first treatment demanders, primary cocaine 
users show the highest lifetime first treatment rate. Cocaine prevalence as secondary 
drug has decreased from 43% in 2004 to 39% in 2006. Crack is never reported as main 
problem drug and very rarely (0%) as secondary or occasional drug.   
 
A recent trend has also to be seen in the increasing number of treatment demands 
related to cannabis use. The percentage of the latter has passed from 4% in 1997 to 
11% in 2002 and tends to decrease since 2004. Treatment demands related to ecstasy 
use are rare (1-3%) and have shown a fair stability over the last years. The same 
comments apply to ATS use. 
 
By centre types 
 
The present section is based on RELIS data and on in-house statistics of all specialised 
drug treatment agencies at the national level. The overall number of clients and number 
of admissions in specialised drug treatment agencies has constantly increased over the 
last decade. More recently, one has observed a stabilisation of treatment demands in 
outpatient drug agencies and an increasing demand for inpatient therapies and for low 
threshold offers. 
 
The proportion of first treatment demanders observed in 2006 was 10% (1998: 4%). 
For the sake of a comprehensive presentation of main observed trends, the following 
typology of treatment settings is applied: 
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¾ Outpatient, adults 
After several years of decrease, national outpatient drug counselling centres show 
decreasing admission rates and first treatment rates between 2004 and 2006. 
Gender distribution shows a weak upward trend in female treatment demanders 
(2006: 42% / 1997: 34%). Age distributions have to be analysed according to the 
geographical situation of treatment centres. The proportion of treatment demanders 
aged 30 years and beyond 57% (2005: 58%) has sensibly increased, during recent 
years. The proportion of underage treatment demanders (4.8%) has been increasing 
in recent years but stabilised in 2004 (4.4%) and tends to decrease mainly because 
specialised agencies for minors have been implemented meanwhile. Treatment 
demands for problem i.v. opiate use associated to multiple-use, is still the main 
demand pattern although it has clearly decreased during the last years and shows 
stability for 3 years now (2006: 51% / 2005: 47% / 1997: 72%). Cannabis-related 
demands have shown a clear upward trend since 2000 (2003: 15% / 1997: 1%) and 
stabilised after 2003 (2006: 13%), which may also be due to the development of 
specialised treatment offers for minors. The prevalence of problem cocaine use has 
stabilised. 
 
¾ Outpatient, underage 
Specialised drug care agencies for minors only exist in the centre of the country. The 
rate of new treatment demanders has discontinuously increased since the 
implementation of the referred agencies. Gender distribution in minor treatment 
demanders has been showing a slow decrease over recent years (2006: 30%). The 
proportion of clients aged below 15 (33.7%) has decreased since 2002. Cannabis use is 
the main reason of treatment demands (73.3%, stable), followed by heroin and polydrug 
use. 
 
¾ Inpatient, drug therapy 
The proportion of new clients has increased in inpatient therapy settings in past years. 
The proportion of male treatment demanders has increased during recent years and 
stabilised in 2006 (74%) as well as the observed mean age (2006: 30Y7M / 2004: 
31Y11M / 1998: 27Y). The referred age distribution reflects an overall trend observed in 
most adult drug treatment demanders, that is, a decrease of patients under 25 and an 
increase of patients older than 25 years. An increase is observed as to the proportion 
of natives within the inpatient treatment demanders. All treatment demands are related 
to opiate abuse, mainly i.v.. 
 
¾ Inpatient, detoxification 
Drug detoxification units throughout the country show a recent significant increase 
regarding number of admissions and patients (382 patients in 2004 vs. +/- 600 patients 
in 2006). First treatment demands also tend to decrease. Gender distribution has 
remained fairly unchanged and the mean age of clients has been on the decrease for 
the last six years. Multiple drug addiction including heroin is the main reason for 
detoxification demand. 
 
¾ Substitution treatment 
The number of patients admitted to the national substitution programme has been 
decreasing (105) for the last 7 years, which is probably due to the increasing access to 
low threshold substitution provided by GPs. The proportion of female substitution 
treatment demanders (32% stable) is higher than the proportion of female PDUs in the 
overall drug treatment population. The mean age of clients has significantly increased 
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compared with 1997 data (28Y2M) especially due to the step increase of the number of 
treatment demanders over 39. The proportion of native substitution treatment 
demanders has stabilised in recent years (70-75%). The socio-economical situation of 
substituted patients is consistently more beneficial than the one observed in other 
treatment demanders, which has been confirmed by the latest external evaluation 
(Dellucci, 2003). The number of patients who did receive substitution treatment by 
prescription from independent general practitioners tends to stabilise [(939 patients in 
2006 multiple counts excluded (2005: 970)]. 
 
¾ Low threshold services 
The number of contacts indexed by low threshold agencies has increased dramatically 
over the last ten years (2006: 63,129 / 2005: 47,739 / 1996: 6,456), and so has the 
number of syringes distributed by the same agencies, although the number of syringes 
distributed in 2005 has stabilised for the first time since the existence of the national 
NEP and even decreased in 2006 (see Fig. 4.2.). The proportion of new clients within 
low threshold settings is on the increase. The number of female clients has been 
showing a weak but constant decrease (currently stable at 21%). Approximately 65% of 
clients are aged between 19 and 34 years, and a higher proportion of clients aged 35 
and more is observed. 
 
 
5. Drug-Related Treatment 
 
 
Overview 
 
Drug treatment is the ‘use of specific medical and/or psychosocial techniques with the 
goal of reducing or abstaining from illegal drug use thereby improving the general health 
of the client’.27 
 
Specialised drug treatment infrastructures are relying on state financing and on 
ministerial control and quality insurance mechanisms. Treatment offers are decentralised 
and most commonly provided by state accredited NGOs. 
 
For the purpose of the present chapter, drug treatment is divided in the following 
categories: 
 
- Outpatient treatment: the patient receives drug treatment without staying overnight; 
- Inpatient treatment: the patient is staying overnight, including detoxification; 
- Substitution treatment: a type of medical treatment provided to opiate addicts 
primarily based on the delivery of a similar or identical substance to the drug 
normally used. Substitution treatment may be accompanied by psycho-social care; 
- Low threshold measures28: refer to measures aimed at reducing the harm 
associated with drug use without necessarily requiring a reduction in consumption. 
In recent years inpatient and outpatient drug treatment demand has been slightly 
increasing. A weak increase has also been observed in substitution treatment 
demanders and a very significant increase has been reported in low threshold care 
                                                                  
27 SOURCE: Classification of drug treatment in EU member states and Norway, Expert meeting, 8-9 February 2002 
28 Although harm reduction measures are specifically addressed under chapters 6 to 9, low threshold services are to been 
seen as a possible alternative to treatment and thus need to be included in the analysis of treatment demand patterns. 
 50
demanders. In general, a continuous yet decelerating increase of the number of drug 
treatment demanders is observed.  
 
The national drugs action plan 2000 – 2004 has largely contributed to fill a series of gaps 
in the drug treatment network. Increased admission figures related to harm reduction 
offers may be linked to the implementation of new low threshold services under the 
former action plan. The outcome of the 2000 –2004 action plan has been largely taken 
into account for the elaboration of the 2005 – 2009 drugs action plan. 
 
As can be seen on map 5.1 drug treatment facilities are regionalised showing however a 
high concentration and diversity within the area of Luxembourg City. All listed services 
are specialised with the exception of regional general hospitals providing detoxification 
treatment. In June 2005, the first ‘consumption room’ has been opened in Luxembourg 
City, namely ‘the injection room for drug users’ integrated in the ‘TOX-IN centre’’ 
providing day care, night shelter and low threshold services to drug addicts. 
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• TREATMENT SYSTEMS 
 
 
 
Map 5.1 Geographical coverage of specialised drug agencies in the Grand Duchy of Luxembourg (status 2007) 
 JDH : Counselling, substitution, low threshold and after care 
 TOX-IN (CNDS) : Low threshold 
 TOX-IN (CNDS): Night shelter, Injection room 
 MSF SOLIDARITE JEUNES : Youth counseling 
 CENTRE EMMANUEL : Counseling and referral 
 CHNP : Treatment and referral 
 CTM : Residential therapy, reintegration measures 
 CTM : Aftercare, supervised housing 
 General hospitals providing detoxification 
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All drug treatment infrastructures, general hospitals excluded, are relying on 
governmental support and control. Most of specialised agencies have signed a 
convention with the ministry of Health, which guarantees their annual funding. NGOs 
involved in drug treatment fall under the obligation of the so-called 'ASFT' law (8/09/98)29 
and the subsequent grand ducal decree of 10 December 199830, both regulating the 
relation (duties and rights) between State and NGOs or organisation providing psycho-
medico-social and therapeutic care. The overall management of the referred agencies is 
ensured by a 'co-ordination platform' that includes 3 members of the concerned 
institution and at least one representative from the competent ministry. All major 
decisions have to be approved by the co-ordination platform. All referred institutions 
work in close collaboration and have to be viewed as an interdependent therapeutic 
chain even though there are no formal agreements between them. With the exception of 
detoxification departments, all treatment units or agencies accept any drug using patient 
independently of the type of substance(s) that are involved. 
 
The governmental quality standard certification, as foreseen by the law ‘ASFT’ of 8 
October 1998, represents the main tool towards a standardised quality control. However, 
funding is not directly related to clearly defined evaluation requirements. The quality 
standard certification commits respective NGOs to undertake necessary evaluation 
measures of their activities by means, however, they deem adequate. Drug treatment 
agencies have developed proper evaluation strategies mostly in collaboration with 
external evaluators. Recent examples are the evaluation of current offers in the field of 
socio-professional integration, which future development has been promoted by the 
national drugs action plan, the implementation of a computer based evaluation 
procedure by the national substitution programme and prevention interventions in 
schools by CePT. 
 
Also, the RELIS database on problem drug users provides relevant data for evaluation 
purposes since it includes detailed data on drug consume patterns, socio-economic 
situation, risk behaviour and treatment or law enforcement contacts, etc. In the long run, 
drug ‘careers’ can be analysed by means of the RELIS indexing system, which allows 
following up treatment demands and law enforcement contacts of indexed drug users. 
These data can be used to assess the impact and the performance of specific treatment 
approaches. A practical example of the application of evaluation results is to be seen in 
the conceptualisation of the national drug action plan 2000-2004, which did greatly rely 
on RELIS data and ad hoc evaluation initiatives from field institutions. Table 5.1 records 
admission and contact statistics of national drug treatment agencies according to applied 
typology from 1994 to 2006. Intra-institutional multiple counts are excluded meaning 
that all treatment demanders indexed by a given agency is only indexed once by the 
referred agency during a reporting year. Inter-institutional multiple counts are not 
excluded since a given treatment demander may have contacted several national 
agencies during a given year. More detailed admission data, including low threshold 
agencies are produced in respective sub-chapters. 
 
 
 
 
 
 
                                                                  
29 Loi du 8 septembre 1998 réglant les relations entre l’Etat et les organismes oeuvrant dans les domaines social, familial 
et thérapeutiques (entry in force: 24/09/1998) 
30 Règlement grand-ducal du 10 décembre 1998 concernant l’agrément à accorder aux gestionnaires de services dans 
les domaines médico-social et thérapeutique (entry in force 18/12/1998) 
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Table 5.1 Drug related institutional contacts (Inter-institutional multiple counting included)  
NUMBER  OF ADMISSIONS (A) AND/ OR 
CONSULTATIONS (C) AND/OR CONTACTS (CO) 
NUMBER OF DRUG TREATMENT 
DEMANDERS 
(intra-institutional multiple counts excluded) SETTING 
98 2000 2002 2004 2005 2006 98 2000 2002 2004 2005 2006 
 
DEMAND REDUCTION: SPECIALISED DRUG TREATMENT 
 
OUTPATIENT 
- Drug Free  
 
- Substitution 
 
1,089 
 
/ 
 
2,185 
 
/ 
 
3,412 
 
/ 
 
 
4,312 
 
/ 
 
 
4,682 
 
/ 
 
 
4,597 
 
/ 
 
 
535 
 
986 
 
636 
 
1,002
 
828 
 
1,040 
 
916 
 
1.,065 
 
876 
 
1,084
 
 
928 
 
1,044
 
INPATIENT  
- Drug free  
 
- Detoxification 
 
 
39 
 
/ 
 
43 
 
/ 
57 
 
/ 
53 
 
/ 
35 
 
/ 
44 
 
/ 
127 
 
243 
158 
 
316 
153 
 
289 
182 
 
382 
176 
 
568 
183 
 
60031
LOW 
THRESHOLD 
AGENCIES 
9,499 13,083 29,536
 
39,526
 
 
47,730
 
 
63,129
 
 
 
SUB TOTAL A: Number of drug treatment demanders 
(Multiple counts not excluded) 
(Multiple counts excluded) 
 
1,891
n.a. 
 
2,112 
637 
 
2,310 
n.a 
 
2,545 
n.a. 
 
2,704
n.a 
 
2,755
n.a 
 
SUPPLY REDUCTION: LAW ENFORCEMENT INSTITUTIONS 
 
National prisons 
 
Police - Judicial Police - Customs 
167 
 
1,170
161 
 
1,758
101 
 
2,217 
92 
 
1,808 
247 
 
2,034
243 
 
1,573
SUB TOTAL B: Number of  drug law offenders 
(Multiple counts not excluded) 1,337 1,919 2,318 1,900 2,281 1,816
TOTAL 
NUMBER OF PERSON SHOWING DRUG RELATED 
INSTITUTIONAL CONTACTS (Multiple counts not excluded) 
3,228 4,031 4,628 4,445 4,985 4,571
Source: RELIS 2006 
 
Table 5.1 summarises drug related institutional contacts of PDUs. Inter- and intra-
institutional multiple counts are not excluded meaning that a given PDU could be 
indexed twice and more. Hence, these data do not provide the national prevalence of 
PDUs but they allow following up the increase or the decrease of the latter. 
 
As far as drug treatment demanders are concerned on observes a fairly stable situation 
for the last 3 years. Substitution treatment demands are remarkably stable and 
Outpatient counselling have even been showing a decreasing trend during the same 
period. 
 
If treatment demands and drug law offences are added to serve as an indicator it is 
reasonable to presume that the national PDU prevalence has stabilised since 2002. 
 
 
 
 
                                                                  
31 Estimated since ICD-10 episodes’ data were not yet available at the time of editing 
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• DRUG FREE TREATMENT 
 
Definition: ‘Drug free treatment focus on psycho-social and therapeutic techniques and is 
not primarily based on the routine prescription of a substance or medicament with the 
goal of reducing or abstaining from illegal drug use thereby improving the general health 
of the client’. 
As far as admission criteria to drug free treatment are concerned, no specific 
standards exist. Specialised drug treatment is free of charge and detoxification treatment 
is reimbursed by health insurance funds. Admission and type of treatment are assessed 
individually with the client. 
 
For the purpose of the present report low threshold, harm reduction services and 
detoxification have been excluded from the present sub-chapter. Distinction will be made 
between out- and inpatient treatment. 
 
Outpatient treatment 
 
RELEVANT TREND: Stabilization of total number of clients. Decrease of first treatment 
rates. Stable gender distribution. Increasing proportion of clients over 30. Currently 
stable number of underage treatment demanders. 
 
The most relevant national outpatient treatment facility is the ‘JDH Foundation’. Regional 
antennas of JDH are respectively implemented in Luxembourg City, in the South and in 
the North of the Grand Duchy and are entirely financed by the Ministry of Health. ‘MSF 
Solidarité–Jeunes’ is addressing youngsters who have run into conflict with law 
enforcement for drug related offences. The Emmanuel Centre is primarily a counselling 
and referral agency. 
 
Further agencies provide social care or therapeutic settings that are attended by drug 
addicts. These agencies, however, rarely provide drug specific treatment and separate 
data breakdowns are not available.  
 
Inpatient treatment 
 
RELEVANT TREND: Stable admission rates, aging clients and increasing 
proportion of natives 
 
The only therapeutic community called ‘Syrdallschlass’ (CTM-CHNP) is situated in the 
East of the G. D. of Luxembourg. The therapeutic programme of the CTM is divided into 
three progressive phases that have been revised during 1997. The duration of a 
therapeutic stay varies from 3 months to 1 year. 
 
In addition to individual and group therapies, the centre offers the opportunity to follow 
training activities in several professional domains and post therapeutic accommodation 
facilities. The final objective is the psychological, professional and social reintegration of 
treated clients. The latter is highly facilitated by the quality of provided professional 
training to patients. The collaboration with several employers willing to employ ex-drug 
addicts and the active involvement of social services guarantee a fair social and 
professional framing to released patients. 
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The national drug action plan had foreseen the extension of CTM offers by creating a 
network of modular therapeutic annexes for specific target groups as for instance 
pregnant women, drug addicted couples, treatment demanders on methadone, etc. 
These annexes are operational since September 2002 and are situated in the vicinity of 
the main centre (see map 5.1) in order to take advantage of training and social 
reintegration facilities offered by the CTM. The new 2005-2009 drugs action plan 
foresees the further development of these annexes. 
   
As the national inpatient therapeutic facilities are limited and not covering the whole 
spectrum of drug related symptoms (e.g. double diagnosis) a series of patients are 
referred to specialised institutions abroad. Related costs are covered by the national 
social security schemes. 
 
Table 5.2 Drug treatment abroad covered by health insurance scheme (1996-2006) 
AGE GROUP  1996 1998 2000 2002 2004 2005 2006 Males 
(2006) 
Females 
(2006) 
 N N N N N N N N % N % 
< 20 years   3 5 3 3 1 1 1.2 0 0 
20 à 25 
years   33 33 37 29 41 25 29.4 16 51.6 
> 25 years    66 63 72 89 74 59 30.6 15 48.4 
TOTAL 55 71 102 101 112 121 116 85 100 31 100 
Mean age   27Y9M 28Y 28Y5M 30Y7M 30Y 31 27 
Source : Administration du Contrôle Médical : Cures de désintoxication (drogues dures et polytoxicomanie) à l’étranger - Exercices 1996-2006 
 
A new project foreseen by the 2005-2009 national drugs action plan relates to minor 
PDUs. A specialised residential centre for problematic youngster will be opened in the 
beginning of 2007 in the North of the country under the management of CHNP. The 
referred case management programme has filled a current gap in the care system for 
minors.  
 
• PHARMACOLOGICALLY ASSISTED TREATMENT 
 
o Detoxification, In-Patient 
 
RELEVANT TRENDS: Significant increase in number of admissions, first 
admissions and number of clients stable – Increasing mean age – Increased 
proportion of clients over 30 years.  
 
Physical drug detoxification is provided by 5 different hospitals via their respective 
psychiatric units. The most important detoxification unit implemented within a specialised 
department of the CHNP (15 detoxification beds) has been restructured and do not 
provide detoxification treatment anymore. The ‘Hôpital du Kirchberg’ has joined the list in 
2005. Medical interventions and psychosocial support are provided to control and reduce 
withdrawal symptoms in the framework of a 1-2 week detoxification programme. Ideally, 
detoxificated patients are referred to more therapeutic oriented institutions.  
 
Detoxification treatment is provided by psychiatric units within five general hospitals:  
Clinique St. Louis – Ettelbrück (North)  
Centre Hospitalier Emile Mayrisch – HVEA (South)  
Centre Hospitalier de Luxembourg – CHL (Centre)  
Clinique Ste. Thérèse (Centre)  
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Hôpital du Kirchberg (Centre) 
o Substitution Treatment, Out-Patient 
 
RELEVANT TRENDS: Continuous decrease in number of patients in structured 
programme and for the first time overall decrease (including low threshold 
substitution) of national substitution treatment demand - stabilisation of gender 
ratio (2 males/1female) - Increase of substitution treatment demanders 35 years+.   
 
Substitution treatment is currently defined as a medical assisted treatment with opiods’ 
agonists and with antagonists (and antagonistic agonists). The objectives of substitution 
and maintenance treatment are manifold. They range from no dose-digressive, out-
patient low threshold maintenance to abstinence oriented (digressive doses) 
rehabilitation offers. The primary goal is the psychosocial and medical stabilisation of the 
patient by replacing ‘street’ drugs by quality controlled substitution drugs. The further 
development and outcome of the treatment is assessed individually. Both components, 
condition of the patient and reduction of public nuisance are considered. 
 
Substitution treatment is provided at the national level since 1989 (JDH). Until the 
beginning of 2001, however, there has been no legal framework regulating drug 
substitution treatment. The law of 27 April 2001 modifying the basic drug law of 19 
February 1973 introduced a legal framework for substitution and maintenance treatment. 
The grand ducal decree of 30 January 200232 regulates the practical modalities of 
substitution. The new law regulates drug substitution treatment in general rather than it 
legalises a single national substitution programme. The law does this by means of 
substitution treatment licenses granted to MDs and specialised agencies, the 
application of training requirements for prescribing MDs and adequate control 
mechanisms of multiple prescriptions (i.e. centralised register of substituted patients). 
It should be stressed that following the application of the new legal framework, there still 
exists a structured substitution treatment programme (JDH - mainly liquid oral 
methadone – 105 patients in 2006) provided by specialised agencies (JDH) and a lower 
threshold substitution treatment offer provided by freelance state licensed MDs 
(MEPHENON ®, METHADICT ® and SUBUTEX ®).  
 
Until 2001 methadone and buprenorphine have been prescribed as part of a long-term 
treatment with a medium or long-term abstinence goal. There are, however, a series of 
cases in which substitution treatment has to be considered rather as a harm reduction or 
maintenance measure than abstinence oriented therapeutic action. The grand-ducal 
decree of 30 January 2002 lists medicaments as well as preparations containing 
methadone (liquid oral form in programme and pill form in lower threshold prescription) 
and buprenorphine if the notice mentions substitution treatment as a possible 
therapeutic indication. Furthermore, morphine-based (salts) medications can be 
prescribed if the listed substances are deemed inadequate by medical authority. Finally, 
the decree allows for heroin prescription in the framework of a pilot project managed by 
the Directorate of Health. The list of substitution substances may be rapidly modified 
by amending the referred decree. In addition to drug prescription and medical care, the 
grand ducal decree on drug substitution treatment (30/01/2002) defines a series of 
psychosocial counselling services to be provided by licensed specialised centres. 
                                                                  
32  The decree of 30 January 2002 regulating the modalities of substitution treatment can be downloaded at: 
http:www.eldd.emcdda.org 
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Licensed MDs may refer substitution patients to licensed treatment centres for 
psychosocial counselling. 
Diverted MEPHENON ® (methadone in pill form prescribed by accredited MDs) is 
largely available on the national black market. This situation is primarily due to 
uncontrollable multiple prescription of mephenon® and dealing between patients and 
other drug addicts. Given that no centralised substitution treatment register does 
currently exist, prescribing MDs have major difficulties in determining rapidly whether 
their patient is simultaneously be prescribed a substitution drug by one or more of 
his/her colleagues. In that respect, a central substitution register is about to be 
implemented jointly by the ‘Surveillance Commission on Substitution Treatment 33’, the 
national drug coordinator and involved specialised treatment centres. The permission for 
its creation has been granted by the national data protection commission in June 2006 
and it should be operational by the end of 2007. 
 
The union of national sickness funds annually provides the number of patients receiving 
referred substitution drugs on prescription as well as the number of prescribing MDs. 
One observes a recent stabilisation of low threshold substitution demands and a 4-years 
decrease of the number of patients choosing the official substitution programme, more 
demanding in terms of therapeutic constraints.   
 
Table 5.3 Outpatient, low threshold prescription of substitution drugs by the national network of liberal MDs 
YEAR 1999 2000 2001 2002 2003 2004 2005 2006
Number of indexed patients (double counting 
controlled) 
745 844 849 820 913 / 970 939 
Number of prescribing GPs (double counting 
included)  
/ / / 1,487 1,554 1,553 / / 
Number of prescribing GPs (double counting 
controlled)  
125 145 147 157 154 158 163 121 
Source : Union des Caisses de Maladie 2006 
 
A first scientific evaluation of the structured JDH substitution programme occurred in 
1995. In 1998, new evaluation software has been developed in collaboration with the 
NFP, which, in the medium term, aims at the integration of substituted patients' data 
directly in the RELIS database. In 2003 a third evaluation by an external expert occurred 
on basis of data provided by the referred evaluation software.  
 
The main conclusions of the evaluation exercise (Dellucci 2003) show the following 
trends: 
 
- Significant improvements of residential status, social independence of patients, 
occupational situation, financial situation and indebtedness status, frequency of 
penal and judicial contacts, health indicators and frequency of risk behaviours, 
 
- No significant improvement of parallel consumption patterns of illicit opiates by 
substitution patients. 
 
 
 
                                                                  
33 The decree of 30 January 2002 replaces the former ‘Methadone Commission’ by the ‘Surveillance commission on 
substitution treatment’ mandated to control all aspects of substitution treatment at the national level. Established in 2002, 
it is composed of delegates from the programme, the Directorate of Health, two pharmacists and two GPs affiliated to the 
programme, and is in charge of admissions, releases and exclusions of substitution treatment demanders or patients. The 
composition of the new commission is similar to the one of the former Methadone commission. 
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6. Health Correlates and Consequences  
 
 
Overview 
 
At the national level two drug-related deaths indexing routines do currently exist: 
 
1. The Special Drug Unit of the Judicial Police (SPJ) maintains a register on acute 
drug deaths (RSPJ). The RSPJ indexes all direct overdose cases due to illicit drug use 
documented by forensic evidence. RSPJ applies the following definition of acute/direct 
drug-related death:  
 
‘Lethal intoxication, voluntary, accidental or of undetermined intent, confirmed by 
forensic and contextual evidence, and caused directly by the use of illicit drugs or by any 
other drug(s) if the victim has been known to be a regular consumer of illicit drugs’. 
Death has occurred due to an adverse somatic reaction to substance intake’. 
 
2. The statistical department of the Directorate of Health maintains the General 
Mortality Register (GMR) indexing all deaths that occurred on the national territory by 
means of death certificates provided by GPs. Since 1998 the GMR applies the 10th 
revision of the International Classification of Diseases (ICD-10). Special software jointly 
developed by the statistical department and the national focal point allows to extract 
drug-related death cases from the GMR by the application of a predefined standard (e.g. 
DRD). 
 
Infectious diseases, including HIV and viral hepatitis have to be reported following 
diagnosis to the Directorate of Health (Ministry of Health) that compiles data and is in 
charge of nation wide epidemiological follow up. The national drug monitoring system 
RELIS provides self reported data on infectious diseases in PDUs. Furthermore specific 
studies provide complementary information. The report includes data from the most 
recent Origer & Removille (2007) study on infectious diseased in PDUs applying 
serological test results to assess current prevalence rates and apply vaccination 
schemes if medically indicated. 
 
• DRUG RELATED DEATHS AND MORTALITY OF DRUG USERS 
 
o Direct Overdoses and (differentiated) indirect drug related deaths (see 
ST5 and 6) 
 
Based on the outcome of the study:  ‘Epidemiological study on drug-related deaths and 
on the analysis of methodological aspects of indexing procedures applied in the Grand 
Duchy of Luxembourg from 1992 to 2000’ (Origer & Dellucci  2002), the NFP has 
decided to update annual figures by comparing SR (RSPJ) data with DRD version 3.0 
data.  
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As can be seen in figure 6.1 the DRD v. 3.0 standard (selection B) appears to be a fair 
proxy of direct/acute drug deaths as indexed nationally by the RSPJ. Overall drug 
related mortality, however, should not be assessed by the same standard as far as 
Luxembourg is concerned.  
 
The number of fatal acute overdoses indexed at the national level has shown an 
increasing trend from 1985 to 1994 (29 cases), followed by a slow decrease until 1997 
(10 cases). A similar evolution has been observed between 1997 and 2005, showing a 
peak in 2000 (26 cases) decreasing anew to almost historically low level of 8 cases in 
2005. A new upward trend is observed in 2006 and will probably be confirmed by 2007 
data. This trend is unfortunately consistent with latest developments in most other EU 
Member states.  
 
Compared to national prevalence figures on problematic drug users in 2000 (N = 2.450), 
in 1999 (N = 2.350) and in 1997 (N = 2.100) (Origer 2001), overdose cases represent a 
rate varying between 0.48% in 1997 and 1.1% in 2000 (0.77% in 99). Referred to the 
total number of drug-related deaths, indexed by national law enforcement agencies 
and forensic institutes, the same proportion shows weaker variations: 1.346% in 2000, 
1.361% in 1999 and 1.333% in 1997. In absence of new drug prevalence estimates for 
2001 and 2002, drug related death prevalence rates for those years have not been 
computed. 
 
Figure 6.1 Evolution of drug-related death cases (direct - indirect - total mortality) 
from 1990 to 2006 (Origer 2007)
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The overdose rate in the national general population figured 6.43 overdose deaths 
per 100,000 inhabitants34 in 2000 (2.09 in 1997). An international comparison shows that 
the overdose rate of the G. D. of Luxembourg in 2000 was among the highest within EU 
Member states. 2001 and 2002 figures, however, show significant decreases. In 2006 
overdose rates of 4.13 and 6.16 per 100.000 inhabitants and 100.000 inhabitants aged 
15 to 64 years respectively have been observed. 
The overall discontinuous decrease of acute overdose cases from 1994 onwards has 
been associated to the regionalisation and extension of the methadone substitution 
programme as well as to the further development of low threshold facilities. Whether the 
latest upward trend in acute drug deaths is due to increasing drug user prevalence, a 
changing drug market profile and use patterns, remains uncertain. A national expert 
group, jointly with the national drug coordinator is analysing potential risk factors and 
contexts and will report their conclusion and recommendations to the minister of Health. 
 
The decreasing trend from 2000 to 2002 may be a medium term consequence of the 
higher proportion of non-i.v. opiate users observed during that same period followed by a 
stabilisation around 4.5 percent. Also, availability and quality of drugs available on the 
national market, multiple-drug use, associate morbidity and contexts of drug-related 
deaths are some of the relevant topics that have been addressed by a study on drug-
related deaths (Origer & Dellucci 2002). The positive evolution of direct drug deaths is to 
be associated to the implementation of a drug consumption room in 2005. Considering 
that since the opening in 2005 of the drugs injection room more than 80 overdose 
victims could be assisted and reanimated in this same facility, the life-saving 
effectiveness of such an offer is proven. This said, the actual increase of overdose cases 
                                                                  
34 All age groups  
Figure 6.2   Evolution of drug-related mortality rates (direct - indirect - total mortality)
per 100,000 inhabitants aged 15 to 64 from 1990 to 2006 (Origer 2007)
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in 2006 would be much more important and is associated to other factors that most other 
Member States seem to be confronted to, to a similar extend. 
 
A retrospective study (1992-2006) on drug-related death cases performed in 2007 
allowed a better understanding of risk and protective factors (Cocsit, in press). 
 
Forensic data by the department of National Toxicology Laboratory on Health35 show 
that the most frequently involved substance in overdose cases is heroin, followed by 
methadone and cocaine. To stress that since 2000, methadone presence in blood 
samples of overdose victims has been increasing. 
 
The vast majority of victims are male (83%) and their mean age at the moment of death 
shows an important increase over the past 10 years (in 1992: 28.4 years and in 2006: 
32.5 years). Although the mean age of drug overdose victims has been increasing, the 
number of victims aged less than 20 years remains relatively unchanged during 
observation period. 
 
A confirmed majority of drug-related victims are natives. During the entire observation 
period Portuguese citizens stand in second place, followed by Italian and French 
residents. Recently, one could observe an increasing number of victims from the frontier 
zone (BE, DE, F) and a dropping number of victims of Portuguese origin. 
 
Also worth mentioning is that a majority of acute drug death victims are known by law 
enforcement agencies (75%) for their drug user “career”, which lasts for 10 years (in 
average). Furthermore over 80% of the known victims made at least one treatment 
before their death and half of the individuals had an accommodation that could be 
qualified as stable. As far as the place of death is concerned, since 2004 approximately 
50% occurred at the victims’ home, followed by public place and detention centre.  
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Figure 6.3  Gender distribution of direct drug-related death cases (1992 - 2006) (%)
females 5 0 23 18 26 6 24 17 18
males 95 100 77 82 74 94 76 83 82
2006 2005 2004 2002 2000 1998 1996 1994 1992
 
Source: RELIS 2006 
 
 
 
 
 
 
 
 
                                                                  
35 Département de Toxicologie du Laboratoire National de Santé 
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Table 6.1. Age distribution of direct drug death cases indexed from 1992 to 2006 
 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 Total 
< 20 1 1    2 1 1   1  3 3  12 
20-24 4 2 1  4 2 8 3 2 2 5 6 6 6 6 55 
25-29 4 1 4 2 1 5 6 6 5 5 5 10 13 2 6 73 
30-34 2 1 3 4 3 2 6 3 2 2 4 5 6 3 3 46 
35-39 5 1 2 3 1 5 4 3 4  1 2 1 1  28 
40-44 2 1 2 3  2 1 1 3   2   1 16 
45-49   1 2 2  1     1   1 7 
> 50 1 1         1     2 
Mean 
Age 32.5 31.48 32.17 36.64 31.18 31.5 29 29.35 32.3 26.7 28.5 29.85 26.8 24.6 28.4 239 
 
o Mortality and causes of deaths among drug users 
 
In terms of drug-related mortality (direct and indirect deaths indexed by RSPJ), 38 
cases have been indexed in 2006 (17 in 2005); prevalence has been showing small 
variations since 1996 figuring roughly 17 to 33 cases per year. 
 
The above mentioned study (Origer & Dellucci 2002)36, has revealed that, as far as the 
Grand-Duchy of Luxembourg is concerned, the mere application of the DRD standard 
does not allow for a valid computation of drug related death cases. Therefore, the 
authors did compute the total number of drug-related deaths by adding cases of the SR 
that were not indexed by the application of the DRD standard to the GMR. The figures 
resulting from corrected DRD v.3.0. data are referred to as ‘national selection’ and 
provide the annual total number of controlled drug-related fatalities at the national level 
[38 in 2006 of which 19 direct/acute death cases (17 & 8 in 2005)].  
 
In 2000, a first cohort study on the mortality in the national drug population has been 
performed by the NFP in the framework of a multi-methods prevalence study (Origer & 
Pauly 2000). The cohort included 242 opiate drug addicts followed from 1991 to 1999. 
Mortality data have been collected from treatment agencies, the RELIS database, the 
GMR and the Special Overdose Register of the SPJ. In accordance to applied 
methodologies, results show mortality rates varying between 2.36 and 2.51 per cent. 
 
Origer & Dellucci (2002) reported 38 drug-related death cases in 2000. Applied to the 
estimated number of problematic drug users in 2000 (2,450) (Origer 2001), one obtains 
a rough mortality rate of 1.51%. The difference might be explained by the fact that the 
cohort study only included IVDUs whereas the prevalence estimation, on which the 
present calculation is based, refers to PDUs. 
 
Since the implementation of ICD-10 coding by the GMR (1998), a vast majority of acute 
drug death cases have been recorded as “accidental poisoning” (X40 – X49), which is 
consistent with the national definition of an acute overdose death. To date over 60 % 
overdose cases have indexed as follows:  X42.-, T40.-, T42.- T43.- . At a more restricted 
level the code sequence: X42.-, T40.- includes around 70% of all reported overdoses. 
The low DRD selection B figure for 2004 is partly explained by the fact that a consistent 
number of acute drug death cases have been encoded X49.0 +T50.9 or X44.9 + T50.9 
in the GMR. Knowingly, these selections are not retained by the DRD version 3 
(selection B) standard. 
                                                                  
36 A full text version of the study can be downloaded under: http://www.relis.lu 
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Main causes of indirect deaths between 1996 and 2006 are, in order of importance: 
suicide (32)37, traffic accidents (22%), associated cardio-vascular or pulmonary 
complications (15%) undefined intoxication (11%), pharmaco-dependance (7%), liver 
failure (6%), HIV/AIDS (4%) and other (2%).  
 
• DRUG RELATED INFECTIOUS DESEASES  
 
o HIV/Aids, viral hepatitis, STD, tuberculosis, other infectious morbidity 
 
Official data from the national Retrovirology Laboratory of the CRP-Santé provide the 
number and proportion of IVDUs in HIV infected patients. Between 1984 and 2006, 
767 HIV infected persons have been registered at the national level; 103 of the former 
were reported IVDUs, which leads to an average proportion of IVDUs in the national HIV 
population of 13.43 per cent since the registration of the first HIV case in Luxembourg in 
1984.  
 
Currently intravenous drug use appears to be the third most reported 
transmission mode of HIV infection (new HIV infections after heterosexual and 
homo/bisexual transmission). This sequence has remained fairly stable since 2000. The 
proportion of intravenous drug use transmission has noticeably decreased between 
1998 (23%) and 2004 (5%), although the number of newly indexed HIV infection has 
increased from 30 to 60 cases during the same period and figured 52 in 2006. 
 
 Source : Laboratoire de Retrovirologie – CRP-Santé. 2007 (data formatting NFP) 
 
Since 1996, the national drug monitoring system RELIS allows for breakdowns of HIV 
and AIDS data by IVDU and treatment status. In 2006, 83% of RELIS indexed PDUs 
reported a test during the last 5 months. Female PDUs tend to report higher testing 
rates than males. 
 
In 1997, a significant decrease of HIV rates in drug users, mainly in IVDUs, occurred. 
Subsequently, HIV rates in current IVDUs have been increasing to reach 2.76% in 
2006. Treatment demanders show the highest HIV prevalence rate (3.49%). 
 
                                                                  
37 Valid percentage 
Fig. 6.4   Proportion (%) of  IDUs in newly infected HIV patients 
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A study on HIV and HCV prevalence in prison, commissioned by the Ministry of 
Justice in 1998 (Schlink, 1998), tends to confirm RELIS figures. The study included 90% 
of the total national prison population and applied saliva antibody testing.  
 
A recent study by Origer and Removille (2007)38 assessed the national prevalence 
via serological test results HIV, HCV, HAV and HBV in the population of problematic 
users of illicitly acquired drugs. Furthermore the authors performed a cross sectional 
analysis of the relation between the studied infections and selected observable factors, 
to increase the national vaccination coverage and to refer infected persons towards 
appropriated medical treatment centres. (See ST 9) 
 
Eight month data collection in 2005 allowed establishing 1,167 contacts, of which 395 
were conclusive and numerous new cases of infection have been identified. It is the first 
study of this type ever conducted at national level. 
 
The study shows that the self reported data do not mirror validly the prevalence (both 
furnished by the study) but the latter show a satisfactory match between the self 
reported rates provided by the national drug monitoring system (RELIS). 
 
The HCV prevalence rate of the total study sample is 71.4% and reaches 81% in ever 
injectors. The highest prevalence rate (86.3%) was observed in in-prison respondents, 
followed by those in inpatient treatment centres (75.4%) and those in outpatient 
treatment centres (58.2%). 
 
The HBV prevalence (comprising acute/chronic infection and past cured infection) in the 
G.-D. of Luxembourg among PDUs situates around 21.6% and figures 24.7% in ever 
injectors. HBV prevalence in out-treatment centres is 16.4%, 15.1% in the in-treatment 
centres and up to 31.8% in prison. 32% of the PDUs could benefit from hepatitis B 
vaccination. 
 
Concerning HAV prevalence, no case has been identified in the present study. It should 
be stressed, however, that 43% of the participating PDUs are not protected against 
hepatitis A. 
 
The HIV prevalence among the PDUs provided by the study figures 2.9% for the overall 
population and 2.5% if exclusively referred to ever injectors. The HIV prevalence rate is 
1.9% in the in-treatment centres, 7.7% in the prison centres and is null in in-patient 
centres. 
 
One has to bear in mind that among persons infected by HCV, HBV and HIV, 
respectively 96%, 95.2% and 71.4% are ever injectors. It is important to note that the 
highest prevalence rates are observed among the prison population. This has to be 
confronted to the fact that 56.1% of the respondents with current or past prison 
experience (N: 246) declare having consumed illicit drugs in prison whereof 54.3% 
report intravenous use during detention. Among these lifetime injectors in prison 20% 
reported exclusive use of new and sterile syringes, 53.3% declared never having 
exchanged syringes with other inmates and 26.7% report syringes’ exchange in prison.  
The study also refers to a series of determinants such as, inefficient disinfection 
methods such as cleaning injection paraphernalia with water or urine, inadequate 
                                                                  
38 Downloadable at: http://www.relis.lu 
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syringe elimination, a high proportion of PDUs not using condoms during sexual 
intercourse, especially with new partners or irregular partners, the lack of or false 
knowledge of serological status and finally, protection strategies based on subjective 
criteria rather than on established knowledge. 
 
Although strategies for risk reduction in the population of problematic drug users in the 
G.- D. of Luxemburg exist, this study underlines the high prevalence of certain infectious 
diseases in the target group and in particular hepatitis C (HCV). 
 
The existing prevention efforts have to be completed putting particular emphasis on 
young and new drug users. Although the study confirms a low compliance of the target 
population, screening and vaccination facilities have to be further developed. In this 
context the authors put forward a series of approaches that may contribute to reduce 
incidence of infectious diseases and related risks in PDUs (see Origer, Removille, 2007). 
 
Table 6.2 Synopsis of national data on HIV infection rate in drug using populations (valid %) 
YEAR 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
HIV rate in problem drug users  
(RELIS self-report) 
3 2.9 2.9 4.3 4.07 4.49 3.88 3.98 3.31 2.9 
HIV rate in problem drug 
users  
(Origer & Removille, 2007) 
        2.90 / 
HIV rate in drug treatment 
demanders  
(RELIS self-report) 
3.8 2.6 3.4 4.87 4.78 4.32 3.88 4.93 3.84 3.49 
HIV rate in current IVDUs  
(RELIS self-rep.)) 
3.6 3.5 3.3 3.6 3.41 4.08 4.17 5.10 3.96 2.76 
HIV rate in current IVDUs 
treatment  
demanders (RELIS self-report) 
4.5 3.4 3.9 3.9 4.24 4.32 4.24 6.41 4.59 3.33 
HIV rate in life-time IVDUs  
(Origer & Removille, 2007) 
        2.50 / 
HIV rate in current IVDUs 
prisoners  
(Schlink 1998) 
/ 4.4 / / / / / / / / 
Source: RELIS 2006 
 
Table 6.3 Synopsis of national data on AIDS rate in drug using populations (valid %)   
YEAR 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
AIDS rate in problem drug 
users (RELIS) 
2.5 2.5 1.25 1.35 2.03 1.72 1.71 2.13 1.81 1.19 
AIDS rate in drug treatment 
demanders 
/ / 1.66 1.76 2.43 1.60 2.04 2.69 2.37 1.65 
Source: RELIS 2006 
 
The prevalence of HBV infection in problem drug users has been showing a decreasing 
tendency during recent years based on self-reported data. The results provided by 
Origer and Removille (2007) study based on blood sample provide slightly higher yet 
consistent rates in PDUs. The significant increase of the HCV infection rate during 
the same period is particularly marked in IVDUs, figuring 64.94% to 81% according to 
risk groups (current, ever -injectors) and applied methodologies (self-reports vs. blood 
tests).  
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Table 6.4 Synopsis of national data on self-reported HBV infection rate in drug using populations (valid %) 
YEAR 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
HBV rate in drug users 
(RELIS self-report) 
29 30 30 28 25 22 20.51 21.34 18.67 17.21 
HBV rate in PDUs 
(Origer & Removille ) 
        21.6  
HBV rate in drug  
treatment demanders  
(RELIS self-report) 
/ 27 32 27 24 20 19.79 22.69 18.58 16.46 
HBV rate in IVDUs  
(RELIS self-reports) 
/ 33 35 30 30 25 22.76 23.93 20.08 18.32 
HBV rate in ever-
injectors 
(Origer & Removille) 
        24.7  
Source: RELIS 2006 
 
 
Table 6.5 Synopsis of national data on HCV infection rate in drug using populations (valid %) 
YEAR 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 
Self-reported HCV rate 
in drug users (RELIS) 
26 25 32 46 50 49 59.92 64.55 64.94 64.95 
HCV rate in PDUs 
(Origer & Removille) 
        71.40  
Self-reported HCV rate 
in drug treatment 
demanders 
/ 29 41 53 54 54 60.49 66.16 66.22 63.23 
HCV rate in IVDUs 
prisoners  
(saliva tests) 
/ 37 / / / / / / /  
Self reported HVC rate 
in IVDUs (RELIS) 
 45 50 53 56 53 67.97 74.14 74.38 69.58 
HBV rate in ever-
injectors 
(Origer & Removille) 
        81  
Source: RELIS 2006 (Origer 2007) 
Summarily, HBV infection prevalence in PDUs and in drug treatment demanders is fairly 
stable while HCV prevalence in PDUs has significantly increased during the last 5 years. 
HIV infection rates show a decrease especially referred to IVDUs. 
 
• PSYCHIATRIC CO-MORBIDITY (DUAL DIAGNOSIS) 
 
o Personality disorders, depression, anxiety, affective disorders 
 
To date any genuine study on co-morbidity patterns in PDUs has been performed at the 
national level. Data presented in the present chapter have been provided by specialised 
drug agencies and the RELIS drug monitoring system and thus reflect common 
experiences and trends as observed during recent years. 
 
Most common mental disorders observed in clients seeking help in specialised drug 
agencies or in contact with other institutions are: anxiety, depression, neurosis, 
psychosis and borderline behaviour. Residential drug care settings estimate that 10% of 
their clients show psychotic symptoms. Furthermore, Post Traumatic Stress Disorders 
(PTSD) are most common and show great similarities with border-line behavioural 
aspects as for instance rapidly changing mood and auto-destructive tendencies. 
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Referring to annual data provided by the national drug monitoring system RELIS one 
could draw the following picture: 
 
Fig 6.5  Previous contacts with psychiatr ic services .1998- 2006
87 85
22
42 41
88
8381
8487
82
87
3928 31
43
32
0
10
20
30
40
50
60
70
80
90
100
1998  (214) 1999  (211) 2000 (247) 2001 (313) 2002 (380) 2003 (320) 2004 (301) 2005 (298) 2006 (310)
Contacts with psychiatric services
Contacts with psychiatric services
excluding detoxification
  
SOURCE: RELIS 2006 
 
  SOURCE: RELIS 2006 
 
Figure 6.5 differentiates between contacts with psychiatric services and psychiatric 
contacts excluding detoxification. This distinction is necessary since, at the national 
level, most of detoxification treatments are provided by psychiatric departments of 
general hospitals. 
 
Data from 1996 to 2006 reveal a quite stable proportion of PDUs showing a psychiatric 
history, unlike the proportion of clients reporting contacts for mental problems excluding 
detoxification treatment, which has been following an increasing trend in recent years.  
 
There seem to be no significant differences of psychiatric profiles in clients according to 
the type of institutional settings. Consume patterns of double diagnosis (DD) patients are 
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most frequently chaotic ranging from moments of absolute abstinence to life-threatening 
doses intakes. Multiple drug use is observed in almost every DD patient. 
DD patients are considered as drug treatment demanders with specific and highly 
diversified needs that are difficult to encounter in traditional drug agencies. The concept 
of ‘multiple vulnerabilities’, that is, concomitant vulnerabilities to drug abuse and mental 
disorders, tends to be recognised by professionals. DD patients very often present a lack 
of behavioural structure or stability. Usually those patients are unable to function in a 
regulated environment. For instance, they show great difficulties to respect time frames 
(e.g. appointments, length of therapeutic sessions) or any other form of commitment. 
Moreover, the requirement of most therapeutic settings include that the patients submit 
to detoxification treatment prior to admission. This latter requirement is often impossible 
to meet with DD clients as drug intake often represent a kind of self-managed auto-
medication, dangerous to change radically at the beginning of a therapeutic process. It is 
therefore most difficult to integrate DD patients in traditional drug care settings also in 
terms of consistency of rules to be respected by all drug treatment demanders. This 
specificity has lead to the concept of ‘dry, damp and wet house’ in several countries, 
meaning that there should exist settings with modulated tolerance policies with regard to 
drug use during the treatment process. Several national treatment centres do try to 
implement similar concepts, although the legal situation does not facilitate such 
developments. 
 
Moreover DD patients do require time and cost intensive care strategies as for instance 
individual case management and emergency interventions. This kind of additional 
service providing does often lead to conflicts in terms of human resources management 
and economical constraints. 
 
The overall impression of specialised drug workers reflects a lack of qualification when it 
comes to the handling of DD patients. Training of drug workers did most commonly not 
include practice oriented intervention tools to be applied to DD patients. If required, drug 
agencies’ staff is provided with on-the-spot training. Since there exist no care facilities 
specialised in drug addiction co-morbidity at the national level, the Department of 
Medical Control of Social Security Administration, in collaboration with drug agencies, 
assesses whether a given patient should be referred to specialised institutions in foreign 
countries. There exist agreements between the latter administration and a series of 
specialised care agencies abroad. If the referral demand is approved, related costs are 
reimbursed by Social Security.  
 
Low threshold agencies do not provide psychiatric counselling. If required, clients are 
referred to specialised drug treatment centres or directly to psychiatric care departments. 
 
As far as treatment of DD patients in prison are concerned a collaboration convention 
between the national prison administration (CPL) and the national neuro-psychiatric 
hospital (CHNP) has been signed in 2002. The convention sets the framework for the 
creation of a psycho-medical department within prison and regulates prevention, care 
and referral of mentally disabled as well as alcohol and drug dependent inmates. 
Therapeutic care, substitution treatment and counselling is provided ad hoc. In case of 
severe mental disorders, imprisoned patients are referred to a high security department 
within the CHNP. 
 
Compulsory treatment or confinement does only occur if there is a proved offence 
against the law by which the offender is declared irresponsible of his/her own behaviour. 
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This only occurs following a legal psychiatric expertise. Due to the lack of specialised 
infrastructures, the NFP disposes of no data on DD treatment and outcomes. 
The pertinence of ‘case management’ has been recognised by professionals during 
recent years. Although this method is cost and time intensive, it has proven to be most 
effective with double diagnosis patients. Not only tend the DD patients to have very 
specific needs; they also often present extreme variations in mood and behavioural 
patterns. 
 
The above quoted priority areas result from professional experience sharing. As the 
implementation of drug treatment and prevention strategies are traditionally planed and 
executed by the national drug coordinator’s office in close collaboration with field 
agencies, emerging needs are effectively integrated in political debates and action 
planning. The 2005-2009 national drugs action plan foresees the creation of a 
specialised therapy centre for DD drug patients by 2007. 
 
• OTHER DRUG-RELATED HEALTH CORRELATES AND CONSEQUENCES 
 
Health indicators retained by RELIS suggest a stabilisation of the general health state of 
indexed PDUs except for HCV prevalence. In 2006, 84 per cent of problem drug users 
.reported a self-perceived satisfying general health condition against 53 per cent in 
1997. Half of indexed PDUs report single or multiple suicide attempt(s) during lifetime. 
No significant changes have been observed during the last 5 years. 
 
 
 
7. Responses to Health Correlates and Consequences 
 
 
Overview 
 
Responses to Health Correlates and Consequences of drug use aim at minimising the 
resulting damage on the drug users him/herself and on his/her environment and at 
increasing individual/collective resources. The concept of risk and harm reduction are 
directly linked to it, whereas nuisance reduction is seen as a correlate of the latter. 
Health care offers to drug users are provided by specialised drug care agencies as well 
as by the general health care system. No reliable data and drug treatment demands 
from general healthcare providers are currently available with the exception of 
detoxification treatments provided exclusively by psychiatric departments of general 
hospitals and ambulatory substitution treatment prescribed by authorized GPs. 
 
In May 2006 a new national HIV/AIDS action plan covering the period 2006 to 2010 
has been launched by the Ministry of Health. The action plan is based on 8 pillars 
including prevention of infectious diseases and harm reduction in drug using 
populations. It complements or enhances measures included in the national drugs action 
plan 2005 – 2009. The document can be downloaded under http://www.ms.etat.lu. 
 
• PREVENTION OF DRUG RELATED DEATHS 
 
o Overdose prevention 
 
In 1999 the NFP has commissioned a study on epidemiological and methodological 
aspects referred to drug related deaths. Results were published in 2002: 
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‘Epidemiological study on drug-related deaths and analysis of methodological aspects of 
indexing procedures applied in the Grand Duchy of Luxembourg from 1992 to 2000’ 
(Origer & Dellucci 2002). The epidemiological part of the study was designed to provide 
information on the process that leads a drug user to a drug induced fatality and to 
contribute to implement prevention measures.  
 
Several risk factors or profiles have been stressed by the study: 
 
- A statistically significant difference in age between male and female overdose 
victims has been observed (F: 25.65 years, M: 29.17 years). The same result applies to 
the overall number of drug-related death cases. Female PDUs often report relationships 
with older drug using partners, who have initiated them to drug use and accelerated their 
drug careers in terms of rapid transition from non-i.v to i.v. use and an increased 
disposition towards risk behaviours such as needle sharing and prostitution. (Origer & 
Dellucci 2002) 
 
- The release from an institutional setting (e.g. prison, residential therapy, etc.) often 
creates a high-risk context for concerned persons in terms of social deprivation and 
substance tolerance levels. A significant number of drug-related death cases occur 
rapidly after institutional release (sometimes only a few hours). 
 
- A majority of drug-related deaths cases (direct & indirect) are natives (64.6 to 90.9%). 
The same observation applies to direct and indirect drug deaths analysed separately. 
The non-native subpopulation of victims is primarily composed of Portuguese citizens, 
which proportion is much higher than the one observed in the general population. 
Italians follow Portuguese natives and citizens from border countries which proportion 
has remained fairly stable during the last four years. 
 
The following measures have been recommended: 
- opening of supervised injection rooms as foreseen by the national drugs action plan 
- medical controlled heroin distribution programme (foreseen by the national drugs 
action plan) 
- first aid training courses provided to users and their relatives and partners 
- gender and ethnic specific interventions 
- provision of morphine receptor antagonists to users and selected persons 
- creation of  ‘transition centres’ for ex or current drug addicts leaving an institutional 
setting, 
- development of reintegration programs for prisoners in the framework of the recent 
‘Global care programme for drug addicts in prison’ 
 
At the time of writing, 6 of 8 of these recommendations have been put to action. 
 
The law of 27 April 2001 introduced an important modification of the basic drug law with 
regard to overdose prevention. Art.10-1 of the referred law exempts drug users who call 
for assistance in case another user is in need of medical help, from prison sentences. 
This change is supposed to reduce drug-related deaths occurring in consumer groups. 
 
Finally, in the line of the recommendations of the Origer and Dellucci (2002) study, a low 
threshold service in collaboration with the Ministry of Health edited a documentation kit 
on overdose prevention and emergency intervention by peers. The information kit 
includes flyers on following issues: 
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- First aid in case of an overdose. Useless interventions (such as salt injections). 
Epileptic crisis. Potential added risks of substance mixtures. Vein care. Potential risk 
of specific injection points. Inhalation as administration mode. Risks of abscesses 
and endocarditis. 
 
Provision of first aid and harm reduction training to drug users and peers takes place in 
low threshold agencies. 
 
A drug injection room is defined as a facility allowing IVDUs who meet certain criteria 
to inject their own drugs in a medically supervised environment.  Drug consumption 
(user) rooms meet the same definition; in terms of target population, they, however, 
give access to IVDUs and non IVDUs meeting the admission criteria. 
 
Articles 2 and 3 of the law of 27 April 2001 have set the legal framework for ‘user rooms 
and other means duly licensed by State’, which also includes controlled distribution of 
certain narcotics (e.g. heroin). The implementation of such facilities is included in the 
national drugs action plan 2005-2009 of the Ministry of Health.   
 
The implementation of a drug injection room has to be seen as a part of a broader harm 
and nuisance reduction oriented strategy. The national drug action plan referred to the 
creation of a low threshold emergency shelter facility for drug addicts to be implemented 
in the vicinity of the city railway station. During the planning phase of this centre it has 
been decided to integrate a drug user room due to obvious advantages to combine both 
of them (in terms of logistics staff and situation).  
 
In July 2005, the first injection room at national level has become operational and has 
been integrated in the low threshold emergency centre for drug addicts. Besides the 
drug consumption room, as it is called officially, the emergency centre provides the 
whole range of harm reduction services, counselling facilities, accommodation, washing, 
laundering and storing facilities. It should be added that the night accommodation is not 
to be seen as a permanent housing facility; there is indeed a daily admission procedure. 
Target population for the consumption room are primarily IVDUs. Inhalers might be 
admitted in a second phase. The main objective of the project is the reduction of drug-
related harm and nuisances. More precisely it aims at reducing the risks of infectious 
diseases, overdoses and public nuisance in the neighbourhood, contact making with 
difficult to reach addicts, provision of special designed night shelter facilities and 
avoiding unnecessary prison journeys over night. The project was designed with the 
support of law enforcement agencies.  
 
An expert group has been visiting similar projects in the EU in order to fine-tune the 
concept and implement quality control standards. The national drugs coordinator’s office 
elaborated the operational concept of the injection room. All involved parties meet once 
a month to assess the current situation and emerging problems related to the functioning 
of the consumption room. Opening hours are currently from 3 pm to 10 pm from Monday 
to Friday and Sunday. 
 
According to the first two-years’ evaluation of the injection room (June 2007), 381 
injectors had signed the mandatory user contract and proceeded to 14,330 injections 
supervised by trained staff. In September 2007 over 450 were already registered. The 
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facility were mostly used by men (79%); the most commonly used drugs were heroin 
(81%), cocaine (12%) or both of them (6%); age category 25-34 is most represented 
(56%). No fatal overdose has occurred thus far but over 80 overdoses have occurred 
and due to the immediate intervention of ad hoc staff all victims could be assisted, 
reanimated and saved. No drug scene concentration and no disturbances or nuisance in 
the neighbourhood have been observed. Over 600 safer use counselling sessions have 
been provided to clients. The concept of the drug injection room can be ordered at the 
Ministry of Health (alain.origer@.ms.etat.lu). 
 
As most relevant drug scenes concentrate in the City of Luxembourg and in the main city 
in the South of the country, Esch-sur-Alzette, intense discussions are currently held with 
the community council of Esch/A in order to implement a similar facility in the latter city. 
The aim is to further decentralise low threshold offers and enhance local city authorities’ 
commitment in the management of regional and urban drug problems. Involved national 
and local authorities have recently found an agreement on the geographical location of 
this facility although the concept has still to be agreed on. 
 
• PREVENTION AND TREATMENT OF DRUG-RELATED INFECTIOUS DISEASES 
 
o Prevention 
 
Interventions aiming at the prevention of drug-related infectious diseases have been 
initiated and developed prior to the set up of a proper legal framework. At that time, 
services as needle exchange and substitution programmes have been tolerated and also 
financed by the state. The last drug law amendment did not only allow maintaining and 
to further developing existing harm reduction offers but also set the first stone for the 
implementation of new services such as shooting galleries and medically assisted heroin 
distribution as foreseen by the national drugs action plan. 
 
The objective of these interventions is straightforward, that is an optimised management 
of risk factors and mental/physical damage associated to drug use. Reduction of public 
nuisance is a secondary objective. Traditionally harm reduction (HR) measures have 
been focusing on IVDUs since most exposed to a variety of health risks. Nevertheless, 
initiatives such as the provision of aluminium foils to heroin users and the current 
discussion on the future distribution of ‘strawbags39’ for sniffing purposes witness a 
progressive switch from IVDUs users to PDUs being considered as target groups. 
Furthermore infectious diseases prevention does not focus specifically on IVDUs as 
shows a recent action-research project on HIV and hepatitis infection among PDUs 
(Origer & Removille, 2007). 
 
The most relevant measure in the field of prevention of infectious diseases in drug users 
is the national needle exchange programme established in 1993 and co-ordinated by 
JDH. In addition to free of charge needle provision by specialised drug and AIDS 
agencies, automatic syringes dispensers/collectors have been placed in the most 
appropriate locations in five different cities of the Grand Duchy. Regarding the quantity 
of distributed syringes, table 7.1 shows an increase of 470 per cent during the period 
1996 to 2005. However, for the first time since the setup of the NSP, the number of 
distributed syringes stabilised in 2005 and significantly decreased in 2006. The reasons 
for this trend are yet unknown.  
 
                                                                  
39  A ‘straw bag’ contains one-way straws especially designed not to hurt the nasal cavities, thus avoiding wounds and 
bleeding, a special liquid to smooth tissues, a professional condom and lubricants. 
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Syringes return rates witness a steady upward trend reaching up to 93% in 2006 (88% in 
2005). Obviously automatic dispensers show lowest return rates.   
 
 
Table 7.1 National needle exchange programme 1996-2006 
  
Distributed syringes 
 
 
 
 
Collected used syringes 
 1996 1998 2000 2002 2004 2006 1996 1998 2000 2002 2004 2006 
TOTAL  76,259 109,743 189,413 254,596 435,078 332,347 28,646 
(38%) 
58,886 
(46%) 
112,625 
(59%) 
211,621 
(83%) 
376,491 
(87%) 
282,909 
(93%) 
 
Source: RELIS 2006 
 
Condoms and syringes are provided by the Division of Preventive Medicine 
(Directorate of Health) to field actors in the framework of the national programme on 
prevention of infectious diseases. Vaccination for HAV and HBV is free of charge for 
persons under 18. Several local outreach prevention activities have to be mentioned as 
for instance contact making with sex workers within their daily work environment for HIV 
and hepatitis testing and subsequent health care, if needed. These specific activities are 
currently further developed by the ‘Drop In’ centre for drug users and prostitutes (RED 
CROSS). 
 
Moreover, outreach interventions targeted at (drug using) prostitutes aiming to establish 
contact and to prevent dissemination of infectious diseases have taken place. According 
to EMCDDA’s key indicators and with a view to improve quality of national data on 
infectious diseases, the NFP has set up an action-research with the objective to 
estimate HCV and HIV prevalence in PDUs based on medical diagnosis data (blood 
testing) and to implement required health care infrastructures (Origer & Removille, 
2007).  
 
The project relied upon a cross-sectional study design, which analyses the relationship 
between the prevalence of hepatitis A, B, C and of HIV in the population of drug users 
with other relevant factors. Additionally a quantitative questionnaire (questions based on 
socio-demographic, illicitly acquired drugs consumption, consume patterns, sexual 
behaviour, consumption in prison, piercing/tattoo) allowed analysing associated factors. 
Serological analysis identified the number of contaminated cases with hepatitis A, B, C 
and HIV. In case of medical indication a vaccination against hepatitis A and/or B has 
been offered. Drug users meeting the selection criteria were recruited in LTS, NSEP, 
Inpatient Treatment Centres, Hospitals and in the prisons of Luxembourg. The NFP has 
been granted a full financing of the project by the FLTS.  
 
Hereafter some of the recommendations of the report: 
 
- Increase knowledge of serological status among general population and risk groups 
- Include  drug users in the planning process of prevention strategies 
- Reinitiate safer-use counselling for young and new drug users since they are often 
not aware of risk compared to older or more experienced users 
- Insure availability and free access to the whole range of injection paraphernalia (e.g. 
spoons, stericups, filters) in order to neutralise a maximum of infection vectors 
- Inform on ineffective disinfection and syringe elimination techniques. Often drug 
users think they do the right thing but their risk reduction strategies are ineffective 
due to a lack of knowledge (e.g. using only water for disinfection, throwing needles 
away and bringing only the syringe back to NEPs) 
 74
- Insuring 24/24 hours syringes availability and providing additionally spoons and 
filters in NEPs 
- Ensuring a better vaccination coverage and above all vaccination follow up by 
involving the general health care network (e.g. providing GPs with free Twinrix®)  
 
The final report has been published in September 2007 and may be downloadable at 
http://www.relis.lu. 
 
o Counselling and testing 
 
AIDSBERODUNG (RED CROSS) is the main national counselling and prevention centre 
for HIV and AIDS. Prevention campaigns are conceptualised by the AIDSBERODUNG 
team in collaboration with the Ministry of Health and an important network of volunteers. 
AIDSBERODUNG is part of the RELIS network. Testing is provided by the CHL and the 
LNS and is free of charge. The above-mentioned action-research aims at increasing the 
testing coverage of PDUs since it includes anonymous on-site testing and diagnosis 
transmission facilities. Furthermore, HAV, HBV, HCV and HIV testing and vaccination for 
HAV and HBV is proposed to each person entering prison. 
 
A new project foreseen by the national HIV/Aids action plan 2006-2010 focuses on 
outreach measures in order to better reach target populations and in particular 
vulnerable groups.  DIM (Mobile Intervention Facility) aims to access difficult to reach 
sub-populations and provide prevention counselling and infectious disease testing on 
site to various populations. The project is under preparation and should be operational 
by mid 2008. 
 
o Infectious disease treatment 
 
Treatment of HIV and hepatitis infections is covered by the insurance scheme. 
Specialised treatment is provided by a special unit in the CHL in collaboration with the 
counselling staff of the AIDSBERODUNG/Red Cross. In case the patient has no or no 
valid health insurance, treatment costs can be covered by state. 
 
• INTERVENTIONS RELATED TO PSYCHIATRIC CO-MORBIDITY  (NNIA) 
 
• INTERVENTIONS RELATED TO OTHER HEALTH CORRELATES AND CONSEQUENCES 
 
o Somatic co-morbidity 
 
The vast majority of specialised out- and inpatient and low threshold drug care facilities 
include medical or paramedical care in their service provision. If needed patients are 
referred to specialised treatment. Related costs are covered by health insurance 
schemes or by the Ministry of Health in case the patient has no valid insurance. 
 
In 2006 a concept of a specialised addictology department within a general hospital of 
Luxembourg-City has been presented to the Minister of Health. The concept foresees a 
holistic and network based care programme for patients presenting substance abuse 
and has been discussed by experts in the currently ongoing psychiatric reform in 
Luxembourg. 
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o Non-fatal emergencies and general health-related treatment 
 
No reliable data on drug related emergencies are currently available at the national level. 
Roughly estimated, 25% of emergencies are related to substance abuse (all substances 
included) (Rauchs 2006). Figure 7.1 refers to RELIS data on previous non-fatal and 
medically assisted drug overdose self reported by PDUs. The proportion of indexed drug 
users reporting at least one overdose (as defined) (16%) during lifetime has slowly 
decreased during the last six years. 
Fig. 7.1 Non fatal, medically assisted drug overdoses in RELIS respondents (1994-2006) (valid %) 
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Source: RELIS 2006 
 
o Prevention and reduction of driving accidents related to drug use 
 
The law of 18 September 2007 modifies the national traffic code and introduces testing 
of illicit drug use in vehicle drivers. The homologation of respective road side saliva tests 
(Drugwipe II) has still to be regulated by a grand-ducal decree. For more details on the 
new legislation please refer to chapter 1 (laws). 
 
o Other health consequences reduction activities 
 
The future implementation of a second drug consumption room in the South of the 
country and a medically controlled heroin distribution programme, as foreseen by the 
national drugs action plan 2005-2009 will further contribute to reduce drug related health 
damage. As far as the latter is concerned the Inter-ministerial Group on Drugs agreed on 
the opportunity of a national heroin distribution programme in September 2007 and the 
national drugs coordinator has been mandated by the Minister of Health to finalise the 
operational concept by March 2007. 
 
o Interventions concerning pregnancies and children born to drug users 
 
Since several years and in the context of the development of social paediatrics at 
national level, child care professionals and paediatricians call for the implementation of 
specialised care structures for children at risk. The approach of social paediatrics 
considers a child in his global context including physical, psychological, social and 
cultural health, family and environmental context and promotes coordination and 
collaboration between different social and medical services. 
 
In order to meet specific needs of children and parents at risk, especially children from 
drug addicted parents, the Ministry of Family and Integration has implemented a project 
of “out-of-hospital nursery” (Maison Françoise Dolto) targeting children aged 0 to 3 years 
 76
whose parents are temporarily not able to ensure child care and education. The centre 
aims to provide temporary admission to these children and helps to compensate the lack 
of parents’ involvement in child care. Besides, the structure offers therapy options, 
diagnostic testing and functions as a resource centre for parents. The project has a 
capacity for approximately 20 children and started in spring 2007.   
 
 
8. Social Correlates and Consequences 
 
 
Overview 
 
Social correlates of drug use typically involve Justice, Health and Educational 
competences. The Ministry of Health and the Ministry of Family both intervene to reduce 
social consequences by measures ranging from early detection of drug use to social-
professional rehabilitation measures. The reduction of drug related crime involves the 
Ministry of Justice, focuses on supply reduction activities and the Ministry of Health 
implements measures targeting socio-professional re-integration aiming at reducing daily 
expenses and depths of drug addicts and thus the prevalence of acquisition crimes. 
 
Due to obvious disparities at the European level in terms of concept definitions in the 
field of law enforcement data, the respective national terminology should be clarified:  
 
- ‘Interpellation’ (Eng. Interpellation/peremptory questioning, to call on):  
 
Intervention of law enforcement agents based on reasonable suspicion. The 
‘interpellated’ person is heard and a police officer’s record occurs. In practice the 
number of police records fits more or less the number of convictions (usually slightly 
inferior). At this level, however, there is no notification to the Public Prosecutor and no 
mention in the judicial record. 
 
- The term ‘prévenus‘ (interpellated/indicted person): 
 
Refers to persons who have been apprehended by legal enforcement agents for alleged 
offences against the national drug law (or against law in general). 
 
- ‘Arrestation’ (Eng. Arrest) :  
 
Interpellation followed by a deprivation of liberty and notification to the attorney at law. 
The preliminary examination (instruction) refers to the subsequent judicial procedure that 
leads to public audience, which claims the sentence. 
 
- ‘Condamnation’ (Eng. Conviction) : 
 
Judgement by which the accused person is found guilty. 
 
- ‘Détention’ (Eng. Imprisonment) : 
 
Deprivation of liberty. Distinction is made between protective custody (prior to the 
judgement) and regular detention (following conviction). 
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• SOCIAL EXCLUSION (AMONG DRUG USERS AND DRUG USE AMONG SOCIALLY 
EXCLUDED GROUPS) 
 
o Social exclusion 
 
The question whether substance abuse leads to social degradation and exclusion or 
social factors (e.g. family situation, poverty, low education or job perspectives) lead 
individuals to substance use is an unsolvable one, although it tends to raise competence 
discussions between ministries. Fact is that a vast majority of homeless and socially 
excluded people living in Luxembourg also present to various extends licit and/or illicit 
substance abuse. Taking care of the latter is not enough as the social situation of these 
people needs to be improved before there is a chance to obtain sustained results in drug 
treatment. This said, the national strategy of care for socially excluded people is based 
on the principle on progressive reintegration trough capacity building and the 
improvement of the social abilities and environment. Associations as ‘Stëmm vun der 
Strooss’ (Street voice), financed by the Ministry of Health, try to implicate the target 
population again in active life by providing a safe and common environment and 
respecting individual capacities and resources by applying case management 
methodologies further described in the chapter 9. 
 
o Homelessness 
 
Housing status of registered drug users has markedly improved during recent years 
and tends to stabilise. Since 1995, the proportion of persons disposing of a stable 
accommodation has more than doubled. Currently 76 percent (68%) of PDUs report a 
stable housing situation. This positive evolution may be linked to an increased 
awareness of the housing problem and the set up of new housing networks for socially 
deprived people by the Ministry of Health and specialised agencies referred to under 
chapter 9.  
 
Source: RELIS 2006 
 
 
Fig. 8.1 Last known housing situation of problem drug users. 1995 - 2006 
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o Unemployment 
 
Recent data suggest that the employment status of respondents tend to worsen. Also 
the unemployment rate has increased in 2006 (72%).  
 
Source: RELIS 2006   
Remark: STATEC: Statistical Department of State – Unemployment rate in active general population. 
 
Data on revenues confirm observed trends in occupational status: 
 
- increase of social dependence associated to a stable financial autonomy. The 
Guaranteed Minimum Income constitutes the primary source of revenue of PDUs; 
 
- illegal activities as main revenue have witnessed an ongoing downward trend since 
1995; 
 
- a high proportion of respondents reporting major debts (>2,500 EURO) (36%). 
 
Source: RELIS 2006 
 
A new occupational project foreseen for 2008 and run by the ‘Street voice’ (‘Stëmm vun 
der Strooss’) association could have a positive impact on the observed situation, 
knowing that there is a current lack of occupational offers for drug addicts at the national 
level. 
 
 
 
 
 
 
Fig. 8.2  Unemployment rate in problem drug users (1995 - 2006) 
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Fig. 8.3   Primary source of income of problem drug users (1995 - 2006) 
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o School drop out 
 
The educational level of PDUs is low and has been showing slow deterioration since 
1999. However, an increasing proportion of respondents start secondary school without 
bringing their studies to term. The average age at the end of studies shows a global 
decreasing tendency and currently situates under 17 years. Lower levels are particularly 
observed as regards acquired secondary and high school diploma. Post primary school 
is a special educational setting for primary school pupils with learning difficulties.  
Source: RELIS 2006 
 
o Financial problems (See below) 
o Social network (NNIA) 
o Sex workers (See Chapter 9: DIM Project)  
 
• DRUG-RELATED CRIME 
 
The NFP collects and re-formats nation-wide data on drug-related offences provided by 
the SPJ. A staff member of the NFP actively collaborates with the SPJ team in order to 
adapt law enforcement data to standards required for the editing of the national report on 
drugs and the EMCDDA annual report. 
 
o Drug offences 
 
As can be seen in tables 8.1 and 8.2, the total number of arrests (225) has increased 
discontinuously during the last 10 years. Traditionally heroin was the most frequent 
substance involved in drug-related arrests. In 2004 cocaine has turned to be the main 
substance involved in those arrests (confirmed by 2005 data), followed by heroin and 
cannabis. Since 2004, charges on drug traffic have known an important increase. 
 
Table 8.1 Arrests broken down by type reporting institution (1995-2006) 
 ARRESTS 
Year 1995 1997 1999 2001 2003 2004 2005 2006 
S.P.J. 27 25 27 7 25 38 26 39 
Gendarmerie 8 15 15 
Police 32 32 32 
 
45 
 
82 
 
103 
 
94 
 
124 
Customs 61 82 34 40 28 37 35 62 
Total 128 154 108 92 135 178 155 225 
Fig. 8.4  Educational level of RELIS respondents 
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Table 8.2 Arrests broken down by type of offence and substances involved (1995-2006) 
Substance Offence 1995 1997 1999 2001 2003 2004 2005 2006 
Use & Traffic 68 57 48 41 21 32 28 40 
Traffic/Deal 21 53 18 8 22 19 14 29 
Use 24 7 27 8 4 20 20 26 
 
Heroin 
Total 113 117 93 57 47 71 62 95 
Use & Traffic 20 27 21 27 19 21 21 26 
Traffic/Deal 7 23 9 9 30 64 42 38 
Use 10 6 12 4 3 9 15 21 
Cocaine 
Total 37 56 42 40 52 94 78 85 
Use & Traffic 25 18 32 23 52 16 17 42 
Traffic/Deal 1 11 8 1 17 20 27 36 
Use 4 4 3 15 9 14 25 15 
 
Cannabis 
Total 30 33 43 39 79 50 69 93 
Use & Traffic  2 1 2 2 0 0 0 
Traffic/Deal    0 0 0 1 0 
Use 2   0 0 0 0 2 
 
Amphetamines 
Total 2 2 1 2 2 0 1 2 
Use & Traffic 3 3 3 1 1 1 3 4 
Traffic/Deal 1 3  0 0 1 6 1 
Use 1   0 1 1 3 2 
 
Ecstasy (MDMA, etc.) 
Total 5 6 3 1 2 3 12 7 
Use & Traffic  1 1 0 0 0 0 0 
Traffic/Deal    0 0 0 0 0 
Use    0 0 0 0 0 
 
LSD 
Total  1 1 0 0 0 0 0 
Use & Traffic    59 57 48 46 85 
Traffic/Deal    13 61 93 63 87 
Use    20 15 35 45 47 
Total number of 
arrest motives 
independently of 
involved 
substances Total 128 154 108 92 133 178 154 219 
Source: Specialised Drug Department of the Judicial Police (Data formatted by NFP) 2006 
 
b. Prosecution data 
 
The number of police records for presumed offences against the modified 1973 drug law 
(code: DELIT-STUP), stable between 1996 and 1998, showed an important increase 
from 1998 to 2003 (825 to 1,660) to stabilise from then on. (2006: 1,200 police records) 
 
The number of drug law offenders (‘prévenus’) has declined from 1,368 in 1996 to 1,170 
in 1998 followed by a subsequent increase. From 2003 onwards, one observes a 
significant decrease (1,575) in drug law offenders. The number of arrests on the same 
charge has decreased from 154 in 1997 to 133 in 2003 to increase and stabilise again 
(2006: 225 arrests) (See table 8.2). 
 
Table 8.3 records the total number of law enforcement interventions and number of 
‘prévenus’ at the national level ensured by respective law enforcement actors that are 
the Specialised Drug Department of the Judicial Police (SPJ), Police and Board of 
Customs from 1995 to 2006. 
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Table 8.3 Number of national law enforcement interventions (1995-2006) 
  
DRUG LAW ENFORCEMENT RECORDS 
 
PREVENUS (Offenders) 
Year 95 97 99 2001 2003 2004 2006 95 97 99 2001 2003 2004 2006 
S.P.J. 123 137 343 216 239 267 190 152 182 434 321 369 336 248 
Gendarmerie 198 255 782 319 335 916 
Police40 199 177 189 
 
1,126 
 
 
1,326
 
1,072
 
 
824 371 280 283 
 
1,272
 
1,753 
 
1,268 
 
 
1,007 
Customs41 244 236 173 113 95 129 186 421 408 306 182 148 204 320 
Total 764 805 1,187 1,455 1,660 1,468 1,200 1,263 1,205 1,939 1,776 2,270 1,808 1,575 
Source: Specialised Drug Department of the Judicial Police 
 
The population of drug law offenders is composed of 86% males; a proportion that has 
been varying between 79% and 89% during the past decade. Since 1997, non-natives 
have been representing the majority of drug law offenders (52-68%). The spectacular 
increase in 2002-2003 of the proportion of first drug law offenders is not confirmed by 
2005/2006 data reporting a decrease from 808 in 2003 to 471 in 2006. Also the 
percentage of minors (< 18 years) among drug law offenders having increased 
between 1994 (4.9%) to 2000 (6.7%) shows a clear decrease in 2004 (8.7%) and in 
2006 (6.9%). Cocaine and heroin are the main drugs involved in first drug offences. 
 
Table 8.4 Socio demographic data on ‘prévenus’ (1986-2006)   
YEAR 1986 1988 1990 1992 1994 1996 1998 1999 2000 2001 2002 2003 2004 2005 2006 
AGE                
0-14 9  7 6 1 3 7 27 
 
21 11 15 41 24 9 8 
15-19 121 212 179 320 169 270 249 415 
 
413 399 647 602 334 436 279 
20-24 264 569 383 527 403 447 321 519 
 
497 566 650 557 510 
 
617 415 
25-29 119 220 278 371 309 304 220 448 
 
354 299 388 375 278 345 323 
30-34 49 67 124 159 186 191 187 269 
 
208 194 219 254 250 230 188 
35-39 17 29 27 52 65 80 76 131 
 
113 139 177 162 190 174 136 
>40 17 19 43 46 21 42 78 84 
 
108 113 82 174 126 153 181 
unknow
n 
27 21 30 50 20 31 32 46 
 
44 55 40 106 99 70 43 
TOTAL 623 1,137 1,071 1,531 1,174 1,368 1,170 1,939 
 
1,758 1,776 2,218 2,271 1,811 2,034 1,575 
Male 503 970 851 1,248 938 1,138 958 1,658 
 
1,415 1,546 1,905 1,935 1,581 1,751 1,319 
Female 120 166 220 256 209 173 193 248 
 
241 215 292 288 181 237 218 
gender 
unknown 
0 1 0 27 27 57 19 33 44 15 21 48 49 46 38 
Source: Specialised Drug Department of the Judicial Police 2006. 
 
Table 8.5 Distribution of ‘prévenus’ according to first offence and underage status (1992-2006) 
 1992 1994 1996 1998 2000 2002 2004 2005 2006 
First offenders  
697 
 
382 
 
508 
 
422 
 
608 
 
828 
 
585 
 
657 
 
471 
Offenders underage 96 57 102 79 154 145 103 86 72 
 
TOTAL (‘Prévenus’) 
 
1,531 
 
1,174 
 
1,368 
 
1,170 
 
1,758 
 
2,217 
 
1,808 
 
2,034 
 
1,575 
Source: Specialised Drug Department of the Judicial Police (Data formatted by NFP) 2006. 
 
 
                                                                  
40 The general activity report of the Government Grand-Duchy of Luxembourg can be downloaded from: 
http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html 
41 A summary of the general activity report of the "Anti-Drugs and Sensible Products’’ division of Customs can be found in 
annex H. The original report can be downloaded from : 
http://www.gouvernement.lu/publications/informations_gouvernementales/rapports_activite/index.html 
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Table 8.6 Distribution of first offenders (use and use/traffic) according to substance involved ad minima (1992-2006) 
 1992 1994 1996 1998 2000 2002 2004 2005 2006 
High risk substance involved 
ad minima 
         
Heroin 162 154 121 109 133 114 103 110 84 
Cocaine 64 39 34 30 37 64 125 86 52 
Amphetamines 5 15 11 18 9 12 2 3 3 
Type ‘ Ecstasy ‘ 1 9 20 26 11 34 8 17 4 
Illicitly acquired medicaments 1 3 0 1 7 0 1 1 4 
Substitution substances 0 1 0 0 0 1 0 1 1 
TOTAL  (substances HRC) 233 221 186 184 197 225 239 218 148 
Source: Specialised Drug Department of the Judicial Police (Data formatted by NFP) 2006 
 
o Other drug-related crime 
 
The data protocol of the national drug monitoring system (RELIS) includes a series of 
drug-related offences’ items: The following results are worth to be retained for 2006:  
 
- 94% of drug users indexed42 by specialised health care institutions have already 
been in conflict with law enforcement agencies during lifetime. 77% (stable) of 
the total PDU population show multiple law enforcement contacts. 
- The proportion of ‘interpellations’ for other reasons than presumed offences against 
the drug law (e.g. petty crime) has been decreasing since 1997 (38%) and has been 
fairly stable in recent years (2006:34%). The extension of substitution treatment and 
the intensification of socio-economic reintegration measures appear to have 
contributed to the currently observed situation. 
- 69% (73%) of indexed PDUs have already served at least one prison sentence 
during lifetime. The proportion of PDUs having served more than one prison 
sentence at the time of reporting (36% stable) is still on the increase. Compared with 
2005, an improvement of the penal situation of indexed drug users must be stressed; 
associated to a decrease of the duration of served prison sentences. 
 
• DRUG USE IN PRISON 
 
In 1998, the Ministry of Justice commissioned the medical department of the state prison 
(CPL) to perform an epidemiological study on HIV and HCV prevalence in prison 
population (Schlink 1999). The research protocol relied on a self-administrated 
anonymous questionnaire on health behaviour and injecting drug use prior and during 
prison sentence.  
 
MAIN RESULTS:  
Drug use in prison 
- 32% of prisoners qualified themselves as injecting drug users; 
- 28% reported current drug injection in prison; 
- 9% have been initiated to injecting drug use in prison; 
Risk behaviour 
- 58% of current IVDU prisoners report life-time needle sharing in prison; 
- 8%  of current IVDU prisoners report last month needle sharing in prison; 
- 70% of IVDU prisoners only use water to clean up syringes, 22% do not clean syringes at all; 
- 90% of prisoners reporting sexual intercourse in prison did not use condoms. 
Miscellaneous 
- IVDUs have served more prison sentences than non drug users (control group); 
- IVDUs showed lower average age than non drug users; 
- a majority of imprisoned IVDUs were natives 
- 
Source: Schlink, 1999 
                                                                  
42 Persons who have been indexed by the RELIS network during a reporting year. 
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The recent study “Prevalence of viral hepatitis A, B and C and HIV in problematic drug 
users of illicitly acquired drugs” (Origer & Removille, 2007) also addressed drug use and 
drug-related harm in prison settings. Among all settings (inpatient, outpatient treatment, 
low threshold, etc.) prevalence rates of HIV, HBV and HCV were highest in persons 
recruited in prison settings. Referred to the total study sample 56.1% of respondents 
who have prison experience (N:246) reported illicit drug use in prison, Differences in 
results in reference to the to the Schlink study are due to the fact that the Origer & 
Removille study addressed lifetime use and injections as well as current and previous 
prison experience. 
 
• SOCIAL COSTS 
 
Origer (2002) assessed the direct economic costs of policies and interventions in 
the field of illicit drug use referred to year 1999 (see www.relis.lu). An update of the 
Origer 2002 study has been performed according to data requirements for 2007 selected 
issues. Between 1999 an 2005, total public drug-related expenditures went up from 
23,345,000 to 35,345,000, which equals to an increase rate of 51%. More specifically, 
the budget allocated by the Ministry of Health to drug related services and programmes, 
as foreseen by the national drug action plan, has known an increase rate of 217 % 
between 2000 and 2006. Concerning the 2006 budget 6,584,000.- EUR have been 
granted to involved services representing a progression rate of 6.27% compared to 
2005. Further results of the referred study can be found in chapter 11. 
 
In July 2006, the STATEC (Central service of statistics and economical studies) 
published a study estimating the economic impact of the illegal drugs related 
activities in Luxembourg over the period 1999 to 2004 (Statec, 2006). The study was 
carried out within the framework of a European project intended to improve the 
comparability and the coverage of national accounting. 
 
One of the main aggregates of national accounting, the gross national income (GNI), is 
accounted for in the calculation of the contribution of the Member states to the EU 
budget. The concept of the European system of accounting (SEC95) also includes illegal 
activities. Due to methodological difficulties and a lack of reliable data, illegal activities 
have not yet been integrated at this stage in the national accounts of the EU Member 
States. The European Commission expressed the wish to include the illegal activities in 
the national accounts in view of equal treatment of its Member states. 
 
Similar studies are underway in other countries of the EU. These studies must allow the 
Commission to decide upon the feasibility of the future inclusion of the illegal activities in 
the national accounts of the Member states. 
 
Luxembourg had at its disposal for this exercise statistical data of high quality as far as 
problematic drug use is concerned (RELIS). However, the data allowing to assess 
consumption of drugs by the occasional/recreational users are insufficient given there 
are no regular surveys in general population covering this topic. 
 
The economic and geographical situation of Luxembourg makes an extrapolation of 
statistical data on the seizures impossible and did not allow for a valid confrontation of 
drug supply and drug demand on the national market. Thus, the estimate on drug 
consumption has provided the main benchmark for the study. 
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The annual consumer households’ expenditure for drugs is estimated at 37.8 million 
Euro over the period 1999 to 2004. According to information provided by field experts, it 
was possible to set down realistic hypothesis concerning the provisioning of the drug 
market in Luxembourg. Nevertheless these results must be interpreted with caution as 
they are rough estimates. 
 
The impact of the illegal drugs-related activities for 2004 is estimated at 0.11% of the 
GDP (gross domestic product) and 0.08% of the GNI (gross national income). Although 
this impact is limited, it reflects those observed in the European Union countries having 
carried out similar estimates. Three substances have a major impact: heroin, cocaine 
and cannabis representing together more than 90% of the measured impact. 
Nonetheless, levels observed during the period 1999 to 2004 highly vary according to 
the evolution of the consumption and the traffic of heroin, which clearly has the most 
important economic impact in this field. 
 
 
9. Responses to Social Correlates and Consequences  
 
 
Overview 
 
• SOCIAL REINTEGRATION 
 
Social reintegration measures, and in particular improvement and diversification of 
housing offers for drug addicts, have been one of the priorities of the 2000-2004 national 
drugs action plan. The 2005-2009 drugs action plan foresees the expansion of existing 
projects and the implementation of new decentralised reintegration measures based on 
the previously described principle on progressive reintegration through capacity building 
and the improvement of the social abilities and environment.  
 
In the framework of the 2000-2004 action plan, the Ministry of Health, jointly with the City 
of Luxembourg opened a night shelter (called Nuetseil) for drug addicts in December 
2003 which has evolved in an integrated low threshold care centre for drug addicts 
(TOX-IN) including day and night shelter offers, accommodation and a supervised drug 
injection facility.  
 
A project called ‘Les Niches’ functions as a social real estate agency for drug addicts.  
Approximately 30 flats and apartments are rented by a drug-counselling centre and 
provided to drug addicts in need by means of tailor made renting contracts. One of the 
medium term aims of the project is to allow demanding drug addicts to take over the 
renting contract on basis of their own financial means and thus dispose autonomously of 
a stable accommodation. The project is jointly financed by the National Fund against 
drug trafficking and the Ministry of Health. 
 
A network of supervised housing facilities for specific target groups as for instance 
pregnant women, drug addicted couples, treatment demanders on methadone are 
operational since September 2002 and are situated in the vicinity of the main centre in 
order to take advantage of training and social reintegration facilities offered by the CTM. 
The CTM also offers educational aid in several domains as well as professional training 
opportunities. 
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Aiming professional reintegration, a series of residential drug care centres, offer oral and 
written language courses in order to provide clients with basic language skills if 
necessary or to improve their writing skills. 
 
“D’Stëmm vun der Strooss” association (Street voice association) primarily takes care of 
homeless people in providing them with low threshold facilities and in offering social and 
professional reintegration activities. The editing, printing, publication and distribution 
of an in house magazine addressing social matters is supposed to help client to regain 
a sense of responsibility and to increase the level of acceptability in the general public. 
PDUs constitute a significant fraction of their clients. 
 
The 2005-2009 national drugs action plan foresees to further develop capacities of the 
above mentioned services and includes new projects such as an occupational centre 
for drug addicts, that provides the opportunity of a series of paid day jobs for the target 
population. The centre is supposed to open in 2009 and will provide approximately 30 
addicts daily job opportunities adapted to their respective skills and physical and mental 
resources without imposing restrictive contractual requirements on them. The 
geographical site of the Centre has been agreed on, information sessions with residents 
of the concerned village have been organised and the budget made available allowing 
the start of the construction process in 2008. 
 
• PREVENTION OF DRUG-RELATED CRIME 
 
o Assistance to drug users in prisons 
 
The Grand Duchy of Luxembourg counts two state prisons at the national level; the CPL 
situated in the vicinity of Luxembourg City and the CPG implemented in the East of the 
country. Figure 8.5 (see above) provides the number of general admissions and number 
of admissions according to drug-related convictions in both prisons from 1989 to 2006.  
 
The law of 27 July 1997 concerning the modification of the penitentiary organisation 
regulates the creation of specialised medical units for drug addicts and psychiatric 
patients within prison. 
 
Following the law of 27 July 1997 concerning the modification of the penitentiary 
organisation, a pilot project named “Global Drug Care Programme in Prison” (2000-2005 
- TOX project) was set up by a group of experts assigned by the Ministry of Justice in 
1999. The concept was designed to implement, among other objectives primary, 
prevention measures in regard to drug consumption and infectious diseases. The overall 
aim of the project was to integrate drug dependant inmates into a medico-psycho-social 
drug care network in order to reduce recidivism, risks and criminality after release from 
prison. The implementation of the project had to be adapted to the two different prison 
settings. Joint financing by the Ministry of Justice, the National Fund against drug 
trafficking and the EU (regarding evaluation) was ensured.  
 
Since 2003, both penitentiary centres offer individual and collective interventions. 
Discussion groups are guided by drug care services and RPT training, a programme to 
prevent drug related recidivism is organized by specialised drug treatment agencies. 
Updated information on the TOX project is available in both prisons by members of the 
in-house services and by means of information desks. A voluntary group of inmates 
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called “Tox-Contact” acts as a plate-form between the TOX project and the overall 
population of inmates. 
All penitentiary in-house services, from prison probation service to the medical care 
service, are actively involved in the TOX project and collaborate with specialised drug 
treatment institutions. 
 
At the beginning of 2004 the pre-therapeutic programme called “Switch” (change the 
lane) was set up and the drug free unit of the CPG got operational. The capacity runs 
up to 6 persons simultaneously. All candidates have to meet strict selection criteria. The 
programme ensures the preparation of post-release ambulatory or residential drug 
treatment and creates a dynamical process of drug prevention, care and staff education 
throughout the CPG and the CPL. Candidates from the CPL entering the programme are 
transferred from the CPL to the CPG. 
 
The programme normally takes 8 months and includes individual and group therapy, 
social behaviour and social administration courses, sport sessions and therapeutic 
activities. Besides, a coordination office is at the disposition of all inmates interested in 
therapy, courses, CPG programme attendance and post-release preparation.  The active 
implication of inmates as also the intensive network collaboration succeeded to 
implement in a long term syringe exchange, therapeutic programmes, prevention (health 
flyers, health cards), education and sensitization of prison staff. 
 
In 2007, the external evaluation report43 has been published that recommended the 
continuation of the action. 
 
Detoxification treatment is either provided in-house under the responsibility of the 
prison medical unit, or by external detoxification units of general hospitals according to 
strict rules and procedures. CPL has signed a convention with a major general hospital 
situated in Luxembourg City ensuring out-of-prison medical care if required. 
 
Psychosocial and therapeutic care is provided by both, in-house staff members and 
specialised external agents from accredited drug agencies. Therapeutic in-house 
resources are deemed insufficient. An example of good practice in this respect is the 
inclusion of clearly time on content defined service providing of external specialised drug 
agencies contractually foreseen by state conventions (in the framework of the global 
drug care programme). This mechanism also applies to external agents in the field of 
HIV and other infectious diseases. One should also stress the role of the Central 
Probation Service (SCAS), which motivates inmates to undergo treatment and enables 
contacts with external therapeutic agencies. Although the psychosocial care strategy is 
similar in both national prisons, the CPG currently disposes of a more structured 
intervention programme. The CPL runs a proper psychosocial and educational 
department (SPSE). Jointly with the SCAS and the prison guards’ association, it has set 
up a project called ‘DEFI’ (Challenge) that aims at the development of therapeutic 
means, training facilities, socio-professional reinsertion measures and indebtedness 
management, during prison journey and during the prison release phase. 
 
The future development of synergies with external drug care agencies aiming at a 
comprehensive concept of throughcare it in terms of psychosocial measures, 
substitution treatment or economical start-up help are some of the cornerstones of 
national after-prison reintegration strategies. 
                                                                  
43 TREPOS, J.-Y. (2007) Evaluation du projet global de prise en charge des personnes toxicodépendantes en milieu 
penitentiaire au Grand-Duché de Luxembourg, Univbersité Paul-Verlaine, Metz. 
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Regarding substitution treatment in prison, no formal or binding guidelines do 
currently exists. Three scenarios may occur: 
 
- most frequently encountered situation applies to new prisoners who underwent 
substitution treatment prior to their current incarceration. Medical prison staff inquires 
the accuracy of the information provided by involved inmates by contacting the 
prescribing GP or the national substitution programme. In case of confirmation, 
substitution treatment is continued and may be followed by maintenance, dose 
reduction or detoxification treatment, 
- increasingly substitution treatment is initiated within prison. It also includes inmates 
who have started opiates use in prison, 
- opiate using or already substituted prisoners may introduce an admission demand to 
the national substitution programme 6 weeks before release. Continuity of care and 
re-socialisation measures are ensured by the intervention of social workers from 
external field agencies (Substitution, HIV, hepatitis, etc.), 
 
The main substitution opiates prescribed in prison are methadone (MEPHENON®), and 
to a lesser extend buprenorphine (SUBUTEX®) and codeine. Prescription of 
benzodiazepines is widespread. 
 
A strictly structured syringes distribution programme has officially been started in 
2005 in the framework of the global drug care programme in prison. Condoms are 
available at different discrete spots of the prison. 
 
As far as treatment of psychiatric co-morbid patients in prison are concerned a 
collaboration convention between the national prison administration (CPL) and the 
national neuro-psychiatric hospital (CHNP) has been signed in 2002. The convention 
sets the framework for the creation of a psycho-medical department within prison and 
regulates prevention, care and referral of mentally disabled as well as alcohol and drug 
dependent inmates. Therapeutic care, substitution treatment and counselling is provided 
ad hoc. In case of severe mental disorders, imprisoned patients are referred to a high 
security department within the CHNP. 
 
o Urban security policies in the prevention of drug related crime 
 
• Collaboration between national and municipal levels 
 
In recent years involvement of major cities in the management of drug-related problems 
and nuisances has clearly increased. So called municipal “prevention committees” that 
include local authorities, police forces and specialised NGOs are in place. These 
committees also address the social correlates and consequences of drug abuse at the 
city level. Ministerial representatives may be invited to assist these committees. The 
setup of the first national drug injection room in Luxembourg City obviously enhanced 
the involvement of municipal authorities. The Ministry of Health chairs a management 
group that is mandated to follow up developments with regard to the injection room and 
to react precociously to upcoming problems. The national action plan clearly emphasises 
the importance the visible involvement of major cities in the management of public order, 
urban nuisance and hygiene problems related to drugs to guarantee the necessary 
decentralisation of demand reduction offers and supply reduction interventions. 
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• Measures for young drug law offenders 
   
In 1996 a separate mechanism has been put in place with regard to underage and 
juvenile drug use offenders. The MSF Youth Solidarity (Doctors Without Frontiers) 
project is financed by the Ministry of Health and intervenes in case a minor of age has 
been running in conflict with law enforcement forces with respect to a drug-related 
offence. In this respect the MSF Youth Solidarity team may be considered as a crisis 
situation manager, offering their services to drug offenders referred by judicial and penal 
institutions. Proposed services are free of charge. 
 
The MSF intervention team, in direct collaboration with Youth magistrates and 
competent law enforcement actors, offers a large variety of services with the primary aim 
to prevent minor aged drug offenders to enter in the criminal justice system. 
Interventions are based on a holistic approach of the problem, including the involved 
person him/herself and his/her family. MSF directly reports on intervention progress to 
the demanding authority. Client statistics show an increasing demand for this kind of 
intervention from both the criminal justice system and the social oriented institution. 
 
Table 9.1  Clients core statistics  MSF SOLIDARITE-JEUNES 1997 – 2006 
  1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Number of clients  27 46 99 132 195 208 231 267 249 322Ò
Referral from the criminal 
Justice system 
 26.1% 26.3% 41.4% 44.1% 44.2% 37.2% 179 136 46.2%
Gender distribution Female 
Male 
26%
74%
28%
72%
26.3%
73.7%
34.1%
65.9%
32.3%
67.7%
34.1%
65.9%
31.6% 
68.4% 
31.9% 
68.1% 
 
31.3%
68.7%
30.1%
69.9%
Age distribution <  15 
15-17 
> 18 
7%
82%
11%
11%
81%
8%
16.1%
73.8%
10.1%
12.6%
74.2%
12.9%
13.8%
80.9%
11.3%
17.8%
71.6%
10.6%
23.8% 
63.6% 
12.6% 
17.7% 
64.1% 
18.6% 
25.7%
48.6%
25.7%
33.7%
49.3%
17%
Main substance involved Cannabis 
Heroin 
Solvents  
Ecstasy 
Cocaine 
Other 
45%
33%
7%
4%
11%
49%
22%
11%
12%
3%
3%
65.7%
21.2%
5.1%
3%
1%
4%
78%
12.9%
1.5%
3.8%
3.1%
72.3%
7.2%
0.5%
3.6%
2.6%
13.8%
82.2%
2.4%
0.5%
1%
1%
12.9%
83.1% 
3.5% 
0.0% 
0.9% 
0.4%% 
12.2 
 
72.4% 
4.5% 
0.4% 
1.1% 
1.1% 
20.5% 
71.5%
5.6%
0.4%
0.4%
22%
73.3%
3.7%
1.6%
1.6%
Source: Solidarité Jeunes (MSF). 2006 
 
 
 
10. Drug Markets 
 
 
Overview 
 
Drug markets are of changing nature. They rely on factors such as supply mechanisms, 
on the economic situation and on the efficiency of law enforcement strategies. 
Availability and supply indicators should be interpreted with caution as they rely on the 
interplay of all these factors. Law enforcement authorities, the National Laboratory of 
Health and special surveys have provided data presented in the present chapter. 
 
2006 data confirm that cannabis, heroin and cocaine are widely and increasingly 
available on the national market. New distribution networks have developed in recent 
years and operate in an obviously professional way and by doing so have significantly 
increased drug availability and in particular the supply of cocaine and cannabis. 
Seizures of all substances have increased compared to 2005 as far as quantity is 
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concerned although the number of seizures is stable and the number of offenders 
involved in seizures has been showing an overall decreasing trend. This may suggest 
that greater quantities of drugs are trafficked by smaller groups of traffickers. 
 
In general, quality of cannabis, ecstasy, STA and heroine show a mid term decrease but 
cocaine purity is fairly stable while prices show broad ranges for heroin and cocaine, and 
a still ongoing decrease for ecstasy like products. Cannabis and derivates however have 
known a fair stability during the last 5 years as far as street prices are concerned. More 
concerning is the fact that maximum THC concentrations in cannabis are still raising 
(2006: over 25%). 
 
Asylum demanders implicated in illicit cocaine trafficking mainly originate from West 
African countries, particularly from the Ivory Cost. Currently also Albanian citizens are of 
particular concern to law enforcement authorities. In regard to heroin trafficking, no 
predominant profile of nationality has been reported. A large number of drug traffickers 
come from North Africa by transiting through Belgium. Numerous traffickers have 
changed from heroin to cocaine traffic and currently are also involved in cannabis traffic.  
 
Overall, the drugs market has become of a more aggressive nature in terms of 
selling techniques. Dealers increasingly tend to actively approach confirmed or potential 
clients.  
 
Also, the perceived illicit drug availability in general population is high and follows a 
weakly increasing trend. 
 
• AVAILABILITY AND SUPPLY 
 
o Availability of drugs 
 
Law enforcement sources44 indicate that currently the majority of illicit drugs consumed 
in the G. D. of Luxembourg originate from the Netherlands (cannabis production and 
transit of other drugs), followed by Belgium (ecstasy and ATS production) and Morocco 
(cannabis production). Till the beginning of the nineties, most of the persons involved in 
illicit drug distribution were consumers who supplied themselves in the Netherlands or 
acquired limited extra quantities of drugs in order to sell them within restricted local 
networks. Since the opening of EU borders, more organised distribution networks tend to 
develop within the national drug market.  
 
The expansion of more structured distribution networks by organised criminal 
associations has been reported. The proportion of non-natives implicated in drug 
trafficking has been increasing over the last four years and may be stabilising according 
to 2006 data. Typically, involved dealers carry small quantities of drugs hidden in their 
mouth ready to be swallowed promptly in case of police controls. Initially drugs of high 
quality have been sold at low prices. Progressively however the quality and diversity of 
sold drugs have been decreasing. Recently, the national drug market has been 
flooded with low quality injection drugs, which has induced major changes in 
consume patterns of national drug users. 
Little, however, is known on the provision sources of the referred dealer networks. They 
seem to rely on important stocks of cocaine. They are highly organised and have 
                                                                  
44 Non published information from the Specialised Drug Unit of the judicial Police 
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managed to significantly increase the supply and availability of drugs at the national 
level. In 2005 it was estimated that 0.5 kg of cocaine are daily sold to drug users 
within the Luxembourg City drugs scene. 
 
In 2006 no clandestine drug-manufacturing laboratory has been dismantled at the 
national level. Local cultures of cannabis remain rather insignificant in terms of quantity. 
 
In addition to availability indicators from law enforcement sources, perceived 
availability of the general public provides a complementary insight in the current 
situation. Both, the 2004 Flash Eurobarometer 158 survey “Young people and Drugs” 
and the 2002 Eurobarometer 57.2 survey inform about the level and the evolution of illicit 
drugs availability in the G. D. of Luxembourg.  
 
Tab. 10.1 Ease of acquisition of drugs in Luxembourg (2002/2004) 
 
QUESTION a: It is easy to get drugs? 
 
 Near where I live In or near my school/college At parties In pubs/clubs 
 2002 2004 2002 2004 2002 2004 2002 2004 
 
Luxembourg 
 
62.2 
 
66% 
 
60.5 
 
63% 
 
74.7 
 
74% 
 
73.2 
 
70% 
 
EU  
 
61.9 
 
63% 
 
54.9 
 
57% 
 
76.0 
 
79% 
 
72.3 
 
76% 
 
The results among the population of young people in Luxembourg lie within the scope of 
the European average. However the perception of ease of acquisition of drugs near 
schools and the immediate vicinity of where the youngsters live, is slightly more 
pronounced than the European average. The overall availability of illicit drugs seems to 
have slightly increased during recent years. 
 
o Production, sources of supply and trafficking patterns 
 
• SEIZURES 
 
o Quantities and numbers of drug seizures 
 
Striking variations have been observed as to the quantity of illicit substances seized 
since the beginning of the nineties. A longitudinal data analyses indicates a general 
decreasing tendency of heroin, cocaine and cannabis seizures until 200245. Since 2002 
however, one observes a significant increase in the quantity of drug seizures mainly 
concerning heroin and herbal cannabis. Cocaine seizures (quantity) are highly variable 
since the beginning of the nineties. 
 
Notwithstanding the quantities seized, the number of seizures has grown 
discontinuously since 1993. Since 2000 the number of cannabis and cocaine seizures 
has clearly increased and the number of heroin seizures tends to stabilise. Markedly, the 
number of cannabis seizures has risen from 167 to 581 between 1994 and 2006. The 
total number of persons involved in traffic has followed a constant upward trend until 
2002 and is showing a recent decrease. A confirmed majority of offenders are involved 
in cannabis traffic and are non-natives. For detailed information, see standard table 13. 
 
                                                                  
45  Non –transit drugs destined to the national market 
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Crack (cocaine-base) seizures have not been reported to date by national authorities. It 
has, however, appeared on the national market according to field agencies. The first 
national seizures of ecstasy type substances (MDMA, MDA, etc.) were recorded in 
1994. The availability of ecstasy appeared to soar between 1994 and 1996.  Most recent 
seizure data indicate however a stabilization at low level. 
 
F ig .  1 0 .1  T o ta l  q u a n t i ty  o f  s e iz u r e s : he r o in ,  c o c a in e ,  e c s t as y  ty pe  
( 1 9 8 8  -  2 0 06 )  
0
8 0 0 0
1 6 0 0 0
2 4 0 0 0
3 2 0 0 0
C a n n a b i s (g r . /10 ) 1 90 0 3 3 25 0 34 4 8 30 8 7 6 9 3 9 5 5 2 5 2 2 3 6 9 2 2 4 0 6 7 0 0
H e r o in  ( gr . ) 1 48 8 8 52 7 66 8 2 29 3 4 3 5 9 2 1 1 3 5 8 2 9 5 7 6 2 5 5 4 2 6 1 9 2 9 8
C o c a in e  ( gr . ) 4 57 9 2 32 6 0 12 0 9 2 12 8 9 1 5 9 9 5 1 0 7 5 7 2 4 8 6 4 4 8 1 1 2 2 9 3 8 2 5
M D M A  (p i l ls ) 0 0 0 55 4 5 1 4 5 3 1 8 1 1 3 9 2 2 3 2 4 9 2 5 5 5
19 8 8 19 9 0 1 9 9 2 1 9 9 6 1 9 9 8 2 0 0 0 2 0 0 2 2 0 0 4 2 0 0 5 2 0 0 6
 Source: Specialised Drug Department of the Judicial Police 2006 
 
F ig .  1 0 . 2   T o t a l  n u m b e r  o f  s e i z u r e s :  C a n n a b i s , H é r o ïn e ,  C o c a ï n e ,  M D M A  
( 1 9 8 8  -  2 0 0 6 )  
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
6 0 0
7 0 0
C a n n a b i s  1 0 9 1 93 3 3 2 2 8 1 2 7 3 4 0 6 61 6 5 7 8 5 28 6 5 2 5 8 1
H e r o in 8 1 1 33 1 6 9 2 8 4 1 8 9 2 1 1 18 5 1 5 5 1 87 2 3 6 2 3 8
C o c a in e 3 5 3 2 6 5 6 3 2 2 5 1 66 6 9 1 13 1 1 8 8 9
M D M A  (p i l ls ) 2 6 2 2 1 5 26 8 1 5 1 4 9
1 9 8 8 1 99 0 1 9 9 2 1 9 96 1 9 9 8 2 0 0 0 2 0 0 2 2 0 0 3 2 00 4 2 0 0 5 2 0 06
Source: Specialised Drug Department of the Judicial Police 2006 
 
 
 92
Fig. 10.3 Number of offenders involved in seizures according to type of offence  (1988-2006)
0
500
1000
1500
2000
2500
Traffic 630 778 112 143 339 502 640 239
Traffic AND/OR use 424 451 901 653 949 590 1013 2202 1258 2034 1575
Traffic AND use 216 335 228 257 220
Traffic AND/OR use of
heroin
91 186 203 312 347 215 354 715 399 582 591
Traffic AND use of heroin 129 162 116 111 99
88 90 92 94 96 98 2000 2002 2004 2005 2006
Source: Specialised Drug Department of the Judicial Police 2006 
 
• PRICE/PURITY 
 
o Price of drugs at street level 
 
Average street prices of heroin (brown), cocaine and ecstasy type substances have 
fallen from 1996 to 2002/2003 but broader price ranges as well as higher maximum 
prices for cocaine and heroin have been observed in 2005/2006. Cannabis and 
derivates however have known a fair stability during the last 6 years. Heroin is frequently 
sold as ‘boule’ containing 0.2-0.4 grams for 12-25. - euros. Typical street retail cannabis 
is sold in pieces of 2.5 to 3 grams for 25. - euros. 
 
Table 10.2 Price per unit evolution at the street level (1994-2006) 
 1994 1998 2000 2002 2003 2004 2005 2006 
Cannabis 
Haschisch 
Marijuana 
 
5-6 
 
5 – 6 
2.5 - 3 
 
7.4 
6.2 
 
7 
 
8.3 
8.1 
 
7.3 
7.3 
 
7.3 
7.3 
 
8 
 
Cocaine 100-150 120 -170 90 50 30-85 20-120 20 – 110 30-100 
Heroin 
(brown) 
 
65-150 
 
90 -150 
 
74.4 
 
50 
 
40 
 
82 
 
80 
 
50-90 
STA  25-30 ? 25 n.a. n.a. n.a. 5 
Ecstasy  9 - 13 10.7 7 10 10 10 5 
LSD 11-13 11 -13 ? n.a. n.a. 10 10 n.a. 
Source: Specialised Drug Department of the Judicial Police 2006 
Price: expressed in EURO at street level. 
For cannabis, cocaine, heroin and amphetamines, price per gram is indicated. 
For heroin and cocaine, minimum prices refer to traffic units. Maximum and average prices refer to street retail quantities. 
For ecstasy and LSD, price per pill or unit are indicated.      
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o Purity at street level and composition of drugs/tablets 
 
Compared to the situation in 2003, purity of all reported substances is lower in 2006 
except for cocaine that has been showing a fairly stable quality during the same period. 
Attention has to be paid to the striking differences in maximum and minimum purities as 
well as to a historically high maximum concentration of THC in cannabis samples seized 
in Luxembourg.  
 
 
Table 10.3 Purity of drugs at street level (1994-2006) 
 
 1996 1998 2000 2002 2004 2005 2006 
  Pur. (%) Pur. 
(%) 
Pur. 
(%) 
Pur. (%) Pur. (%) Pur. (%) Pur. (%) 
   
AVERAGE 
 
AVRG. 
 
AVRG. 
 
MIN.
 
MIN.
 
AVRG.
 
MIN.
 
MAX.
 
AVRG.
 
MIN.
 
MAX.
 
AVRG . 
 
MIN. 
 
MAX.
 
AVRG.
Cannabis 
(THC) 
    
8,03 
 
0.6 
 
0.6 
 
7.96 
 
0.64
 
14.0
 
6.94 
 
0.6 
 
22.26
 
10.92 
 
0.15 
 
25.85
 
7.36 
 
Cocaine 
  
60-90 
 
60-90 
 
60,25 
 
27.75
 
 
27.75
 
 
62.99
 
9.65
 
94.9
 
62.37
 
27.75
 
 
94.9
 
 
51.52 
 
 
11.7 
 
100 
 
61.78 
 
Heroin 
(brown) 
 
  
15-23 
 
20-25 
 
17,59 
 
4.85
 
4.85
 
9.97 
 
5.0 
 
41.55
 
17.07
 
4.85
 
57.65
 
28.18 
 
3.6 
 
40.9
 
14.48
 
STA 
     
1.2 
 
1.2 
 
15.09
 
1.25
 
40.65
 
9.44  
 
1.2 
 
35.01
 
12.22 
 
3.6 
 
15.35
 
7.1 
 
Ecstasy46 
(MDMA) 
(MDEA) 
(MDA) 
    
 
35,5 
6,8 
 
 
1.75 
 
 
 
1.75 
 
 
 
71.11
 
 
22.35
6.25
 
 
39.5
6.25
 
 
29.77
6.25 
 
 
1.75 
 
 
 
38.33
 
 
 
 
15.82 
 
 
 
1.2 
 
 
43.98
 
 
26.44
 
Psylocine 
     
/ 
 
/ 
 
0.15 
 
0.26
 
0.57
 
0.41 
 
/ 
 
/ 
 
 
/ 
 
 
/ 
 
/ 
 
/ 
Sources: Specialised Drug Department of the Judicial Police / Laboratoire National de Santé. Division Toxicologie. 2006. 
 
 
Purity: For cocaine, heroin and amphetamines, purity is expressed in percentages of pure active substance at the street 
level. 
For cannabis, purity refers to percentage of THC. 
For ecstasy-type substances, purity refers to percentage of MDMA-HCL in relation to total mass in 2000 and to mg of 
active substance per pill from 2000 onwards. 
 
 
 
 
 
 
                                                                  
46 Ecstasy : dose in mg/pill 
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Part B: Selected Issues 
 
 
11. Public Expenditure 
 
 
11.1 National estimates of labelled drug related expenditures 
 
Preliminary remarks 
 
The fight against drugs is multidisciplinary. Thus, in Luxembourg: 11 ministries and 13 
departments are involved to a different extent in the enforcement of national drug 
policies. Although the programming and enforcement of the national drug strategy is 
centralised given the geographical size of the country. 
 
A first study on direct economical public drug-related expenditures (Origer, 2002) 
published in 2002 allowed to assess the feasibility of such studies as well as the range 
of questions researchers are confronted to. 
 
Following are some of the preliminary problems one may encounter in this type of 
studies: 
- Budget lines may be generic (legal & illegal drugs), aggregated (addiction prevention), 
over inclusive (social solidarity) or unidentifiable (others), 
- Apportionment of budgets may not be provided, 
- Difference between provisional budget, voted budget and final expenditure (provisional 
budget often more detailed than voted budget), 
- Expenditures may be annual, multiannual, unique, ordinary, extraordinary, etc. If they 
occur during the study reference year, they should be included even though they might 
give a biased picture of average or routine expenditures, especially when they are 
important (e.g. investments in real estate)47.  
- In terms of follow-up: budget lines may be restructured, integrated or divided over time, 
- In the field of public health, expenditures may result from direct state financing or. 
social security reimbursement, 
- Lack of clarity due to National mixed (Multi-ministries) financing (e.g. Public research 
Centres – multi projects’ financing) or National & EU & International shared financing, 
- Eligibility of cooperation projects vs. variability of yearly contributions, 
- Assessment of impact of general education and educational interventions (e.g.) on 
DDR impossible   
 
This list is not exhaustive. Nevertheless drug related public expenditure studies are 
feasible although they require a fair amount of analytical work for labelled or dedicated 
budget lines as they require a certain degree of creativity as far as non-labelled 
expenditures are concerned.  Researchers may be forced to take decisions whether to 
include or not a series of expenditures. It is important that those decisions are taken 
according to reproducible standards and, even better so, according to harmonized and 
ultimately broadly recognized methodological benchmarks and guidelines. 
                                                                  
47 In order to highlight the different status/nature of budget lines, the following abbreviations have been used 
in the expenditure tables: S. : Standard budget (annual expenditure / budget line) I: Investments (unique 
year dependant expenditure) 
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As these standards are only about to be developed, the answer to the following general 
question should guide the researcher in each single decision he or she has to take, 
namely: Would the service, offer, measures, action, institution, etc. also exist or be the 
same if there were no drug addicts or illegal drugs and related problems to be dealt 
with?  
 
Examples are numerous. In the field of HIV/AIDS, for instance, the creation of a national 
surveillance commission on HIV/AIDS and the associated expenditures has to be 
considered in a different way than the costs of a home for PLWHIV/AIDS. The HIV/AIDS 
surveillance commission would exist even if there were no drug addicts, whereas the 
capacity of the home for PLWHIV/AIDS is dependant on the number of clients living in 
the referred home, of whom a certain proportion had been infected via IVDU. The 
capacities of such facilities have thus to be increased because people are infected 
through drug use and the related expenditures (proportion of clients in total clients) 
should be accounted for. Further examples will be discussed in sub-chapter 11.2 since 
they occur mainly when expenditures are not clearly and equivocally allocated to a given 
action or service. 
 
Given the geographical size of Luxembourg and its political structure, listed expenses 
are of centralised and national nature. There are no significant regional or local drug 
related budgets to be considered in the present analysis. COFOG and REUTERS 
classification systems have been applied according to the requirements of the EMCDDA. 
 
Methodology 
 
The objective of the present analysis is to assess direct public expenditures for the fight 
against drugs and drug addiction. The constituent concepts are defined as follows: 
 
DIRECT: Excluding ‘costs of indirect consequences’ (e.g. loss of income, taxes) and 
‘non quantifiable costs’ (e.g. loss of welfare) as well as expenditures related to the 
acquisition of illicit drugs by the consumer him- or herself.  
 
ECONOMIC: Monetary impact and not social impact or loss of life quality e.g. 
 
COSTS: Expenditures and not revenues created by illegal drug market. 
 
NATIONAL DRUG POLICIES: Public finances and not private expenditures or 
investments. 
 
The applied methodology refers to the concepts of the ‘Cost of Illness’ (C.O.I.) theory in 
opposition to “Cost-Benefit” approach. 
 
The following techniques have been applied or combined according to referred contexts: 
- Analysis of state budget and provisional state budget,  
- Clarification meeting with involved financial authorities, 
- Qualitative interviews, 
- Analysis of activity reports of ministerial departments and NGOs, 
- Analysis of state conventions and financial statements of specialized NGOs, 
- Detailed financial breakdown and budget apportionment provided on demand by a 
series of institutions (NGOs, Social Security, Hospitals). 
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Main reference documents:  
 
- Laws and projects of law regarding the budget of revenues and expenditures of state, 
- Annual ministerial activity reports, 
- Activity reports of specialised agencies, 
- State conventions with NGOs, 
- Annual financial statements of specialised NGOs, 
- Statistical registers of UCM. 
 
The main data sources referred to in the framework of this chapter are as follows: 
 
Ministère des Finances (2004). Projet de loi concernant le budget des recettes et des dépenses de l'Etat. 
Ministère des Finances, Luxembourg. 
Ministère des Finances (2005). Projet de loi concernant le budget des recettes et des dépenses de l'Etat. 
Ministère des Finances, Luxembourg. 
Ministère des Finances (2006). Projet de loi concernant le budget des recettes et des dépenses de l'Etat. 
Ministère des Finances, Luxembourg. 
Ministère de la Santé (2006). Rapport d’activités 2005, Ministère de la Santé, Luxembourg. 
Ministère de la Santé (2005). Stratégie et plan d’action national en matière de lutte contre les drogues et 
les toxicomanies 2005 – 2009. Ministère de la Santé. Luxembourg. 
Origer, A. (2002b). Etude du coût économique direct des interventions et de la politique publique en matière 
de drogues et de toxicomanies. Séries de recherche n°4, Point focal OEDT Luxembourg – CRP-Santé, 
Luxembourg. 
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Tab. 11.1 National estimates of labelled drug related expenditures 
   
Ministry / 
Department 
Budget /Title  Budget / 
Expense (EUR) 
COFOG REUTERS 
01 Ministry of 
Foreign Affairs 
and Immigration 
S 01.2 / 35.031 35.40 
International Relations: 
Contribution to the UN Fund 
against Drug Abuse 
(FNULAD) 
 
S 01.7 / 35.030/35.40/01.53 
Cooperation and 
development: Contribution to 
PNUCID 
 
50,000.- 
 
 
 
 
9,500.- 
 
01.2.2. 
 
 
 
 
01.2.2. 
 
/ 
 
 
 
 
/ 
04 Ministry of 
Finances 
S. 04.3 /12.310 03.20 Staff 
and operational cost of the 
Special Drugs Division of 
Customs 
 
3,430,239.- 
 
01.1.2. 
(03.6.0) 
 
3 
05 Ministry of 
Finances 
Treasure and 
Budget 
S. Operational costs and 
2005 national investments of 
the National Fund against 
Drug Trafficking 
 
I 34.3 74.300 01.22 
Acquisition of drug detection 
equipment for Customs 
Administration 
 
350,028.- 
 
 
57,762.- 
 
01.1.2. 
 
 
03.6.0 
 
1,2,3,4 
 
 
3 
07 Ministry of 
Justice 
S.07.0 35.060  03.10  
International Relations: 
Contribution to EUROPOL 
DRUG UNIT 
 
6,000.- 
 
01.2.2. 
 
3 
10 / 11 Ministry 
of Education of 
Professional 
Training and 
Sports 
S.10.0 12.223  04.01 Drug 
prevention in primary and 
post primary schools 
 
S11.4 12.301 08.30 Drug 
prevention and Sport 
 
64,997.- 
 
3,938.- 
 
07.4.0 
 
07.4.0 
 
 
1 
 
1 
12 Ministry of 
Family, Social 
Solidarity/Youth 
S 12.8 / 12.252 06.32 Drug 
Prevention in retention 
centres for minors 
 
13.545 
 
03.4.0 
 
1 
14 Ministry of 
Health 
S14.0 12.000.05.00 Fees for 
National Drug Substitution 
treatment commission 
 
S14.1 12.343 05.00 Control of 
national enforcement of UN 
drug conventions 
 
S14.1 33.002 05.00 Co-
financing of staff and 
operational coast of the 
national EMCDDA focal point 
 
 
S 14.1 / 33.013 05.23  - 
 
1,500.- 
 
 
 
5,000.- 
 
 
 
122,345.- 
 
 
 
 
4,555,482.- 
 
07.4.0. 
 
 
 
01.2.2. 
 
 
 
07.5.0. 
 
 
 
 
07.2.0 
 
2 
 
 
 
3 
 
 
 
/ 
 
 
 
 
1,2,3,4 
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33.014 05.23 Staff and 
operational cost of specialized 
drug agencies conventionned 
by state 
 
S 14.1 12.311  05.10 
Provision  of drug injection 
material in the framework of 
the national NEP 
 
S14.2 12.301  05.20 / 12.801  
05.20 Toxicological 
surveillance of drug addicts 
 
I 44.7 52.000 05.22 05.23 / 
52.002 05.22 
Construction works and 
acquisition of equipment for 
conventionned specialized 
drug agencies 
 
 
 
 
318,151.- 
 
 
1 
61,950.- 
 
 
 
371,664.- 
 
 
 
 
07.1.2. 
 
 
 
07.4.0 
 
 
 
07.2.0 
 
 
 
 
4 
 
 
 
/ 
 
 
 
2 
22 Ministry of 
Public Buildings 
I.52.4  72.022 05.20 05.22 / 
74.092  74.22 
Construction works and 
acquisition of equipment for 
conventionned specialized 
drug agencies 
 
300,000.- 
 
07.2.0 
 
2 
TOTAL  A Labelled Public drug-
related expenditures 
 
9,822,101,- 
 
  
 
 
11.2 Non labelled drug-related expenditures and definitions of attributable 
proportions 
 
The assessment of non-labelled expenditures requires both analysis of budgetary 
documents and the conceptualization of reliable and reproducible apportionment keys 
(Attributable proportion). It refers to situations that range from expenses that are not 
explicitly referred to in accessible financial documents to the complexity of Health 
Insurance expenses. Indeed, as Health insurance is mostly mandatory and state 
financed, any reimbursement of medical interventions due to the consequences of drug 
use represents a share of resources that cannot be spent for other purposes (COI). It is 
a variable reality researchers are confronted with and harmonization of methodologies is 
crucial if the aim is to produce comparable results.  
 
Table 11.2 provides an exhaustive overview of non labelled drug-related public 
expenditures as well as information on proportion calculations. In case the attributable 
proportion keys are complex, a more detailed description is provided below. 
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Tab. 11.2 National estimates of non labelled drug related expenditures (attributable proportions) 
   
Ministry / 
Department 
Budget /Title  Budget / 
Expense  
(EUR) 
 
Attributable proportion COFOG REUTERS
 
01 Ministry of 
Foreign Affairs and 
Immigration 
 
S. 01.7 Staff ,operational  and mission cost 
related to drug related issues 
 
18,847.- 
 
 
Estimation by MFA 
based on analysis of 
work and mission reports 
and career of involved 
agents  
 
01.2.2. 
 
 
 
 
/ 
 
 
 
05 Ministry of 
Finances Treasure 
and Budget 
 
S. 05 Renting of real estate for specialized 
drug agencies 
 
260,531.- 
 
 
 
Standard rent prices 
according to location and 
surface 
 
0.1.1.2 
 
 
2 
 
 
 
07 Ministry of 
Justice 
 
S. 07.0 Staff ,operational  and mission cost 
of MJ related to drug related issues 
 
 
S. 07.1. 0 Staff ,operational  and mission 
cost of judiciary services (courts, etc) 
related to drug related issues 
 
 
 
S. 07.2  Prison drug related expenditures 
 
 
 
 
 
 
6,000.- 
 
 
 
987,588.- 
 
 
 
 
 
13,885,166 
 
 
 
 
 
 
Estimation by MJ based 
on analysis of work / 
mission / career 
 
Estimation of total cost of 
judicial services x 
proportion of drug 
offences affairs (based 
on ad hoc register) 
 
Total prison budget x 
proportion of drug law 
offenders in total prison 
population 
 
 
 
03.6.0 
 
 
 
03.3.0 
 
 
 
 
 
03.4.0 
 
 
 
 
 
 
3 
 
 
 
3 
 
 
 
 
 
3 
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S.07.4 Police drug related expenditures 
 
 
 
 
1,056,692,- 
 
 
 
 
3,356,003.- 
 
 
 
 
Dedicated staff, 
operational and mission 
costs (Special drug units 
100%)  
 
+ Assessment by Police 
Directorate based on 
analysis of job 
descriptions and related 
operational costs 
03.1.0 
 
 
 
 
03.1.0 
3 
 
 
 
 
3 
12/13 Ministry of 
Family, Social 
Solidarity and Youth 
 
S. 13.1 / 12,140 06. 32  
Information campaigns on drugs 
 
S. 13.1 / 11.000  11.00 
Staff ,operational  and mission cost of MF 
related to drug related issues 
14,960.- 
 
 
17,674.- 
Internal budget 
breakdown 
 
Estimation by MF based 
on analysis of work / 
mission / career 
07.4.0 
 
 
07.4.0 
1 
 
 
1 
 
14 Ministry of Health 
 
 
 
14.1 Directorate of 
Health 
 
 
 
 
 
 
 
 
14.2 Public Health 
Laboratory  
 
 
S 14.0 Staff ,operational  and mission cost 
of MH related to drug related issues 
 
 
S 14.1 / 33.014 05.23 Staff and operational 
cost of National Aids counselling Centre 
 
 
 
S 14.1 / 11.000  05.00  / 12.010  05.00 
Staff and mission costs of Directorate of 
Health allocated to drug related issues  
  
 
S 14.2 / 11.000  05.20 
Staff ,operational  and mission cost of 
Laboratory related to drug related issues 
 
17,674.- 
 
 
 
143,111.- 
 
 
 
 
 
159,940.- 
 
 
 
17,478.- 
 
 
 
Estimation by MH based 
on analysis of work / 
mission / career 
 
25% of total budget : 
average proportion of 
PLWHIV/AIDS infected 
via IVDU in clients 
 
Dedicated staff to drug 
issues +  Estimation by 
MF based on analysis of 
work / mission / career 
 
Estimation by Laboratory 
based on analysis of 
work / mission / career 
 
07.6.0 
 
 
 
07.2 
 
 
 
 
07.6.0 
. 
 
 
 
07.4.0 
 
1,2,4 
 
 
 
1 
 
 
 
 
1,2,4 
 
 
 
 
2 
 101
 
17 Ministry of Social 
Security 
 
 
Health / Social 
insurance 
 
 
S 17.2 Staff ,operational  and mission cost 
for agents in charge of drug treatment 
referral abroad 
 
A. Substitution treatment 
 
- Reimbursement of prescription 
substitution drugs (methadone, 
buprenorphin, etc.) (Net, patient’s 
contribution excluded) 
 
- Reimbursement of medical counselling 
cost related to substitution prescriptions 
 
 
 
B. Inpatient hospital drug treatment 
 
- Reimbursement of inpatient hospital drug 
treatment costs (e.g. detoxification) 
 
 
 
 
- Medical counselling costs associated to 
hospital treatment episodes 
 
C. Drug treatment abroad 
 
 
- Reimbursement of drug treatment costs 
abroad/ e.g. residential therapy or 
therapeutic offer unavailable in Luxembourg
 
70,694.- 
 
 
 
 
 
138,517.- 
 
 
 
 
184,000.- 
 
 
 
 
 
 
2,320,805.- 
 
 
 
 
 
153,645.- 
 
 
 
 
 
1,041,490.- 
 
 
 
Estimation by MSS 
based on analysis of 
work / mission / career 
 
 
 
Detailed breakdown by 
Union of Sickness Funds 
(UCM) 
 
 
Number of substitution 
prescriptions  x 
prescription fees x % 
reimbursed by health 
insurance 
 
 
ICD-10: F11, F12, F14, 
F15,F16, F18 and F19 
hospital episodes x cost 
per episode (provided by 
UCM) 
 
Number of medical 
consultations x 
reimbursed fees 
according to duration of 
stay 
 
Breakdown provided by 
UCM 
 
 
07.4.0 
 
 
 
 
 
07.2.2 
 
 
 
 
07.2.2 
 
 
 
 
 
 
07.3.2 
 
 
 
 
 
07.3.2 
 
 
 
 
 
07.3.2 
 
 
 
2 
 
 
 
 
 
2 
 
 
 
 
2 
 
 
 
 
 
 
2 
 
 
 
 
 
2 
 
 
 
 
 
2 
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D. Cost of HIV/AIDS treatment provided to 
patients infected via IVDU 
 
 
1.672.000.- 
 
Number of HIV/AIDS 
patients infected via 
IVDU in treatment  x 
yearly average cost of 
HIV/AIDS treatment (+/- 
20,000.- EUR) x 
reimbursable proportion 
 
07.2.2 
07.3.2 
 
 
2 
 
TOTAL  B 
 
Non-Labelled Public drug-related 
expenditures 
 
25,522,815 
 
TOTAL A+B 
 
Labelled + Non-Labelled Public drug-
related expenditures 
 
35,344,916 
 
 
 
Tab. 11.3 Overall expenditure on fiscal year 2005 by 1st level COFOG functions 
 
COFOG 1st level function 
 
Labelled expenditures Non-labelled expenditures TOTAL 
3 (Public Order and Safety) 
 
3,501,546.- 19,291,449.- 22,792,995.-   (66%) 
7 (Health) 
 
5,900,027.- 5,630,070.- 11,819,381.- ( 34%) 
TOTAL
 
34,612,376.- 
  
Tab. 11.4 Overall expenditure on fiscal year 2005 by 2nd level COFOG functions  
 
COFOG 2nd  level function 
 
Labelled expenditures Non-labelled expenditures TOTAL 
3.1 (Police services) 
 
3,488,001.- 4,412,695.- 7,900,696.- 
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3.3 (Law courts) 
 
/ 987,588.- 987,588.- 
3.4 (Prisons) 
 
/ 13,898,711.- 13,898,711.- 
7.1 (Medical Products, 
appliances and equipment) 
 
318,151.- / 318,151.- 
7.2 (Outpatient services) 
 
5,227,146.- 1,301,628.- 6,528,774.- 
7.3 (Hospital services) 
 
/ 4,351,940.- 4,351,940.- 
7.4 (Public Health services) 
 
232,385.- 120,806.- 353,191.- 
TOTAL
 
34,339,051.- 
 
y Additional explanatory notes on attributable proportion calculation keys (not addressed in tables) 
 
05 Ministry of Finances Treasure and Budget 
05 FLTS: (Eligibility? / Revenue - Expenditure). Confiscated assets re-invested in the fight against drugs. Only financial means 
invested in national projects have been retained as these would have to be financed by public money if the FLTS did not exist. 
 
07 Ministry of Justice 
07.2 State prisons.  
 
Distinction between new entries and stock of prisoners per year. Prison administration provided proportion of ‘drug offenders’ in 
prison (prevalence: 25%) (Incidence:21% new entries): A) Calculation of total costs       B) 25% of total costs 
 
But: Estimation bias: Prevalence based estimation does not take into account duration of prison stays.  
A more accurate method if data available is the following:  
 
Estimation key = Sum drug prisoners days               =  e.g. 140,160 days   = 20.5%  
                           Total prison/person days per year               28,800 days                                                                                                               
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17 Ministry of Social Security (Health expenditures) 
II.1 HIV/AIDS treatment (IVDU related infections and health costs)  
 
For HIV/AIDS treatment rates the following calculation formula has been applied: 
 
- A : Total number  of  registered PLW HIV/AIDS infected via IVDU (diagnosis reporting) 
(status: alive) 
(If not available: Total number of PLWHIV/AIDS infected via IVDU x mortality rate of 
target population) 
(Higher precision (if available): Total number of PLW HIV/AIDS IVDU in treatment during 
year X that might be provided directly by central social security department ) 
 
- B: Average cost of HIV/AIDS treatment / year N provided by UCM  
 
- TOTAL COST OF PLW HIV/AIDS IVDU TREATMENT = A x B  
 
 
01 Ministry of Foreign Affairs and Immigration 
II.1 National Contribution to the EU ‘drugs budget’ 
 
The first national study on public drug-related expenditures (Origer, 2002) also included 
the national Contribution to the EU “drugs budget” as public money is at stake. The 
following method has been applied: 
 
a) Assessment of the EU “drugs budget” (x EUR) 
= difficult since EU drug budget lines are scattered, affected to internal and external 
programmes and there are multiannual budget lines. At the time of study only an 
inventory of drugs related EU budget lines did exist (COM (2001) 301 final).  
Methodology: Sum of annual EU drugs budget lines + proportional share of multiannual 
EU drugs budget lines for year of study 
 
b) Determination of the national contribution share to the total EU budget (y%) 
c) Estimation of national contribution: X x Y 
 
Remark: Other international contributions are accounted for in the budget lines of the 
Ministry of Foreign Affairs and Cooperation. The referred expenditures have not been 
included in the present analysis since EMCDDA guidelines do not refer to. 
 
y Relevant or pertinent expenditure breakdowns: 
 
The following minimum breakdowns on total expenditures should be performed if 
required data are available: 
- Expenditure per inhabitant (EUR) 
- Expenditure per estimated PDU or IVDU (EUR) 
- Demand reduction / Supply reduction / Risk/damage reduction / Research 
(COFOG level 3 and 7 is insufficient) 
- % of GDP 
- % of total national public expenditures / state budget 
- % of total national social expenditures / social budget 
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11.3 National studies on drug-related public expenditures 
 
The first study on drug-related public expenditures has been published in 2002 and 
refers to fiscal year 1999: 
 
Origer, A. (2002). Etude du coût économique direct des interventions et de la politique 
publique en matière de drogues et de toxicomanies. Séries de recherche n°4, Point focal 
OEDT Luxembourg – CRP-Santé, Luxembourg 
 
Abstract:  The ‘Origer 2002 study’ focuses on the estimation of direct economic costs of 
policies and interventions in the field of illicit drug use. The estimation applies to 
budgetary year 1999. The study exclusively refers to direct economic costs, thus 
excluding ‘costs of indirect consequences’ and ‘non quantifiable costs’ as well as 
expenditures related to the acquisition of illicit drugs by the consumer him- or herself. 
The applied methodology refers to the concepts of the ‘Cost of Illness’ (C.O.I.) theory.  In 
1999, the direct economic costs of national policies related to illicit drug use reached 
approximately 23.345 million euros, which represents an annual per capita expenditure 
of 54.- €. Based on the results of the latest national drug prevalence study (Origer 2000), 
the author calculated an average annual cost per problem drug user of 9,934.- €. 39% of 
estimated expenditures are related to supply reduction measures against 59% that are 
devoted to demand reduction interventions. Annually 1% of public resources are 
invested in drug research and international cooperation respectively. The total annual 
costs the collectivity has to stand for annually represents 0.13% of the gross national 
product and 0.5 of the total state budget in 1999. 
 
 
 
12. Vulnerable Groups of Young People 
 
 
12.1 Profile of main vulnerable groups 
 
• Children living in government care institutions 
  
The activity report 2006 of the Ministry of Family and Integration shows the evolution of 
minors placed from 2001 to 2006 in government care institutions or care families. 
 
Tab. 12.1 Minors placed from 2001 to 2006 in government care institutions or care families 
Type of placement 2001 
 
2002 2003 2004 2005 2006 Total 2006 
Conventioned  children centres 305 309 318 321 320 344 37.23% 
Conventioned day and temporary 
admission homes 
47 47 36 39 38 38 4.11% 
State children homes 60 64 60 60 60 69 7.47% 
Socio-educative state centres 64 73 79 68 82 65 7.03% 
Abroad placement 
 
78 83 103 114 123 149 16.13% 
Family placement 
 
227 224 227 233 249 259 28.03% 
Total 
 
781 800 823 835 872 924 100% 
SOURCE: Activity report 2006, Ministry of Family and Integration 
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• Early school leavers/ academic failure 
 
The study of “School leave in Luxembourg”48 (2006) surveyed a population of 37,347 
secondary school students. During a period from 1st November 2004 and 30 April 2006, 
a total of 2.422 students have been leaving school without a professional certification 
(temporary stay offs from school have also been taken into consideration). The study 
refers to a proportion of 6.5% of “school leavers”. This proportion figures 3.6% if one is 
considering the total number of students having been reached but who have not 
reintegrated a school in Luxembourg. Concerning this category of school leavers, 
composed of students attending courses abroad, being employed, following professional 
insertion measures and those without occupation (N=1,357), the situation was as 
follows: 41.2% of students who dropped school have integrated the job market (work or 
professional insertion measure), 39.8% didn’t work nor went to school and 19% attended 
school courses abroad. In general boys, youngsters from abroad and aged more than 15 
years (age of school obligation) are more vulnerable to the risk of early school leave.  
 
Tab.12.2 Early school leavers in native population 2006 
School leavers  
Total % Total % 
School attendance in Luxembourg 345 14.2%   
School attendance abroad 258 10.7% 258 19.0% 
With employment 250 10.3% 250 18.4% 
Insertion measure 309 12.8% 309 22.8% 
Without occupation 540 22.3% 540 39.8% 
Not reachable/without information/left country 720 29.7%   
Total 2422 100% 1357 100% 
Source: Ministère de l’Education nationale et de la Formation professionnelle (2006). Le décrochage scolaire au 
Luxembourg. Luxembourg 
 
• Youth in families with drug and/or alcohol use 
 
No studies have been performed on youth in families with drug and/or alcohol use. 
Concerning the item “drug consumption within the family of origin”, the national 
monitoring system on drugs and drug addiction RELIS reported in 2006 a proportion of 
62% of regular, sustained or problematic substance use among at least one member 
belonging to the family of origin of PDUs (illegal psychotropic substances and/or alcohol 
and/or medicaments). As additional information, one may add the age of RELIS 
respondents. Data from 2006 suggest a total of 6% of RELIS respondents aged 15 to 19 
years. 1% of youngsters aged less than 15 years have been indexed by RELIS.  
 
• Homeless youth 
 
According to latest estimations 715 persons are currently estimated to be homeless in 
the Grand-Duchy of Luxembourg49. The study reported a proportion of 54% males and 
46% females and a relatively young age of homeless population. Half of the population 
of homeless people is aged 18 to 34 years and only 9% are aged more than 55 years. 
Youngsters aged less than 25 and living on the street is referred to as a quite new 
phenomenon and linked to the societal evolution. Societal changes as the increase of 
mono parental families, an increase number of divorces, the decrease of married 
                                                                  
48Ministère de l’Education nationale et de la Formation professionnelle (2006). Le décrochage scolaire au Luxembourg. 
Luxembourg 
49 Centre d’Etudes de Populations, de Pauvreté et de Politiques Socio-Economiques (2007). L’exclusion liée au logement 
des personnes prises en charge par les centres de jour, les foyers de nuit, les centres d’accueil et les logements 
encadrés. Luxembourg 
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couples and the necessity of work of women obliged to work for economical reasons are 
likely to have negative impacts on youngster’s psychological development and 
education. 
 
• Young offenders 
 
A specialized drug counselling agency for minors, MSF Youth-Solidarity, provides 
psycho-social support to youngsters in breach with drug laws by including family and 
institutions. In 2006, MSF counted a total of 1,579 (2005: 1,289) structured interviews. 
Concerning age groups, 4.9 % of youngsters were aged less than 14 years, 28.8% were 
aged 14 to 15, 49.3% were aged 16 to 17 and 17% aged more than 17 years. The 
psychoactive substance primarily involved was cannabis (73.3%) followed by heroine 
(3.7%) and legal drugs (3.1%). Poly-consumption was reported in 3.7% of cases. 
 
The 2006 annual report of the Grand-Ducal Police shows that 11.5% of all law offenders 
are minors (youngsters aged less than 18 years).   
 
Tab.12.3 Minor law offenders 2006 
Adults Minors (less than 18 years) Categories Total 
offenders male female total % male female total % 
Offences against 
property 
4,059 2,531 708 3,239 79.8% 640 180 820 20.2% 
Offences against 
the person act 
5,338 3,726 1,078 4,804 90% 437 97 534 10% 
Others 
whereof 
drug offences 
5,403 
 
1,732 
4,016 
 
1,288 
1,040 
 
234 
5,056 
 
1,522 
93,6% 
 
87.9% 
261 
 
166 
86 
 
44 
347 
 
210 
6.4% 
 
12.1% 
TOTAL 14,800 10,273 2,826 13,099 88.5% 1,338 363 1,701 11.5% 
SOURCE: Activity report 2006, Grand-Ducal Police 
 
 
• Youth in deprived places/ neighbourhoods and/or with drug availability 
 
No studies specifically addressing youth in deprived places/ neighbourhoods and/or with 
drug availability have been performed thus far. However, the Research Centre on the 
situation of Youngsters in Europe (CESIJE) coordinates and promotes projects on 
youngsters’ living conditions and performs research projects to contribute to national 
youth policy. Not specifically specialized in drug-related research, a recent study (in 
press) ‘Youngsters in urban areas’. Analyses of structures, habits and problems of 
youngsters in the South of the Grand Duchy of Luxembourg’ will give insight into 
problems encountered by youth in also deprived places.  
 
• Ethnic minorities 
 
The national drug monitoring system RELIS reported in 2006 a proportion of 53% of 
native PDU respondents (n=769). Since 1994 the proportion of non-natives in PDUs has 
been showing a discontinuous upward trend. National drug agencies had to adapt their 
programmes and concepts to this situation. Persons of Portuguese nationality are the 
most represented. The neighbouring countries (France, Germany and Belgium) showed 
in 2006 a remarkable upward trend (34%). The number of PDUs originating from non EU 
countries has been showing an upward trend until 2003 but decreased since then. 
 
An NFP study called “Comparative study on the drug population of Portugal and a 
representative sample of Portuguese drug addicts residents of the Grand Duchy of 
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Luxembourg”50 was published in 1999. The most important group of foreign drug addicts 
treated within national health care institutions have been of Portuguese origin (50% of 
foreign drug treatment demanders). 
 
• Party goers 
 
No national studies have been performed on party goers. However, to combat the 
sustained consumption of legal drugs in youngsters, new laws concerning the prohibition 
of selling alcohol to youngsters aged less than 16, as well as a restriction of the tobacco 
law have both entered in force in 2006. Taxes on the so called “alcopops” have been 
raised in January 2006 in order to make designer drinks less attractive for youngsters. 
 
• Youth from vulnerable families 
 
The national action plan against drugs and drug addiction (2005-2009) foresees among 
other prevention projects the development of concepts of prevention in homes, 
admission centres and socio-educative centres for children and youngsters as this target 
population constitutes a risk group. The national prevention centre CePT is in charge of 
these measures and will evaluate this project. 
 
12.2 Drug use and problematic drug use among vulnerable groups 
 
Given the “low” national drug prevalence as far as the absolute number of PDUs is 
concerned, only few studies exist on specific sub-groups, as for instance vulnerable 
groups.  
 
• Prevalence, patterns of drug use, social and geographical profiles 
 
The before mentioned comparative study on the drug population of Portugal and a 
representative sample of Portuguese drug addicts residents of the Grand Duchy of 
Luxembourg (Origer, 1999) showed that 82% of Portuguese addicts treated in 
Luxembourg and 98% of Portuguese living in Portugal used opiates as primary drug. 
Concerning the route of administration, it seems that far more Portuguese drug addicts 
treated in specialized national institutions injected drugs than Portuguese native 
treatment demanders. Cocaine abuse was more frequently observed among Portuguese 
addicts living in Luxembourg, while inhaling seemed to be a far more common practice 
in Portugal. Portuguese drug addicts treated in Luxembourg have been far younger than 
native addicts. The mean age of opiate drug addicts entering treatment in Luxembourg 
tended to increase. 
 
• Trends in the last 10 years 
 
Over ten years of RELIS data confirmed a predominance of Portuguese citizens among 
PDUs varying from 50% to 58%. Data from 2005 however suggest a slight decrease 
(39%) of Portuguese population among PDUs and an increase of France citizens 
(2004:11%; 2005: 23%). 
 
 
 
                                                                  
50 Origer A. (1999). Comparative study on the drug population of Portugal and a representative sample of Portuguese 
drug addicts residents of the Grand Duchy of Luxembourg. EMCDDA National Focal Point, Ministry of Health, 
Luxembourg. 
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• ESPAD 
 
Luxembourg is not a participating country of ESPAD studies. 
 
12.3 Vulnerable groups among the treated population (See chapter 1 and 2) 
 
12.4 Correlates and consequences of substance use among vulnerable groups 
 
• Psycho-social and health problems related to substance use 
 
No special studies on correlates and consequences of substance use among vulnerable 
groups have been conducted so far. (See comment under 2.) 
 
• Criminal behaviours 
 
In 2006 1,575 drug law offences have been registered at the national level. 0.5% of 
offenders were younger than 15, in 6.7% they were minors of age and in 18.2% they 
were younger than 20 years. 64% of the drug offenders were non-natives.  
 
12.5 Policy and legal development 
 
• National and legal development 
 
In line with the EU commitments, Luxembourg set up a national action programme 
against poverty and social exclusion (NAP 2006-2008). Concerned ministries in 
collaboration with social partners elaborated measures against social exclusion.  
 
The national action plan against drugs and drugs addiction (2005-2009) includes 
measures specifically addressing youngsters to prevent social exclusion by reason of 
substance abuse and addiction. These measures primarily include prevention projects in 
school environment and children homes as also selected prevention programmes 
addressing first time consumers (CHOICE). 
 
• Strategies and policies for social exclusion 
 
To better respond to the situation of homeless people, the Government charged the 
International Network for Studies in Technology, Environment, Alternatives, 
Development (CEPS/INSTEAD) to study the population of homeless persons in the 
Grand-Duchy of Luxembourg.  
 
In the context of the reform of psychiatry in Luxembourg, new youth care structures are 
implemented to better respond to the situation of drug dependent youngsters. In the 
framework of the 2005-2009 drugs action plan, the Neuro-Psychiatric Hospital Centre 
(CHNP) implemented in 2006 a treatment centre for youngsters with addictive, anti-
social and behavioural problems aged 12 to 18 years with a capacity of 18 clients. 
The ministry of Family plans for 2008 a specific structure for minors on the run. 
Furthermore, “security units” will be implemented in the framework of the socio-
educative state centres in order to avoid that minors come in contact with adult prison 
settings. 
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• Definitions and concepts of vulnerability in the national context 
 
As stated above, the national action plan against drugs and drug addiction defined 
measures for vulnerable populations. Primary prevention projects target very young 
children in post primary and primary schools, children and youngsters in admission 
homes and drug-dependent parents.  
 
12.6 Prevention and Treatment 
 
• Specific treatment options for vulnerable groups 
 
National drug treatment agencies take into account specificities of the national context 
(geographical size of the country, multi nationalities - cultural context…). Prevention and 
treatment are not substance specific but take into account the individual and his 
environment. 
 
• Institutional responses/ responses in the area of social inclusion 
 
In the area of social exclusion special attention is paid to professional/occupational 
reintegration structures for drug dependant persons. The national drugs action plan 
2005-2009 foresees the implementation of a day structure offering further education and 
daily occupation to persons with drug related problems. 
 
• Responses to public nuisance 
 
By means of round-tables, all actors concerned (citizens, ONG, drug dependant 
persons, ministries, City of Luxembourg…) discuss solutions regarding public nuisance. 
One may note that the City of Luxembourg regularly organizes prevention committees 
discussing public nuisance issues in collaboration with concerned NGOs. The 
implementation of the first drug consumption room in Luxembourg City in July 2005 
required regular meetings between the Ministry of Health and all actors concerned. The 
latter are ongoing and of routine nature in order to solve, among others, public nuisance 
related problems as soon as they occur. 
 
• Trends and changes in recent years 
 
In recent years, a restructuring of the “Interministerial Group of Drugs” (GIT), an advisory 
platform of ministries involved in drug related issues, discusses and approves measures 
of the national drugs action plan (2005-2009). New trends and changes are also directly 
reported by field workers from NGO’s. 
    
• Early intervention strategies 
 
The national prevention centre CePT assures primary prevention sessions for children in 
kindergarten and primary schools in order to reach the very youngsters. 
 
• Selective prevention for families at risk 
 
Since 2003 the Youth-and Drughelp foundation (JDH) is running a parental project with 
the aim to provide psycho-social aid to drug-dependant parents and their children. The 
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primary objective of the project is to ensure security and well-being to children and to 
strengthen parents’ educative abilities. This long term project is based upon contractual 
commitments, co-intervention, home visits and functions in close collaboration with 
involved services. In 2006, 69 different family situations have been treated, 62% of them 
being mono parental situations involving in all 50 children. An essential part of the 
project constitutes the outreach work. Meetings and interviews are held within the 
natural environment of the family (at home). 
 
 
13. Drug-Related research in Luxembourg  
 
 
13.1. Research structures 
 
13.1.1 Drug related research in national policy 
 
The EMCDDA National Focal Point implemented in the Public Research Centre of 
Health is the main national research centre for drug related epidemiological research. 
The laboratory of toxicology associated to the National Health Laboratory is the State’s 
reference laboratory in the context of toxicological analyses and related drug research. 
 
The national drug action plan 2005-2009 elaborated by the Ministry of Health explicitly 
refers to research and information as an integrated part of the transversal axes of 
demand and supply reduction and stresses that research and information constitute a 
primary need for all anti-drugs policy. The research domains include: fundamental, 
epidemiological, sociological research, elaboration, harmonization and standardization of 
methodological applications, evaluation and exchange of knowledge. The objective of 
national policy in regard to research is to develop infrastructures and research means, to 
build up a national and international research network, to optimize the transfer of 
knowledge between research actors and the decisional level, to rationalize the diffusion 
of information to different target audiences, to put special attention on the evaluation of 
planned actions, to contribute to need assessments (e.g. treatment, infrastructures) and 
the conceptualization of strategies/policies. Investment into research constitutes a 
necessity even if results are often only visible in the long term.  
 
13.1.2 Relationship research-policy 
 
As stated above, the EMCDDA National Focal Point is the centre of reference for 
epidemiological drug research at national level. National policy and practice are highly 
interlinked with the RELIS national monitoring system, Luxembourg information network 
on drugs and drug addiction. The national drugs action plan is based upon the findings 
of the RELIS drug monitoring system. Besides, NGO’s working in the drug field and 
financed by the State’s budget, can call for research activities in the field of sociological 
research and often participate in European projects funded by the European 
Commission. In regard to Public Health, the Ministry of Health in close collaboration with 
NGO’s, define national research needs.  
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13.1.3 Main national structures for drug-related research 
 
• Coordination bodies for drug-related research 
 
Since 2000, the Ministry of Health entrusted a national drug coordinator to assure drug 
coordination between ministerial and NGO level. In 2006, the national drug coordinator 
was appointed chair of the interministerial group on drugs and drug addiction (“GIT” 
Groupe Interministériel Toxicomanie) and ensures the set up of the national drugs action 
plans, which is to be approved and followed up by the GIT. 
 
The main coordination bodies involved in drug related research are the Ministry of 
Health and the Public Research Centre of Health, run under the supervision of the 
Ministry of Culture, Higher Education and Research and the Ministry of Health. 
 
• Main research institutions and organizations 
 
The Public Research Health Centre (CRP-Santé) and more precisely the EMCDDA 
National Focal Point is the national reference centre for drug related research.  
 
The National Prevention Centre for Drug Addiction (CePT), partly financed by the State 
budget in close collaboration with the NFP, ensures research in the field of drug 
prevention. Several other research actors (University departments of the University of 
Luxembourg, external experts…) operate as subcontractants to the NFP or the CePT. 
 
The Central Service of Statistics and Economic Studies (STATEC), national statistical 
centre of the Ministry of Economic Affairs and External Trade, has published in 2006 a 
socio-economical study in regard to drugs called “Illegal activities related to drugs: 
estimation of economic impact in Luxembourg”51. The respective method was mainly 
based on RELIS data provided by the NFP. 
  
• Main funding frameworks and size of funding 
 
The CRP-Santé disposes of different budgetary resources. Financial contributions can 
originate from the state’s budget, from financial participation from third institutions, 
national or international, for contractual research projects or by donations and legacy 
contracts or other resources originating for example from the cession of property rights. 
 
The Ministry of Culture, Higher Education and Research assures the Interministerial, 
European and International coordination of research.  
Since 1999 the National Research Fund managed by the Ministry of Culture, Higher 
Education and Research aims to promote research activities at national level, attributes 
awards to researchers and scientists, allocates subsidies to individuals and associations 
and promotes programmes of the European Commission and international 
organizations. 
 
The National Fund against Drug Trafficking manages assets and capital confiscated in 
the framework of drug law offences by virtue of the law of 19 February 1973 and co-
                                                                  
51 Service Central de la Statistique et des Etudes Economiques (2006), Les activités illégales liées à la drogue: estimation 
de leur impact économique au Luxembourg, Statnews n°35/2006 et Bulletin du Statec n°2-2006, Luxembourg. 
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ordinates, among other tasks, the allocation of respective financial resources to drug-
related prevention, care or research projects at national and international level. 
 
According to Origer (2002 b)52 the proportion of the national budget invested in the fight 
against drugs dedicated to drug research amounts approximately 1%. 
 
13.2 Main recent studies and publications 
 
13.2.1 Main recent studies since 2000 
 
• Prevalence and spreading of viral hepatitis A, B ,C and HIV among 
problematic users of illicitly acquired drugs53 (Origer & Removille 2007) 
 
The study “Prevalence and spreading of viral hepatitis A,B ,C and HIV among 
problematic users of illicitly acquired drugs” was conducted by the NFP of the EMCDDA. 
The National Fund against Drug Trafficking ensured the funding of the study. 
 
The objective of the “action-research” was to assess the national prevalence of blood 
borne viruses HIV, HCV, HAV and HBV in the population of problematic users of illicitly 
acquired drugs, to perform a cross sectional analysis of the relation between the studied 
infections and selected observable factors, to increase the national vaccination coverage 
and to refer infected persons towards appropriated medical treatment centres. 
 
Eight month data collection in 2005 have allowed to establish 1167 contacts , of which 
397 were conclusive and numerous new cases of infection have been identified. It is the 
first study of this type ever conduced at national level. 
The study shows that the self-reported data do not mirror validly the prevalence (both 
furnished by the study) but the self reported rates provided by the national drug 
monitoring system (RELIS) provide a satisfactory proxy of diagnostic based prevalence.  
The HCV prevalence rate of the total study sample was 71.4% and reached 81% for the 
ever injectors54. The highest prevalence rate (86.3%) was observed in in-prison 
respondents, followed by those in in-patient treatment centres (75.4%) and those in out-
patient treatment centres (58.2%). The study has not allowed to determine the 
proportion of active chronic hepatitis55.  
 
The HBV prevalence (comprising acute/chronic infection and past cured infection) in the 
G.-D. of Luxemburg among PDUs is 21.6% and figures 24.7% in ever injectors. HBV 
prevalence in out-patient treatment centres is 16.4%, 15.1% in the in-patient treatment 
centres and 31.8% in prison. 32% of the PDUs could benefit from the vaccination 
against hepatitis B and 46% are immune due to vaccination. 
 
                                                                  
52 Origer, A. (2002b). Etude du coût économique direct des interventions et de la politique publique en matière de drogues 
et de toxicomanies. Séries de recherche n°4, Point focal OEDT Luxembourg – CRP-Santé, Luxembourg. 
 
53 Origer, A., Removille, N. (2006). Prevalence and spreading of viral hepatitis A, B, C and HIV among problematic users 
of illicitly acquired drugs. CRP-Santé, EMCDDA, NFP Luxembourg 
 
54 Ever injector: injection of drug for non therapeutic reasons at least once. 
55 Active chronic hepatitis: Infection for more than six months with liver inflammation. 
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Concerning HAV prevalence, no case has been identified in the present study. It should 
be stressed, however, that 43% of the participating PDUs are not protected against 
hepatitis A. 
 
The overall HIV prevalence among the PDUs provided by the study figures 2.9% and 
2.5% when exclusively referred to ever injectors. The HIV prevalence rate is 1.9% in the 
out-patient treatment centres, 7.7% in the prison centres and is null in the in-patient 
treatment centres. 
 
One has to bear in mind that among persons infected by HCV, HBV and HIV, 
respectively 96%, 95.2% and 71.4% are ever injectors. It is important to note that the 
highest prevalence rates are observed among prison population. This has to be 
confronted to the fact that half of the respondents declare having consumed illicit drugs 
in prison whereof half report intravenous use during their prison stay.  
 
The study also refers to a series of associated factors such as, inefficient disinfection 
methods, inadequate syringe elimination, a high proportion of Problematic Drug Users 
(PDUs) not using condoms during sexual intercourse, especially with new or irregular 
partners, the lack of or false knowledge of serological status and finally, protection 
strategies based on subjective criteria rather than on established knowledge. 
 
Although strategies for risk reduction in the population of problematic drug users in the 
G.- D. of Luxemburg exist, this study points out the high prevalence of certain infectious 
diseases in the target group and in particular hepatitis C (HCV). 
The existing prevention efforts have to be completed by putting particular emphasis on 
young and new drug users. Although the study confirms a low compliance of the target 
population, screening and vaccination facilities have to be further developed. In this 
context the authors put forward a series of recommendations that may contribute to 
reduce incidence of infectious diseases and related risks in drug users. 
 
• Illegal activities related to drugs: estimation of economic impact in 
Luxembourg (STATEC, 2006) 
 
The study “Illegal activities related to drugs: estimation of economic impact in 
Luxembourg”, conducted between 1999 and 2004, was published in July 2006 by the 
central service of statistics and economic studies STATEC. The study was realized in 
the framework of a European project aiming to improve comparability of national 
accounts. 
One of the particularities of national accounts, the gross national income (GNI) is used 
as a part of contribution to the European budget. In principle, the concept of the 
European system of accounts (SEC95) also includes illegal activities. For 
methodological reasons and absence of accurate data, illegal activities have not yet 
been included into the EU accounts. As there exist numerous definitions of illegal 
activities in the different EU member states and to assure justice and equality of 
treatment, the European Commission requires including illegal activities into national 
accounts. Similar studies are running in different member states. By means of these 
studies the Commission may decide upon the future inclusion of illegal activities into 
national accounts of member states. 
The Grand-Duchy of Luxembourg disposes high quality statistical data of problematic 
drug use. However data on occasional drug use are insufficient in reason of an absence 
of regular general population surveys. The economic and geographic position of 
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Luxembourg does not enable to make a statistical extrapolation of confiscation data on 
drug supply and demand of the Luxembourg drug market. Therefore the basis of data 
produced in this study is build upon the estimation of drug consumption. The drug 
expenditure from households are estimated between 37,8 million euros per annual mean 
in 1999 to 2004.  
Information from experts helped to estimate the drugs supply for the Luxembourg 
market. However produced results are fragile and have to be interpreted only as data 
ranges. 
Results of the study situate the impact of illegal activities related to drugs for 2004 at 
0.11% GNI and to 0.08% GNR. The impact is limited, however it agrees to data ranges 
of studies conducted in several EU member states. 
 
• Benzodiazepine prescribing in the Grand-Duchy of Luxembourg (1995-
2004) 
 
Cloos J.M. (ZithaKlinik, Luxembourg), Ries T., Koch P. (Contrôle Médical, Luxembourg) 
e-mail: cloosj@pt.lu 
 
Objective: The chronic use of benzodiazepines is of limited therapeutic benefit and 
increases the risk of adverse events. The purpose of the study was to examine 
benzodiazepine prescription routines of physicians in domiciliary practice in the Grand-
Duchy of Luxembourg and to obtain reliable results on the prevalence of benzodiazepine 
use within the country (411,600 inhabitants in 1995 vs. 455,000 inhabitants in 2004). 
 
Study design: The survey is retrospective, population-based and covers a ten year 
period (1995-2004). The authors used a database available at the National Social 
Security that includes all the national insurance contributors (with the exception of the 
employees working for the European Union). 
 
Methods: The authors calculated the number of annual prescriptions, the annual 
prescription by drug (converted in equivalent diazepam dosage), the number of patients 
receiving a prescription by year and draw a profile of the consumers (age and sex). The 
authors estimated the mean daily dose and the duration of the prescription 
(discontinuous/continuous intake). The authors finally gave a profile of the chronic 
consumers and reviewed the number of prescription containing more than one 
benzodiazepine. 
 
Results: In Luxembourg, 23 different benzodiazepines are approved for medical usage 
(Table 13.1, with equivalent dose of 10 mg of diazepam):  
 
Tab. 13.1 Benzodiazepines approved for medical usage with equivalent dose of 10mg of diazepam 
Chemical denomination Dose eq. Cloxazolam 1 Lormetazepam 2 
Alprazolam 0.5 Diazepam 10 Midazolam 5 
Bromazepam 6 Flunitrazepam 1 Nitrazepam 5 
Brotizolam 0.5 Flurazepam 30 Nordazepam 20 
Clobazam 20 Ketazolam 30 Oxazepam 50 
Clonazepam 2 Loflazepate 1.33 Prazepam 20 
Clorazepate 20 Loprazolam 1.33 Tetrazepam 50 
Clotiazepam 5 Lorazepam 2.5 Triazolam 0.5 
 
They are reimbursed at 40% by the national health insurance. The number of annual 
prescriptions showed a slight decrease within the study period (228,188 prescriptions in 
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1995 vs. 198,547 prescriptions in 2004), thus not informing about the length of the 
prescription (which may be up to 6 months). 
 
Fig. 13.1 List of seven most prescribed benzodiazepines (and flunitrazepam): 
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The annual prescribed volume of alprazolam nearly tripled during the study period. The 
classification of flunitrazepam as a stupefacient in 2000 decreased its prescriptions 
drastically (2,609,100 mg eq. dose in 1995 vs. 104,560 mg in 2004). The number of 
insured having received at least one benzodiazepine prescription per year passed from 
14.3% (n=58,753) in 1995 to 12.8% (n=58,338) in 2004, with a total number of 166,781 
different persons during the 10-year study period. 2/3 of the all the subjects are older 
than 50 and nearly 2/3 are female (Table 13.2): 
 
Tab. 13.2 Male and Female aged ≤ 49 and ≥50 
Total 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 
≤ 49 19,209 19,671 19,648 19,990 19,711 19,493 19,277 19,310 18,622 18,584 
≥50 39,544 40,401 40,507 40,943 41,037 40,524 40,180 40,357 40,020 39,754 
Men 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 
≤ 49 7,499 7,620 7,541 7,766 7,716 7,615 7,481 7,448 7,205 7,239 
≥50 13,398 13,622 13,723 14,016 14,075 13,723 13,698 13,795 13,712 13,628 
Women 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 
≤ 49 11,710 12,051 12,107 12,224 11,995 11,878 11,796 11,862 11,417 11,345 
≥50 26,146 26,779 26,784 26,927 26,962 26,801 26,482 26,562 26,308 26,126 
 
The estimated mean daily dose calculated in the next table (Table 13.3) is a daily 
average of the yearly delivered dosage per subject and therefore does not necessarily 
reflect the real daily consummation: 
 
Tab. 13.3 Estimated average daily dose 
Eq. dose 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 
0-20 mg 56.247 57.314 57.043 57.658 57.409 56.595 55.913 56.035 54.968 54.646 
21-50 mg 2.154 2.345 2.597 2.738 2.800 2.855 2.881 2.938 2.974 2.953 
51-100 mg 290 338 415 426 438 445 510 541 541 556 
≥101 mg 62 73 100 109 101 122 153 153 159 183 
 
The number of high dosage consumers (≥51mg/day) doubled within ten years. The 
authors divided all the subjects into 3 subgroups, to study the consummation profile: 
 
1) A group of “short term delivery”: the benzodiazepine prescribing for these subjects 
was either unique or no longer than three months (n=58,161). 
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2) A group of “discontinuous delivery”: around one third of all the subjects (n=51,396) 
had several prescriptions but with at least a one year break between the prescriptions. 
The authors calculated the total annual dose prescribed for these subjects in the years 
they were on benzodiazepines and considered a yearly average dose of the equivalence 
of 900 mg of diazepam as not being problematic ,(n=38,554). The rest of the subgroup 
(n=12,842) consumed more. 
3) A group of “continuous delivery”: these subjects (n=57,224) never stopped with the 
benzodiazepines, once prescribed, and represented 34.3% of all the subjects (i.e. 12.6% 
of the general population). Their profile is given in Table 13.4: 
 
Tab. 13.4 “Continuous delivery” profile 
Length ≤ 10 mg 11-30 mg 31-100mg ≥ 100 mg Total (n) 
4-12 months 9,287 1,484 130 5 10,906 
1-3 months 14,433 2,331 228 13 17,005 
4-5 months 3,838 1,159 137 11 5,145 
≥ 6 months 14,948 7,893 1.259 68 24,168 
Total (n) 42,506 12,867 1.754 97 57,224 
 
Nearly three quarters (n=42,506) of the “continuous delivery” subgroup are low dose 
consumers. The daily dose seems to be average (10-30 mg of diazepam equivalence) 
for another 22.5% (n=12,867). High dosage consummation is found in 3.2% (n=1,851) of 
the chronic consumers (i.e., 0.4% of the general population).  
 
40 of the 68 highest consumers (> 100 mg eq. dose since more than 6 years) were 50 
years or older, and 45 of them were female (30 older than 50). The top 2 
benzodiazepines consumed were bromazepam (n=42) and alprazolam (n=52). The 
authors finally examined the number of benzodiazepines per prescription and the profile 
of the prescribers: of all the prescriptions (n=2,189,078), nearly 10% contained 2 
different benzodiazepines (n=211,055), 0.5% of them (n=10,805) listed 3 substances, 
and there was a small number with more than 4 (n=632). The 3 top prescribing specialist 
groups were the neuropsychiatrists, the general practitioners and the psychiatrists. 
 
Conclusions: Benzodiazepine prescriptions in Luxembourg were appropriate for nearly 
two third of the patients and prescribed according to current treatment guidelines. 
However, up to 40% of the consumers had long term prescriptions, most of them at a 
low dosage. The literature estimates a dependency in half of these subjects, thus 
representing around 5% of the general population. High dose dependency and abuse 
remains more rare and is to be suspected in 3.7% of the consumers (i.e., 0,4% of the 
general population). 
 
Implications: The study was presented as a thesis at the University of Strasbourg 
(France). It was published by the national association of physicians and sent to every 
member. It was discussed in an open session by the national government and in the 
press. It has lead to a general awareness of the problem within the country and to 
several concrete measures. 
 
Bibliography: “Les benzodiazépines au Grand-duché de Luxembourg”. Association des 
Médecins et Médecins-Dentistes du Grand-duché de Luxembourg (AMMD): Le Corps 
Médical (nr. 3/2007: part 1, pp. 4-39, nr. 4/2007: part 2, pp. 3-29). 
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• The direct economical cost of policies and public interventions to fight 
illegal drug use in the Grand-Duchy of Luxembourg56 (Origer, 2000) 
 
The study was conducted by the NFP of the EMCDDA and focuses on the estimation of 
direct economic costs of policies and interventions in the field of illicit drug use. The 
estimation applies to budgetary year 1999. 
 
The study exclusively refers to direct economic costs, thus excluding “costs of indirect 
consequences” and “non quantifiable costs” as well as expenditures related to the 
acquisition of illicit drugs by the consumer him-or herself. The applied methodology 
refers to the concepts of the “Cost of Illness” (C.O.I.) theory. 
 
In 1999, the direct economic costs of national policies related to illicit drug use reached 
approximately 23.345 million euros, which represents an annual per capita expenditure 
of 54.-euros. Based on the results of the latest national drug prevalence study (Origer 
2000), the author calculated an average annual cost per problem drug user of 9,934.- 
euros. 
 
39% of estimated expenditures are related to supply reduction measures against 59% 
that are devoted to demand reduction interventions. Annually 1% of public resources are 
invested in drug research and international cooperation respectively. 
 
The total annual costs the collectivity has to stand for annually represents 0.13% of the 
gross national product and 0.5 % of the total state budget in 1999. 
 
• Epidemiological study on drug-related deaths and analysis of 
methodological aspects of indexing procedures applied in the Grand-
Duchy of Luxembourg (1992 – 2000)57 (Origer and Delucci, 2002) 
 
The consequences of drug misuse are manifold. A drug-related death often materializes 
the final outcome of an entanglement whose components are difficult to analyse a 
posteriori. The concept of drug-related mortality embraces both, acute fatal intoxications 
(overdose) and deaths that are not a direct consequence of an adverse somatic reaction 
following substance intake but in which drug use has to be considered as a contributing 
cause. Those scenarios represent two different epidemiological complexities, which the 
present study intends to explore. The first part of the study analyses factors that may 
influence the transition from experimental drug use to a fatal drug-related incident. The 
second part focuses on methodological aspects with regard to the production and 
collection of reliable prevalence and incidence data on drug related mortality. 
 
The number of fatal overdoses indexed at the national level has shown an increasing 
trend from 1985 to 1994 (29 cases), followed by a slow decrease until 1997 (10 cases). 
Afterwards, the prevalence has increased anew to reach 26 cases in 2000. In terms of 
drug-related mortality (direct and indirect deaths), 23 cases have been indexed in 1992; 
prevalence has stabilized since 1995 figuring roughly 40 cases per year. 
 
                                                                  
56 Origer A. (2002), Etude du coût économique direct des interventions et de la politique publique en matière de drogues 
et de toxicomanies. Séries de recherche n°4, Point Focal OEDT Luxembourg – CRP-Santé, Luxembourg. 
57 Origer A., Dellucci H. (2002), Etude épidémiologique et méthodologique des cas de décès liés à l’usage de drogues 
(1992-2000), Séries de recherche n°3, Point Focal OEDT Luxembourg – CRP-Santé, Luxembourg. 
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Compared with national prevalence figures on problematic drug users in 2000 
(N=2,450), in 1999 (N=2,350) and in 1997 (N=2,100) (Origer 2001), overdose cases 
represents a rate varying between 0.48% in 1997 and 1.1% in 2000 (0.77% in 99). 
Referred to the total number of drug-related deaths, indexed by national law 
enforcement agencies and forensic institutes, the same proportion shows weaker 
variations: 1.346% in 2000, 1.361% in 1999 and 1.333% in 1997. 
 
The overdose rate in the national general population figures 6.43 overdose deaths per 
100,000 inhabitants in 2000 (3.95 o.d. cases in 1999 and 2.09 in 1997). An international 
comparison shows that the overdose rate of the G.D. of Luxembourg is among the 
highest within EU Member states, even though it has known a significant decrease in 
2001. 
 
Two action strategies emerge from the epidemiological outcome of the study. Firstly, the 
need of a specialized care network allowing for rapid and active contact making with 
high risk users as profiled by the study and secondly, the set-up of re-integration 
programmes designed to fill the psychosocial gap often observed after a prolonged 
institutional journey (Hospital, prison, therapeutic community). Those programmes have 
to start before clients are released from respective institutions. A proactive approach in 
terms of risk reduction, multidisciplinary networking and an early perception of high risk 
factors appear to be valuable means towards the reduction of drug-related morbidity and 
mortality in drug using populations. 
 
• Estimation of national prevalence of problematic use of illicitly acquired 
drugs. Multi-methods comparative study 1997-200058 (Origer, 2001) 
 
The research focuses on two primary objectives. It is the first comparative multi-methods 
drug prevalence study conducted at the national level.  
 
The research strategy relies on the methodogical framework of the Luxembourgish 
Information System of Drugs and drugs addiction (RELIS), set up in 1994 by the national 
focal point of the EMCDDA. The study specifically aims at the prevalence estimation of 
problem use of illicitly acquired high risk drugs (HRC) in the national population aged 15 
and 54 years. The chosen terminology defines the target population with regard to the 
observable consequences of drug use, the nature of consumed substances as well as 
the context (legal or illegal) of their acquisition. 
 
Data from 1999 and 2000 have been considered in comparison with the first national 
drug prevalence figures from 1997. The following methods have been applied: Case 
finding (CF), capture-recapture on 2,3 and 4 sources (CR 2,3,4), truncated Poisson 
model associated to Zelterman’s and Chao’s estimators (tPm), and four different 
multiplier methods using data from law enforcement sources, drug mortality registers 
(D1,2,3) and treatment agencies (T). 
 
Absolute prevalence and prevalence rates of problem HRC drug use have shown a 
growing tendency aver the past four years. The increase curve observed between 1999 
and 2000 is less ascending than the one observed during the period 1997 to 1999. The 
observed figures comply with the stability of heroin use and intravenous drug use 
                                                                  
58 Origer A., (2001), Estimation de la prévalence nationale de l’usage problématique de drogues à risque élevé et 
d’acquisition illicite – Etude comparative multi-méthodes 1997-2000, Séries de recherche n°2, Point focal OEDT 
Luxembourg – CRP-Santé, Luxembourg. 
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prevalence between 1999 and 2000. Although the total drug use prevalence shows an 
upwards tendency, heroin use does not contribute significantly to the referred 
progression. Intravenous drug use prevalence has even shown a slight decrease in 
2000. 
 
The average prevalence of problem HRC drugs use (2,350) and the related prevalence 
rate of 5.59/1000 (9.58/1000 in national population aged between 15 and 54), in 1999 
are deemed to show good validity according to the non-contradicting estimates obtained 
by the multi-methods approach and the evolution of indirect indicators such as the 
number of fatal overdose cases, the number of distributed syringes through the national 
needle exchange programme, the number of HRC drug law offences, drug seizures and 
admission data of low threshold agencies. Prevalence figures calculated for 2000 (N: 
2,450, total rate: 5.59/1000, rate 15-54: 9.58/1000) also fit the curve of indirect 
indicators. Since the 2000 figures have been obtained by a limited number of estimation 
methods, observed tendencies should be confirmed by further research based on the 
evaluation outcome of multi-source methodologies in the light of national specificity. 
According to experience gathered in the framework of the present research project, the 
application of a routine set of methods including CR3, tPm and D1, currently appears to 
be a highly valuable option. 
 
13.2.2 Peer-reviewed scientific journals 
 
There exist few national researchers publishing in international peer-reviewed scientific 
journals.  
A recent article published in 2005 of the “Forensic Science International” can be cited : 
Appenzeller M.R.B., Schneider S., Yegles M., Maul A., Wennig R. (2005), Drugs and 
chronic alcohol abuse in drivers, Forensic Science International 155, 83-90”, whereas 
Wennig R. represents a national researcher of the Public Health Research Centre, 
National Laboratory of Health, Toxicological Department, University of Luxembourg. 
 
13.3 Collection and dissemination of research results 
 
13.3.1 Information flow 
 
• Description National Focal Point 
 
The National Focal Point can be considered as a national excellence centre in drug-
related research. It also plays a major role in drug-related policy decision process at 
national level. Implemented in the Public Research Centre of Health (CRP-Santé) and 
more particularly in the department of health studies (CES), the NFP depends on the 
State’s and EMCDDA budgetary means. Since 1994 the national drug monitoring 
system RELIS aims to situate prevalence and incidence of problematic drug use. RELIS 
stands for both, a human and technical network. Information is gathered annually by 
means of standardized questionnaires covering all national drug treatment agencies. 
The NFP disseminates research information by publishing research studies on its 
internet platform www.relis.lu, and introduces new research studies to the national press.  
 
13.3.2 National scientific journals 
 
No national scientific journals on drugs and drug addiction exist. 
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13.3.3 Other means of dissemination 
 
• Websites dedicated to research 
 
The NFP internet page www.relis.lu includes all drug related research studies performed 
by the NFP. The bulletin of the society of medical sciences invites researchers to publish 
articles from different scientific specialities (www.ssm.lu).  
A governmental public internet page is dedicated exclusively for innovation and research 
www.innovation.public.lu without however being specialised on drug related issues. 
 
• National drug conferences 
 
In May 2007 the national FP organized a REITOX academy on public expenditure 
analysis in the field of drugs. 
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• Relevant data bases and information systems 
 
a. RELIS drug monitoring system 
 
Relying on a multi-sectorial data network including specialised in- and outpatient treatment centres and low 
threshold facilities, general hospitals as well as law enforcement agencies and national prisons, the RELIS drug 
monitoring system, established in 1995 by the NFP in collaboration with the Ministry of Health enables the 
assessment of new trends in the problem drug users population in general as well as in drug treatment 
demanders in particular. PFN has opted for a holistic monitoring of the drug population, which by definition, is 
heterogeneous and not limited to drug treatment demanders. RELIS data refer to HRC drug users indexed by the 
national specialised treatment and law enforcement network and, as such, defined as problem drug users. 
 
The main objectives of RELIS are the following: 
  
 present comprehensive information on the drug phenomenon in the Grand Duchy of Luxembourg 
 estimate the drug prevalence at the national level (problem drug users) 
 unfold emerging trends 
 track any drug-related activities, be they in policy, demand reduction or research areas 
 assess the impact of offer, demand and risk reduction activities on current drug consume behaviours 
 serve as a data base for research activities.  
 
The RELIS data collection procedure is based on a standardised extensive data protocol including 23 core items and 
over 60 sub-items. The standard protocol, including 95 per cent of the Pompidou protocol’s items, has been last modified 
in 2000 in order to reach compatibility with the TDI (Treatment Demand Indicator) standard. The RELIS standard protocol 
includes a series of internal consistency items that allow to assess quality and consistency of provided data and to 
operate unreliable data extraction.  
 
A second protocol, namely the Actualisation Protocol is completed each time a previously known problem drug user is 
re-indexed after a period of one year following the previous indexing. Finally, a third protocol (Identification Protocol) 
including only the identification code, the name of the contacted institution and the date and context of admission is 
applied if a previously known user is re-indexed in the course of the year following his previous indexing. The registration 
system allows for highly updated, detailed and comparable data and for a follow-up of institutional careers of problem drug 
users by means of a routine and cost-effective data collection procedure. 
 
To avoid multiple counting and to allow for a follow-up of drug users’ careers, RELIS is based on a 9-digit numerical code 
obtained by indating 3 core variables (attributers) namely: gender (i.e. 01/02), date of birth (i.e., 10051967), and country of 
birth into a code - calculator developed by the NFP in collaboration with the CRP-Henri Tudor. The solution found is time 
and cost effective because it relies on a simple HP calculator that runs an attributor-to-code transcription programme 
based on a multiple-step algorithm. 
 
Each contact person from the participant field institutions disposes of such a calculator and produces the code by 
him/herself. The reliability in terms of data protection was approved by national data protection authorities, by German 
partner regions of the Mondorf Group and by the National Commission for Informatics and Liberties (CNIL) of France.  
 
One of the main benefits of the described procedure is that no personal data can be inferred directly from the identification 
code. The indating and encoding procedures are carried out at the very level of the field institutions. Thus, NFP is 
provided with individualised data (reporting protocols) without any reference to identifying information or attributors on the 
indexed persons, which is undoubtedly one of the major preoccupations of field institutions.   
 
RELIS data processing is based on ORACLE ® database software and allows for multiple variable breakdowns as well as 
separated data analysis for different treatment or law enforcement settings. Separate data can be provided for 
participation regions and institutions. 
 
In terms of data provision, RELIS further relies on following national registers: 
 
- Register of drug law offenders - Special Drug Department of the Judicial Police, 
- National Mortality Register - Ministry of Health, 
- Special Overdose Register - Special Drug Department of the Judicial Police, 
- AIDS and HIV Register - Laboratory of retrovirology - CRP-SANTE. 
- Early warning system on new synthetic drugs 
b. Register on drug law offenders (SPJ) 
 
The register on drug law offenders is paper-based and maintained by SPJ. Research and queries on drug law offenders 
are performed manually. Special authorisation has been reached by the NFP to access the referred register and to 
manually include non-nominative data on offenders into the RELIS database. The NPF thus has developed a standard 
data collection protocol relying on SPSS ® based data analysis. This procedures has enabled the NFP to dispose of 
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detailed anonymous data on all drug law offenders indexed by SPJ and to operate breakdowns referring to use and traffic 
offences and to substances involved according to types of drug law offences. 
 
c. General Mortality Register (GMR) 
 
GMR is run by the Health Statistics Department of the Directorate of Health. The main impediment towards refined data 
provision on drug-related deaths and the application of the EMCDDA promoted DRD standard has been the 3-digit ICD 
coding applied by GMR until 1997. In 1998, ICD-10 standard was first applied by GMR. Currently, drug-related death data 
are extracted from GMR by means of a separate extraction routine. Efforts are currently made to implement an integrated 
software based on the DRD ICD-10 standard and relying on the RELIS identification code, thus allowing for cross 
validation of drug-related death data.  
d. Special Overdose Register (SR) of SPJ 
 
The SR is a paper-based register on acute and indirect drug-related deaths run by the SPJ. Over the past years, NFP has 
put major efforts in the development of a computer-based indexing procedure (SPSS ®) of drug-related deaths by means 
of a comprehensive data form. NFP is currently maintaining a standardised database on acute drug-related deaths from 
1985 to 1999. Anonymous drug-related death data is encoded at the SPJ and transmitted to the NFP according approved 
standards. Data on indirect drug deaths that are still paper based is also provided to the NFP.  
 
e.  AIDS and HIV register (CRP-SANTE) 
 
Official statistics from the national Retrovirology Laboratory of the CRP-Santé provide the number and 
proportion of IVDUs in HIV infected patients. Breakdowns by limited core socio-demographic variables are 
available. Provided data has public status.  
f. Early Warning System on Synthetic Drugs (NFP / SPJ) 
 
In the framework of the Joint Action on Information Exchange, Risk Assessment and Control of New Synthetic Drugs, the 
NFP has developed a nation wide cross-sectional data exchange network  
 
Decision has been made to adopt a centralised structure relying on a nation wide EWS partners’ network (local contact 
persons) as well as centralised co-ordination of key data providers’ activities. The national co-ordination unit of EWS is 
implemented within the NFP. The head of NFP has been appointed national EWS co-ordinator. 
 
The new mandate of the Inter-ministerial Group on Drugs (November 2000), which represents the top decision level in 
the field of drug policies, expressively includes the follow-up of the national EWS system. Governmental delegates 
represented within the Inter-ministerial Group have disseminated information on EWS within their respective 
administration and have undertaken the required steps towards an effective inter-ministerial collaboration. 
   
The implementation of EWS relies on a network of institutional key-informants. Currently all specialised drug agencies 
(low/high threshold) at the national are involved in the data providing process in terms of routine data transmission on new 
trends. Recently two new agencies have joined the EWS network, namely a counselling centre for drug users underage 
and a low threshold project. The first does provide relevant data on new consume patterns and trends within youngster 
population and the second focuses on opiate users. One has to stress that the key-informants network does mainly 
provide data on trends in drug use but not on toxicological characteristics of substances since the referred agencies do 
not propose substance related services. 
 
Currently, drug seizures are still one of the most important and the most reliable data source as to substance profiling and 
detection of new drugs. Samples seized by Customs or Police are either analysed (rapid tests) by the SPJ, or sent, via the 
Prosecutors office, to the National Laboratory of the Department of Health (LNS) for toxicological profiling. Respective 
results are not systematically transmitted to the department of Health or the NFP. However, effective bilateral co-operation 
between the NFP and the national Europol unit (SPJ) allow for rapid data transmission in case a new trend or 
substances should be detected by the latter. The active involvement of law enforcement agencies in the national 
monitoring system highly facilitates the implementation of Joint Action-related activities. 
 
Agreements have been made between the National Fund Against Drug Trafficking, the NFP and the National Health 
Laboratory (LNS) on the funding of new technical equipment allocated the toxicology unit of the latter. This achievement 
has largely contributed to the improvement of the quality of toxicological analysis provided by LNS. 
 
General practitioners have recently been involved in the EWS in terms of data provision on new substances and new 
consume patterns. All GPs and psychiatrists registered in the Grand-Duchy of Luxembourg have received a standardised 
data form allowing them to provide relevant information to the NFP in case they were confronted with an unknown 
psychotropic substance or unusual consume patterns. The NFP, as a counter part, committed to provide GPs and 
psychiatrists with information on the detected trends or substances, as far as there is any information available.  
 
Drug-related deaths have to be reported by emergency services to the Police and the SPJ. Non-fatal drug-related 
emergencies requiring medical intervention have not to be reported systematically. Moreover, emergency services do not 
index drug-related interventions separately, which means that no monitoring of those cases can be performed. The 
referred situation is not likely to change and thus, the inclusion of emergency services in the EWS appears to be 
unfeasible at the present stage. 
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National drug legislation does not foresee a legal framework for testing or profiling illicit drugs in nightclubs, public 
events or rave parties. No such activities have been planned or carried out under the authority of public administrations. 
Taking into account that the first official seizure of  ‘ecstasy’ has only been recorded in 1994, harm reduction and close 
monitoring activities in this particular field were previously not viewed as a priority.  
 
In October 1995, a new drug help line was created, under the responsibility of the CePT. Given its easy access and the 
anonymity it guarantees, phone help lines often represent the first step with regard to further orientation or treatment 
demand proceedings and as such are able to provide high quality data on recent trends in drug use. The national Drug 
Help Line has been included in the EWS system in the course of 1999. 
 
The drug issue is largely covered by various media supports. Press, Music, fashion and leisure industries are often the 
mirror of life styles and current trends in substance use. Information could be collected by screening the media targeted at 
young people and sub cultural groups. Radio, television, newspaper, magazines, fanzines, books, comics, announcement 
of events, opening of new clubs, etc., are to be viewed as complementary indicators towards the global monitoring of new 
drug trends. Since the resources of the NFP do not allow for an overall monitoring of media supports, decision has been 
made to compile, in collaboration with the information and press department of the State’s Ministry, a monthly national 
and international press review on drugs.  
 
g. Documentation Centres (NFP / CePT) 
 
The Centre Logistique de Documentation sur les Drogues et les Toxicomanies (CLDDT) is a logistic documentation 
service run by the NFP since 1995. CLDDT runs the only computer-based national documentation management base 
specifically focusing on licit and illicit drugs. The CLDDT indexes about 2,900 documents mainly in French, German and 
English language. Users of information services provided by the CDTL are mainly researchers, journalists, policy makers, 
drug treatment and prevention specialists, and general public. The majority of indexed documents are paper-based and 
abstracts are provided. 
 
In addition to its function of documentation base, CLDDT also ensure the conceptualisation and execution of drug 
documentation dissemination strategies as required by the NFP. Topic-specific mailing lists have been developed and 
maintained by active contact making and demand response. 
 
CLDDT is linked to the Centre de Documentation du Centre de Prévention des Toxicomanies run by CePT since 
1996. The CePT documentation centre mainly focuses on primary prevention, training and evaluation in the fields of licit 
and illicit drugs. The current stock approaches 1,000 documents or media supports. Queries are handled manually and no 
computer-based consultation facilities are provided.  
  
• Alphabetic list of relevant Internet addresses  
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